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 Abstract 
1.1. Zusammenfassung 
Über die letzten Jahre wurde eine große Anzahl verschiedener Verfahren entwickelt, die eine 
gezielte und induzierbare Genexpression ermöglichen. Diese Systeme kommen in einer Vielzahl 
von Feldern zur Anwendung. Hierzu gehören unter anderem die Bereiche akademische 
Forschung sowie industrielle Produktion. Ein beliebter Modellorganismus ist die Bäckerhefe 
Saccharomyces cerevisiae (S. cerevisiae). Obwohl der Einzeller S. cerevisiae bereits seit vielen 
Jahren erfolgreich verwendet wird, besteht immer noch ein großer Bedarf an öffentlich 
zugänglichen und gut charakterisierten genetischen Schaltern. Besonders im Bereich der 
Expressionskontrolle besteht weiterer Forschungsbedarf, denn viele etablierte Systeme 
erlauben keine konzentrationsabhängige Induktion, sind in einem gewissen Maße toxisch für 
den Organismus oder weisen eine hohe basale Expression auf. 
Die vorliegende Arbeit beschäftigt sich daher mit dem Design, der Implementierung und der 
Charakterisierung modularer Schalter in S. cerevisiae. Hierfür dient ein modifiziertes 
CRISPR/dCas9 System als Grundlage. Die dabei verwendete scaffold RNA (scRNA) ist um ein 
RNA-Bindemodul verlängert, welches von dem RNA-bindenden Fusionsprotein MCP-VP64 
erkannt wird und nach Bindung eine Transkriptionsinitiation auslöst. Das verwendete 
CRISPR/dCas9 ermöglicht also die modulare Expressionskontrolle der drei Komponenten 
dCas9, MCP-VP64 und scRNA. Ziel dieser Arbeit war es, alle drei CRISPR/dCas9 Komponenten 
unabhängig voneinander induzieren zu können und im Anschluss die einzelnen Komponenten 
zu einem UND-Gatter zu kombinieren.  
Um einen ersten Schalter zu generieren, wurde die Expression des dCAS9-Proteins unter 
Kontrolle des GAL Promotors gebracht, was zu einer Galactose-abhängigen Induktion der 
Expression des fluoreszierenden Reporterproteins Venus führte. Der Galactose-Schalter 
ermöglichte hohe Expressionsraten, was jedoch auch eine verhältnismäßig hohe basale 
Expression mit sich brachte. Daher wurde ein funktionelles logisches UND-Gatter entworfen, 
bei dem MCP-VP64 unter die Kontrolle von β-Estradiol (ES) gebracht wurde. Nur bei 
Anwesenheit beider Induktoren wurde eine Expression des Reportergens gemessen. Dies zeigt, 
dass ein streng reguliertes, sowie konzentrationsabhängiges UND-Gatter entwickelt wurde. 
Zusätzlich zu Venus als Reportergen wurde ein zweites Reporter-Konstrukt zur regulierten 
Expression von Proteinen mit biotechnologischer Relevanz evaluiert. Hierfür wurde das Zielgen 
durch ein so genanntes T2A Peptid mit dem Fluorophor tGFP verbunden, wodurch die 
Expression beider Gene in einem mRNA Transkript, sowie die direkte Detektion der Expression 
ermöglicht wurde. Um die Möglichkeiten der Toolbox zu erweitern, wurde zusätzlich ein 
positiver Feedback Mechanismus untersucht.  
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Das verwendete System wurde außerdem um eine induzierbare scRNA erweitert. Hierfür wurde 
ein Ribozym-scRNA-Ribozym Konstrukt implementiert und sowohl mit einem konstitutiven als 
auch mit dem ES-induzierbaren Promotor getestet. Alle verwendeten Schalter und Gatter 
wurden auf ihr Expressionslevel, ihre basale Expression und Konzentrationsabhängigkeit 
getestet. Um ein besseres Verständnis der zugrunde liegenden Prinzipien und der 
Funktionsweise des UND-Gatter Designs zu erhalten, wurden die experimentellen Ergebnisse 
durch die Entwicklung eines mathematischen Modells und einer Einzelzellanalyse erweitert. 
Mit dieser Arbeit wurde ein vorhersehbares, modulares und vielseitig einsetzbares 
Expressionskontrollsystem entwickelt. 
 
1.2. Abstract 
Many different routes for targeted gene expression are available and with the help of Synthetic 
Biology (SynBio), more and more controlled expression systems are developed every year aimed 
at robustly and precisely switching one or more genes on and off (1). Targeted repression and 
expression are essential for basic research, as well as for many industrial applications. In this 
context the unicellular eukaryote S. cerevisiae is one of the oldest and most commonly used 
hosts (2,3). Despite the fact, that S. cerevisiae has been investigated extensively for many years, 
researchers are still lacking easy-to-implement and well-organized toolboxes (3). In addition, 
many frequently used regulatory systems influence the viability of the host cell, show high basal 
expression or enable only the overexpression of the target gene without the possibility of fine 
regulation (4).  
Within this work, a modular system for targeted gene expression was designed, implemented 
and extensively characterized to overcome these limitations. Additionally, it was aimed to 
contribute to and therefore improve the already existing publicly available yeast toolbox. A 
scaffold RNA (scRNA) CRISPR/dCas9 system served as a modular expression platform (5). This 
is based on three components namely dCas9, the RNA-binding protein MCP fused to the 
transcriptional activation domain VP64 and a scRNA encoding the desired locus and action. A 
scRNA specifically targeting a tetO binding sequence was used, resulting in Venus reporter gene 
expression. The functionality of the reporter gene setup was demonstrated by the expression of 
the reporter gene Venus. 
A natural switch was integrated based on the well-established Gal10 expression cassette by 
implementation of a GAL promoter in front of dCas9. High expression levels were achieved, but 
comparatively high basal expression was observed. Hence, a second switch based on the 
synthetic LexA-ER-AD heterologous transcription factor was added. A functional AND gate was 
achieved by implementing four β-estradiol (ES) inducible lexA boxes in front of MCP-VP64. The 
AND gate was demonstrated to achieve high expression rates in presence of galactose and ES 
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while being tightly regulated in their absence. Additionally, a reporter gene setup was 
implemented combining a gene of interest (GOI) with the fluorophore tGFP by the ribosomal 
skipping T2A sequence. This setup allows to adapt the system to any gene of interest without 
losing reporter function. To extend the possibilities for applications, a positive feedback loop 
was designed and verified as functional.  
The modularity of the system was demonstrated by the construction of a second AND gate, in 
which the scRNA was placed under the control of ES. For this purpose, a ribozyme-scRNA-
ribozyme construct was introduced and its functionality verified for both, a constitutive 
promoter and an ES inducible promoter. The established switches and AND gates were 
characterized in detail for their expression levels, basal activity and their dose-dependency. A 
better understanding of the underlying principles and the functioning of the AND gate design 
was achieved by backing up of the experimental findings with the development of a 
mathematical model and single-cell analysis. In summary, a predictable and modular, as well 
as versatile expression control system was developed. 
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 Introduction 
2.1. Synthetic biology 
Synthetic biology (SynBio) is an interdisciplinary approach combining both the investigative 
nature of biology and the constructive nature of engineering in order to protect and expand our 
planets habitability and resources (1,6,7). The term synthetic biology was first introduced by 
the French chemist Stéphane Leduc in 1912 (8,9). The field of recombinant DNA technologies 
and genetic engineering, which emerged in the 1970s, is considered as the logical precursor of 
SynBio (10). In the 1980s synthetic human insulin was the first commercially available health 
care product manufactured by recombinant DNA technology. Due to the high demand for 
human insulin, a cost-intense biotechnological process of cloning, expression and up-scaling 
was started by a collaboration of multiple companies (10–12). Conventional genetic 
engineering focuses on approaches to solve complex problems by concentrating only on one or 
few genes. SynBio instead aims for a more comprehensive solution, combining adapted existing 
cellular architectures with novel systems build from ground up (7). Thus, when SynBio 
launched in the early 2000s, one of the main advantages had been the possibility to enable the 
overarching theoretical and practical construction of organisms solving various problems in 
multiple disciplines. These organisms cover a brought range, such as bacteria cleaning 
hazardous waste in inaccessible places (13), plants that are able to detect and report chemicals 
due to a de‐greening circuit (14), algae that produce biofuel in an efficient and sustainable 
fashion (15) and human cell lines recognizing and fighting specific diseases like cancer (16).  
During the so-called “first wave of SynBio” researchers focused on creating and perfecting basic 
genetic elements like promoters or repressors, which improved the understanding of biological 
processes and allowed to establish first principles for the design of small modules. As a result, 
multiple well characterized small modules could be combined to build up a toolbox for targeted 
genetic engineering in order to regulate gene expression or to tune biomolecules or biosynthetic 
mechanisms (7,17). The resulting toolbox includes, among others simple switches, pulse 
generators and oscillators (7,18,19). It has been shown, that, in order to achieve a certain goal, 
the manipulation of both well-established and novel elements is still troublesome. Hence, the 
duty of the ongoing “second wave of SynBio” is not only to effectively assemble elements and 
modules into functional, customizable large-scale systems, but also to formulate new and 
effective bioengineering design principles (7,17,20). To achieve this goal, the approaches of 
genetic engineering have to be combined with the basic principles of chemistry, biology, 
mathematics, biophysics and many more. Especially important is the implementation of 
computational engineering and mathematical models, which play a key role in industrial up-
scaling. Before SynBio, bio-derived materials, like the polysaccharide cellulose, could only be 
produced in small scales, with yields sufficient for research purposes. Due to SynBio nowadays 
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the large-scale production of cellulose in bacteria is possible, which allowed multiple 
applications in the field of optoelectronics, medicine and others (1,17,21,22). Only this holistic 
approach allows scientists to think big, to really understand the underlying biological principles 
and to design and implement whole functioning systems (10,20,23).  
In order to optimize production of bio-derived materials, choosing an appropriate host is of 
utmost importance. Prokaryotes as Escherichia coli (E. coli) are the best understood hosts, due 
to their easy excess and handling, as well as for the long history of research (10,20,24). Besides 
prokaryotes, yeast strains like Saccharomyces cerevisiae (S. cerevisiae) or Yarrowia lipolytica and 
mammalian cell lines like Chinese hamster ovary cells (CHO) have been established for 
industrial production of pharmaceuticals or other bio-derived materials (16,25–27). In order to 
enhance productivity, the nature of SynBio allows to also take advantage of less traditional 
hosts showing promising characteristics. For example, an extremophilic Halomonas strain, 
which can be cultivated under high osmotic pressure and pH, was engineered to produce 
microbial polyesters in saltwater only by using an open fermenter without the need of further 
ingredients, which leads to a significant reduction of production costs (1,17,28).  
Nowadays SynBio is expanding as part of the fourth industrial revolution, generating novel and 
sustainable innovations in the fields of agriculture, healthcare and environmental issues (1,29). 
Even though SynBio will have a decisive influence on our future, there are some basic problems 
that have to be addressed: 
• many of the utilized systems are not fully understood, which makes the targeted 
manipulation more challenging 
• biological systems always produce a certain amount of noise, which has to be especially 
taken into account for models  
• most synthetic systems have been studied in a laboratory setup, but might have a severe 
impact in a living organism or a wider ecological system (7) 
Nevertheless, it is expected, that the impact of SynBio will further increase and that its only 
limitation will be the imagination of researchers and the acceptance by the society. After all, 
science, politics and industry have to openly calculate risks and benefits to build up a culture of 
trust, so that society will get a better understanding of the advantages achievable through 
SynBio (1,7,30).  
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2.1.1. Saccharomyces cerevisiae as a model organism for synthetic biology 
The decision for a host is a crucial step for both, scientific research and biotechnological 
production of bio-derived materials. The baker yeast S. cerevisiae is the most intensely studied 
unicellular eukaryote and one of the oldest and most frequently used microorganisms in 
biotechnological applications. S. cerevisiae has been successfully used for the production of fine 
and bulk chemicals like ethanol, butanol or lactic acid (2,3) and it is especially valuable as a 
cell factory, due to the properties of: 
• fast growth on cheap media containing only a carbon source, vitamins and salt 
• tools for genetic manipulations are well-developed and -established 
• robustness in large-scale set ups 
• growth at low pH is possible, which reduces the risk of bacterial contaminations 
Additionally, there is a large genetic knock-out collection available and new mutants can be 
generated and analyzed in a straightforward approach (31,32).  
At the moment one of the biggest disadvantages of S. cerevisiae as a production host is its 
disability to grow on alternative carbon sources like arabinose or xylose. However, genetic 
engineering may easily solve this issue. Even more problematic is the fact, that even though 
over a hundred synthesis routed for chemicals were genetically integrated into yeast 
successfully, only a few reached commercial-scale productions. Though metabolic engineering 
had already been established in the 1990s, the engineering of product strains is still 
disproportionately time and resource consuming (33,34). Thus, for biotechnological 
applications the integrative usage of metabolic engineering and SynBio is a really promising 
approach, which has already led to (35,36) and will lead to more efficient ways of product-
strain construction in the future (2). The synergy consists of metabolic engineering, which 
defines the direction of manipulation, and SynBio, which provides the tools to establish these 
tasks. Even though SynBio is still in its infancy, many technical challenges were solved, like the 
ever-decreasing costs in DNA-sequencing and synthesis allowing in-depth knowledge about the 
genome of a manipulated host, as well as the de novo synthesis of whole modules. At the same 
time the standardization of DNA assembly and the generation of well-characterized elements 
and modules is expected to lead the way for industrial plug-and-play strains, which can be easily 
modified towards the high-level production of a desired product (2,3,33,37).  
The potential to build up a powerful host from S. cerevisiae and SynBio tools has been 
demonstrated not only by basic research, namely the de novo synthesis of a complete 
chromosome (38), but also by application-oriented engineering, which successfully 
manufactured the complex pathway of vanillin (3,39). For a true benefit in the long run, both 
academia and industry have to communicate openly about general bioprocess bottlenecks, 
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about basic growth and cultivation conditions, as well as about the tools and hosts that are 
actually required (2). Therefore, the established method of “rational engineering” may be 
complemented or even replaced by the cost-effective and more rational method of “predictable 
engineering” (see Figure 1). 
  
 
Figure 1 Schematic representation of models for genetic engineering. 
Transformation of a trial-and-error design-test-build circle to a predictable design-test-build workflow by using high-
throughput screens and multidimensional data analysis. (Figure adapted after (2))  
 
First an iterative design-build-test cycle is used (34), where one or multiple cell-factory variants 
are designed, built and screened using high-throughput methods. The most promising 
candidates are characterized in detail und used for another circle of design and building. In 
order to achieve a new generation of cell factories, the obtained knowledge from the design-
build-test cycle is used to start a computer-aided approach leading to the design-test-build 
workflow. Hopefully, the usage of the design-test-build workflow causes a significant decrease 
of the efforts and resources of development (2,33,40,41). 
 
2.2. Multiple switches established in the yeast Saccharomyces cerevisiae 
Despite the great popularity of S. cerevisiae, research and applications are still lagging behind 
other organisms. Especially in comparison to the omnipresent host E. coli., the collection of well 
characterized biological parts and the standardized assembling methods as part of a toolbox in 
S. cerevisiae are still limited (3).  
Nevertheless, there is a wide and constantly increasing platform of resources and literature 
about the available elements for S. cerevisiae. Just recently Lee et al. published one of the first 
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well characterized publicly available toolboxes for S. cerevisiae (42). Since most regulations take 
place on the transcriptional level, the choice of the right promoter(s) is particularly important 
for the design of every system or pathway (43). Most endogenous yeast promoters respond to 
the concentration or type of a carbon source. Regulation systems based on the induction of 
these natural promotors, like the Gal1 promotor, inducible by galactose, influence cell growth 
and depend on host cell genes for correct performance (2.2.1). Other inducible systems, like 
the copper sensitive CUP1 promotor or the tetON and tetOFF system, which are inducible by 
the antibiotic tetracycline (2.2.2), are even toxic to the host (44,45).  
To overcome these limitations of natural transcription factors (nTF), heterologous transcription 
factors (hTF) consisting of a DNA-binding domain, an activation domain (AD) and a regulatory 
domain have been implemented (2.2.3). Such transcription factors should theoretically not 
influence the host metabolism and generally allow the inducible and concentration-dependent 
activation of transcription. For example, a heterologous transcription factor based on the 
estrogenic hormone ß-estradiol (ES) combined with a transcription activator like VP16, an 
activation domain of the Herpes simplex virus, already showed promising results (45–48).  
 
2.2.1. Switches based on the carbon source 
To express a desired protein, one can choose between inducible or constitutive promoters. 
Constitutive induction leads to high product yields, which is not always desirable; for example, 
in cases where the product has a toxic effect on the host. Hence, the majority of promoters used 
for protein expression in yeast are inducible promoters, sensitive to environmental conditions, 
such as stress or ion concentration inside the cells (49,50). In yeast, the best understood and 
most intensely used set of controllable promoters depends on a certain carbon source, where 
the carbon source either leads to a repression or induction of target gene expression. The main 
advantage of the carbon-source-dependent promoters is to allow growth before the initiation 
of a potentially burdening expression phase (43). Depending on factors like the available carbon 
source, the amount of glucose in the growth media and the promoter itself, there are different 
pathways of induction and repression.  
Since glucose is the favored carbon- and energy-source of S. cerevisiae, it plays a key role in the 
repression and derepression of certain genes. To be precise, glucose interacts in a repressing 
way with genes involved in the oxidative metabolism, in the usage of alternative carbon sources, 
in the gluconeogenesis or the tricarboxylic acid cycle (51,52). This interaction either leads to a 
decrease in transcription or translation on the gene level or to enhanced protein degradation 
on protein level, while mainly relying on the protein kinase Snf1 (53,54). Only after glucose is 
depleted, Snf1 builds a specific complex, which enters the nucleus to initiate derepression (54). 
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Another set of promoters is derepressed by carbon source depletion. Hence, these promoters 
get induced at low glucose levels. A considerable disadvantage of these promoters is the lack of 
a proper induction for activity. Nevertheless, this ability is also a substantial advantage when 
used for biotechnological application, where the expression of the protein of interest does only 
start after cell growth, when the carbon source is typically depleted. So, the gene expression 
can de facto be regulated or even be called inducible in highly monitored environments like fed-
batches – at least to a certain degree (43). The Adh2 promoter is a popular promoter controlling 
the alcohol dehydrogenase II. This strong promoter is strictly repressed by glucose and only 
derepressed when glucose is depleted, which causes the cells to switch to ethanol growth (55). 
Another class of carbon dependent promoter is the carbohydrate-inducible one. The best 
characterized and most used carbon-inducible promoters are controlling the Gal genes, where 
galactose is acting as the main inducer (Figure 2A). In the presence of glucose these promoters 
are strongly regulated by cis-acting elements (Figure 2B) (56). In S. cerevisiae, the PGAL1 and 
PGAL10 are widely used for recombinant protein production. The best results for galactose-
induced protein production can be expected if a low glucose level is maintained. However, it 
should be noted that due to the nature of the glucose/galactose pathway, a certain leakiness 
must be expected (57).  
 
2.2.2. Switches based on tetracyclines - the Tet-On and Tet-Off approach 
During the last two decades, scientists were searching for systems, allowing stringent and 
inducible transcription control of a gene of interest (GOI), especially in complex genetic 
environments such as mammalian cells (58). A first attempt was started to control gene 
expression by endogenous eukaryotic promoters, which can be induced for example by heat 
shock. This attempt was insufficient since it suffered from a broad range of secondary effects 
like the pleiotropic effect of elevated temperatures (59). Hence, scientists embarked on the 
search for non-endogenous systems. The already relatively well characterized bacterial 
regulatory elements seemed to deliver promising elements to start with. One of the first 
elements tested for its functionality in eukaryotic cells was the bacterial lac system (originally 
from E. coli), which is inducible by isopropyl β-d-1-thiogalactopyranoside (IPTG) (60,61). IPTG 
has been proven to be rapidly taken up and intracellularly stable, nevertheless, it showed a 
rather slow and ineffective transcriptional regulation, leading to low induction levels (58,62). 
In contrast, the tet system, based on the Tn10-specified tetracycline-resistance operon of E. coli, 
has proven to be functional in different eukaryotic organism such as yeast or mammalian cells. 
The success of the tet system is based on a rapid uptake of the inducer tetracycline (or derivates) 
and a corresponding rapid induction of target gene expression (58,63).  
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Figure 2 Reaction of the GAL genes to glucose and galactose. 
(A) In the absence of glucose and the presence of galactose a complex pathway leads to the induction of the Gal 
genes. (B) In contrast, in the presence of glucose the Gal gene expression is repressed independently from the 
absence or presence of galactose. (Figure adapted after (54)) 
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Originally the tet system serves Gram-negative bacteria as a defense mechanism against 
tetracyclines (tc) mediated by the resistance gene tetA. TetA is a tetracycline/metal-proton 
antiporter located in the cytoplasmic membrane (64). When overexpressed, TetA is lethal for 
its host (65), hence the tetA genes are strictly regulated on the transcriptional level by the tc-
responsive Tet repressor (TetR). The genes for TetA and TetR are oriented with divergent 
polarity around a regulatory region with overlapping promoters and operons called tet operator 
(tetO) (66). In the absence of tc, TetR dimers bind to the operators tetO1 and tetO2 silencing 
the genes tetA and tetR. As soon as tc enters the cell, it binds TetR with high affinity; about nine 
orders of magnitudes higher than the binding affinity to tetO (67,68). A conformational change 
of TetR leads to the dissociation from tetO (67,69), which in turn leads to a burst-like expression 
of TetA and TetR followed by a rapid reduction of free tc in the cytoplasm. The lack of tc then 
leads to the shutdown of the expression of tetA and tetR (70). During the presence of tc, the 
expression of TetA is fine-tuned, so the tc-concentration in the media cannot reach a level where 
it slows down or even stops translation. To start the whole process, only nanomolar 
concentrations of tc are necessary, especially since tc efficiently penetrates most cell types 
(66,71).  
For the control of gene expression at first a relatively simple tet system was utilized. Therefore, 
the so-called tetracycline response element (TRE), consisting of 7 repeats of the 19 nucleotide 
tetO2 sequence separated by a 41 bp spacer, is placed upstream of a minimal promoter and a 
GOI. Additionally, tetR is expressed from a strong constitutive promoter. In the absence of tc, 
TetR binds to tetO and gene expression is silenced by sterical interference. When tc is added to 
the media, TetR will bind tc instead of tetO and therefore gene transcription is permitted 
(72,73).  
In 1992, Gossen and Bujard established an improved tet expression system, where they fused 
TetR with the C-terminal domain of VP16. This tetracycline-controlled transactivator (tTA) 
binds to the TRE in the absence of tc, and the activation domain VP16 initiates gene expression. 
As soon as tc is added, it binds to tTA with high affinity. The tTA complex is removed from the 
activation site, which leads to a delayed decrease of gene expression (58,74). This tTA-
dependent system is also called the Tet-Off system (Figure 3A).  
For more precise control of the expression time and to prevent prolonged exposure of the 
targeted organisms to tc, a reverse Tet-On system has been established. Random mutagenisis 
was used to identify a TetR-variant showing a reversed phenotype. This reverse TetR (rTetR) 
only binds to DNA in the presence of tetracycline. Hence, after rTetR was fused to the activation 
domain VP16 to build the reverse tetracycline-controlled transactivator (rtTA), the GOI behind 
a TRE is only expressed in the presence of tc and expression decreases in its absence (69,74,75) 
(Figure 3B).  
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Figure 3 Regulation of gene expression by the tet regulators tTA and rtTA. 
The tetO binding region is shown in green boxes, the minimal promotor in grey and the target gene in yellow. The 
transregulators rTA and rtTA are shown in light blue circles and dox in a bright blue one. Target gene expression is 
displayed by an arrow and waves, silenced transcriptions as a X. (Figure adapted after (73)) 
 
Interestingly tTA and rtTA have shown a different sensitivity to tetracycline and its derivates. 
Doxycycline (dox) is the most widely used derivative, on account of a high affinity to both 
systems, a good tissue distribution, low toxicity, a half life of 24 h and low cost. Additionally, 
in 2015 it was shown, that dox has no effect on the global gene expression of S. cerevisiae (76). 
Over the years, many different tc-dependent systems have been invented, showing less 
background expression, a higher affinity to dox or enhanced transcriptional activity (77,78). 
Hence, the tet system is one of the most widely used routes for regulated gene expression in 
many different organisms. Both Tet-On and Tet-Off are well characterized and have proven 
themselves to be functional in S. cerevisiae (73,79,80).  
 
2.2.3. Hormonal switches for tightly regulated gene expression 
One of the major advantages of TetR-based systems is their high binding constant of TetR to tc 
(Ka ~ 109 M-1 (68), in comparison for IPTG, which is commonly used for induction of the lac 
operator in E. coli (Ka ~ 106 M-1 (81)). Hence, low tc-concentrations are necessary for induction 
or repression of gene expression. The Tet-On system shows substantial basal activity, which is 
why the Tet-Off system is still preferred. However, the main disadvantages of the Tet-Off system 
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are the need to constantly add tc and that after removal of tc the system relies on protein 
dilution and degradation to reduce target protein levels (46,79).  
To overcome those limitations, heterologous gene expression controls based on steroid 
hormones were invented. Steroid hormone receptors are (partially) highly conserved 
intracellular receptors, which, upon steroid binding, activate or repress the transcription of 
specific genes (82,83). Naturally occurring steroid hormone receptors regulate gene expression 
due to four main reactions: 
• specific binding to the corresponding response elements 
• formation of stable complexes at the response elements 
• allosteric receptor activation due to the corresponding ligand 
• initiation of target gene expression due to the recruitment of TF and RNA polymerases 
Additionally, for some receptors, like the estrogen receptor, the binding to heat shock proteins 
like hp90 plays a key role. Unoccupied receptors are thought to bind with cellular heat shock 
proteins to form a complex that is unable to bind DNA. Addition of the ligand leads to the 
dissociation of the heat shock proteins, which restores the DNA binding ability and allows target 
gene expression (83,84) . It can be assumed that the steroid binding domain has the ability to 
function as an autonomous regulator, which makes them a valuable tool to build novel 
transcription factors.  
In the 80s and 90s of the last century, the combination of a steroid binding domain with an 
activation domain to an chimeric TF (cTF) has proven to successfully allow hormone induced 
target gene expression in vertebrate cells (47,85). Since several steroid receptors from 
vertebrates have shown to be functional in yeast as well (86), Louvion et al. implemented 1993 
a first steroid hormone dependent regulator in S. cerevisiae cells. They fused the steroid binding 
domain of the human estrogen receptor (ER) to the DNA binding domain (dbd) of Gal4 and the 
activation domain (AD) VP16. This first cTF based on the inducer ES allowed the hormone-
inducible expression of target genes under the control of the GAL1-10 promoters in yeast (47).  
Among others, McIsaac et al. established a tightly controlled and well characterized gene 
expression strategy based on the Gal4 dbd, ER and the AD VP16 (46,68,87). The resulting cTF 
GEV allows a graduated and rapid induction within minutes after addition of ES (Figure 4). It 
reduces target gene expression in the absence of ES to near background activity and only affects 
a few genes unintentionally (46). 
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Figure 4 The mechanism of activation of the GEV system.  
ORF: open reading frame, Gal4 dbd: Gal4 DNA binding domain, ER: hormone-binding domain of the human estrogen 
receptor. (Figure adapted after (45)) 
 
Even though GEV provides significant advantages like tight regulation over the standard Gal4-
based TF, there are still multiple limitations. Since GEV is based on the Gal4 dbd, it binds to 
the endogenous GAL promoter and therefore influences the host cell metabolism and strongly 
limits the growth in galactose-containing media. Additionally, the system is toxic after induction 
with ES (45,46). Hence, Ottoz et al. devised a gene expression strategy, that does not rely on 
the Gal4 dbd, but on the bacterial DNA-binding domain of LexA and is therefore assumed to 
not influence the host organism (45).  
 
2.2.4. A heterologous transcription factor allows regulated gene expression without 
influencing the host organism 
LexA (1-202 aa) is a repressor in E. coli, repressing many genes in a phage repressor like 
manner. The LexA binding region (1-87 aa) binds specifically to the lexA operator (lexA) as a 
dimer (88,89). When the cellular DNA is damaged, the LexA hinge region is cleaved and the 
dimerization is prevented, which results in the loss of operator binding. This leads to the 
activation of LexA-repressed genes (90). In 1984 Brent and Ptashne demonstrated, that LexA is 
able to repress a gene, when lexA is inserted between the UASG of a Gal1 promoter and the 
transcription start (88). Building on the assumption, that LexA is able to enter the nucleus and 
bind to lexA, Ma and Ptashne built a first cTF out of LexA and the Gal4 dbd, which was able to 
induce target gene expression (91). Since the LexA-lexA combination serves as an inducer that 
does not contain yeast analogues (91), it is ideally suited for the combination to a hTF. 
A hTF should not interfere with the host’s physiology and is defined as a fusion of protein 
domains from other organisms, consisting of a DNA-binding domain, a regulatory domain and 
an activation domain (45,92). In Ottoz et al. such a hTF was constructed by genetically fusing 
the bacterial dpd LexA (1-202 aa) (92), the hormone-binding domain of the human estrogen 
receptor as regulatory domain (47) and different ADs. They used the Gal4 AD (93), the VP16 
AD (48) and B42 and B112, two short unstructured acidic peptides originally encoded by DNA 
fragments of E. coli (91,92).  
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Depending on the utilized AD, the range and steepness of target gene expression can be 
controlled, as well as the toxicity of the genetic switch. For example, the fusion of LexA-ER to 
the unstructured acidic peptide B112 as AD allowed strong target gene expression (in the range 
of the strong TDH3 promoter) and a fine-tuned and therefore precise induction of gene 
expression, while not showing any toxic effects. Hence, the selection of the AD is important for 
the performance and targeted control of gene expression (45). Based on the hTF LexA-ER-AD, 
Ottoz et al. established a novel route of gene expression control that operates predictably in 
different growth media without influencing the host organism. Additionally, all steps were 
accompanied by detailed modeling, making this tool a perfect example for a SynBio application. 
 
2.3. Genome engineering 
Genome engineering is a tool that allows one to dissect and therefore understand complex 
genetic interactions, as well as building whole new pathways with the help of SynBio. Genome 
engineering was established in the 1970s, when researchers could demonstrate that it is 
possible to insert endogenous DNA into a target organism and integrate this DNA in the hosts 
genome. With the help of homologous recombination (HR), targeted mutation, deletion or 
integration into a host’s genome is possible. Therefore, a plasmid or linear DNA fragment with 
a homologous region or homologous flanks to a certain site in the genome is delivered into a 
host cell and integrated by HR at the targeted site (94–97). In 1989, Mario Capecchi generated 
the first knock-out mouse, successfully manipulated by HR (95). This technology seemed very 
promising back in the 1980s, but soon turned out to have some main disadvantages:  
• HR occurs with a relatively low frequency, which results in a quite low efficiency (98,99) 
• integration efficiency depends heavily on the HR properties of the host organism 
• HR experiments are time-consuming and labor-intensive, especially when it comes to 
selection and screening strategies 
• there is always potential for mutagenic effects (97,100) 
lexA lexA 
Figure 5 The mechanism of activation of the LexA-ER-AD system.  
ORF: open reading frame, ER: hormone-binding domain of the human estrogen receptor, AD: activation domain. 
(Figure adapted after (42)) 
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Due to these limitations, new approaches had to be developed to allow targeted manipulation 
with a much higher efficiency than possible with HR only. It was found, that the efficiency of 
HR could be greatly enhanced, if endonucleases create a double-strand break (DSB), which are 
difficult to repair for the host (100,101). The DSB is then repaired by one of the intrinsic repair 
mechanisms: homology-directed-repair (HDR) or nonhomologous end joining (NHEJ) (102). 
NHEJ usually occurs after a DSB, when no DNA template is provided. Since NHEJ may repair 
DNA in an error-prone process, this repair mechanism often leads to inactivating mutations. 
HDR occurs, when a DNA template, defining the desired genetic modifications, is present. Thus, 
HDR allows precise genome editing (97,102). 
The discovery that the induction of a DSB increases the frequency of cellular repair mechanism 
dramatically, refocused the field of research into the direction of targeted DNA-binding 
endonucleases. Chimeric nucleases like zinc-finger nucleases (ZFN) or later Transcription 
Activator-like Effector Nucleases (TALEN), combining sequence-specific DNA binding domains 
with a nonspecific DNA cleaving module (100) were established. 
 
2.3.1. CRISPR/Cas – a powerful tool for synthetic biology 
When invented, TALEN seemed to be the most promising tool for genome engineering, but 
when the potential of the novel CRISPR/CRISPR-associated (Cas) approach was discovered, it 
exceeded the potential of previously established TALEN restriction endonucleases by far (103). 
Clustered regularly interspaced short palindromic repeats (CRISPR) originally are part of the 
adaptive immune response of archaea and bacteria (for detailed mechanism and description 
see 2.3.2) and provide immunity via RNA-guided DNA cleavage against invading foreign DNA 
like phage DNA (104).  
Nowadays, due to the simplicity and adaptability, the less time- and cost-consuming production, 
as well as the precise and scalable DNA targeting, CRISPR is the most popular tool for genome 
engineering (97). Multiple CRISPR approaches have already been established for applications 
such as targeted DNA manipulation (2.4.1)(105), transcription control (2.4.4) (106) and many 
more (2.4.5).  
For targeted genome engineering, basically three components are necessary (Figure 6):  
• the CRISPR-associated endonuclease Cas9 
• a guide RNA directing Cas9 to a specific DNA locus 
• a protospacer adjacent motif (PAM), that can be recognized by Cas9 (107) 
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Figure 6 Structure of CRISPR/Cas9 system. 
Designed gRNA recruits Cas9 and binds as a complex with DNA. The gRNA specifically targets 20 bp of the DNA, 
while the Cas9 additionally needs a PAM sequence (marked in red) to allow binding and cleavage of DNA. (Figure 
adapted after (97,100)) 
 
 
2.3.2. The bacterial adaptive immune response by CRISPR 
Since bacteriophages are the most abundant biological entity present in this world, bacteria had 
to develop strategies to defend themselves from their invasive nature (108). Some strategies 
like the prevention of DNA injection, focus on keeping the virus out of the cell, whereas other 
like the CRISPR/Cas system concentrate on the destruction of the DNA that already invaded 
the cell (109,110). Consequently, more than 90 % of all archaea and 40 % of all bacteria possess 
CRISPR genes in their genome (111–113). Notably, the different loci of the CRISPR/Cas 
complexes show a great diversity in sequence and gene arrangement depending on the host 
organism. With the help of a computational approach two classes, five types and 16 subtypes 
of CRISPR-Cas complex were identified (114). Type II found in Streptococcus pyogenes is one of 
the simplest and therefore widely used variant only depending on the Cas protein Cas9 for 
silencing endogenous DNA (105,109). 
The defense efficiency of CRISPR/Cas relies on small RNAs which specifically target the foreign 
DNA to allow silencing/cleaving by Cas proteins. As a first step during the infection, double 
stranded viral DNA invades the host and is recognized as exogenous DNA. If the host contains 
one or more CRISPR loci, it responds by digesting the foreign DNA into ~30 bp DNA fragments 
and integrates them as protospacer into the own genome at the proximal end of the CRISPR 
array (97,104,105). As a second step during the expression and interference phase, the 
genomically integrated repeat-spacer elements are transcribed into the precursor CRISPR RNA 
(pre-crRNA). This pre-crRNA is enzymatically cleaved by Cas proteins to achieve a mature 
crRNA (115,116). In the third and last step of active immune defense, the crRNA containing a 
spacer sequence complementary to the invading DNA directs the Cas proteins to the foreign 
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DNA. The Cas proteins then silence the invading genes (117,118). An adaptive immune 
response is acquired (Figure 7). 
 
Figure 7 Mechanism of adaptive immune system of bacteria and archaea. 
Immunization: foreign DNA, like double-stranded viral DNA, invades the cell and is recognized by the Cas complex. 
After cleavage of the foreign DNA into small fragment, the Cas complex integrates those fragments as novel repeat-
spacer units into the hosts genome at the leader end of the CIRPSR locus. Active immune defense: The repeat-spacer 
array is transcribed into pre-crRNA and processed into mature crRNA by a Cas complex. The so build 
crRNA:tracrRNA:Cas complex can now specifically bind to the viral DNA invading the cell and cleave it into harmless 
fragments. L: CIRSPR leader, triangles: repeats, rectangles: spacers. (Figure adapted after (110)) 
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2.3.3. Components for a CRIPSR/Cas system of type II from Streptococcus pyogenes  
The CRISPR loci were already described by Ishino et al. in 1987 (119), but their function was 
not understood until 2002 (111). A CRISPR locus typically consists of two main elements. First 
the CRISPR-associated (cas) genes encoding for multiple proteins like nucleases, polymerases, 
helicases or polynucleotide-binding proteins (120). Second a CRISPR array consisting of several 
noncontinuous direct repeats separated by variable spacer regions. Each direct repeat together 
with one adjacent spacer encodes for one crRNA (97). The repeat sequences are 23 to 47 bp 
long and highly conserved within a given CRISPR locus while having a broad sequence variety 
across microbial species (110,111). The repeat sequences contain information for the 
processing of the pre-crRNA into a mature crRNA. The spacer sequences on the other hand are 
21 to 72 bp long and each spacer codes for a unique foreign DNA target sequence (110,111).  
In type II CRISPR/Cas systems an additional trans-activating crRNA (tracrRNA) is required. The 
tracrRNA binds to the partially complementary pre-crRNA and initiates the recruitment of 
RNAse III and Cas9 protein to achieve a mature Cas9:crRNA:tracrRNA complex (see Figure 8A) 
(105). Hence, only with the help of the tracrRNA, a successful inactivation of exogenous DNA 
can be achieved (105,116). The Cas9:crRNA:tracrRNA complex can bind to the crRNA target 
sequence only if a PAM is located directly after the binding region. It should be noted that the 
PAM sequence strongly depends on the respective system and Cas protein (121). For the type II 
system the PAM sequence is NGG (116).  
For type II CRISPR/Cas Cas9 is the sole protein responsible for cleavage of the exogenous DNA. 
Therefore, Cas9 contains two endonuclease domains, a HNH nuclease domain in the middle of 
the protein and a RuvC-like nuclease domain near the amino terminus (122). After binding of 
the Cas9:crRNA:tracrRNA complex to the foreign DNA, the complementary DNA strand is 
cleaved three base pairs upstream of the PAM sequence by the Cas9 HNH domain. The 
noncomplementary DNA strand is cleaved endonucleolytically by the RuvC-like domain and 
subsequently trimmed by a 3´-5´ exonuclease (105). Through this process, blunt end DNA 
cleavage of both (supercoiled) plasmid and linear DNA is achieved (105,123). 
 
2.4. Multiple novel CRISPR approaches for targeted genome engineering 
2.4.1. Development from a naturally occurring system to a valuable synthetic tool  
In 2012, Jinek et al. first invented a strategy that allowed for the targeted DNA cleavage in vivo 
with a programmed CRISPR/Cas9 system. Therefore, they developed a chimeric single-guide 
RNA (gRNA or sgRNA) combining crRNA and tracrRNA to a short synthetic RNA. A gRNA is 
composed of a fixed scaffold sequence, which is necessary for the binding of Cas9, and an 
unspecified 20 nucleotide long spacer, which is designed by the user to target a specific 
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sequence (105,106). Therefore, by changing the 20-nucleotide spacer, the target destination of 
Cas9 can be easily changed (see Figure 8B).  
 
 
Figure 8 Comparison of naturally occurring (a) and engineered (b) type II CRSPR/Cas9 system.  
(Figure adapted after (107)) 
 
The CRISPR/Cas9 system is directly portable, e.g. in human cells. Hence, for targeted genome 
engineering, it is sufficient to implement the genes for Cas9 and a gRNA, whose spacer is 
homologous to the target DNA site (103,124). For efficient targeting, a PAM site has to be 
present in the target DNA immediately adjacent to the gRNA homology region. After successful 
targeting, the endonuclease domains of Cas9 induce a blunt end DSB 3 bp 5´ of the PAM (125). 
The DSB is either repaired by error-prone NHEJ or by precise HDR (126). NHEJ often leads to 
insertions, deletions or frameshifts, which makes it a great tool for genetic knock-outs. When a 
repair template with homologous arms is provided, DSB repair is performed using HDR. The 
template will be integrated into the target gene, giving precise information about the desired 
genetic modification. HDR thus creates a variety of options for targeted genome engineering 
(127,128). 
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After the publication of Jinek et al. in 2012, in 2013 the first papers about CRISPR-based 
genome engineering in mammalian cells were published (103,129). Only five years later, 6300 
CRISPR-related publications are listed on PubMed, among others demonstrating efficient and 
precise genome engineering in a brought range of cell lines and organism (for an overview from 
2014 check (107)). This demonstrates the importance of CRISPR genome editing strategies, as 
well as their potential for laboratory research and therapeutic applications (97,100). 
 
2.4.2. CasEMBLR - A practical approach using CRISPR/Cas9 for genomic integration in 
yeast  
Genome engineering, or more precisely chromosomal integration of foreign DNA, was carried 
out by HR for decades. Even though HR is relatively efficient in Saccharomyces cerevisiae, the 
efficiency of HR is only 10-6 to 10-4 (130). In order to enhance the efficiency of chromosomal 
integration, in 2015 Jakociunas et al. published a method called CasEMBLR (Cas9-facilitated 
multiloci integration of assembled DNA parts into S. cerevisiae chromosomes, as a reference to 
the two mutually important methods DNA Assembler and Cas9-facilitated integration). 
CasEMBLR allows the marker-free multiloci integration of in vivo assembled DNA parts. For 
CasEMBLR two plasmids have to be transferred into the yeast cell simultaneously with the DNA 
parts: a plasmid bearing an active Cas9 and a plasmid containing one or more gRNA(s) targeting 
one or more loci for genomic integration. It is noteworthy that the DNA template does not have 
to be assembled before transformation. Instead linear DNA parts, each with 50 bp overlap, can 
simply be co-transformed, are in vivo combined by HR and therefore build the new gene of 
interest (Figure 9)(99). 
 
 
Figure 9 Construction and integration of the CasEMBLR method. 
For marker-free multiloci integration in vivo a gRNA plasmid containing one gRNA for each integration side needs 
to be designed and integrated together with linear DNA template fragments. gRNA plasmids and DNA fragments 
are co-transformed into a yeast cell already containing a Cas9 plasmid. (Figure adapted after (99)) 
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The efficiency of the chromosomal integration depends on the targeted genome locus and the 
number of simultaneous genomic integrations. According to Jakociunas et al. an efficiency of 
nearly 100 % can be achieved for a single locus, ~ 60 % for two loci and ~30 % for three loci 
at the same time (99). In order to achieve maximum efficiency, a web-tool named CRISPy was 
invented for the design of the gRNA target sequence (131). CasEMBLR allowed the simple and 
straight forward integration of multiple genes in the exemplary genomic sites ADE2, HIS3, 
and/or URA3 without the need of a marker or the pre-assembly of parts (99). Hence, CasEMBLR 
delivers a really useful tool for genomic integration and was used for the integration of various 
switches in the scope of this thesis (4). CasEMBLR is a perfect example for the advantages 
CRISPR-based systems offer to every-day research, especially with the focus on SynBio 
applications.  
 
2.4.3. Versatile approaches to optimize the CRISPR/Cas9 target binding specificity  
The CRISPR/Cas9 system delivers a simple and modular tool for genome engineering, further 
it allows to precisely target, cleave and manipulate DNA. Any possible sequence can be targeted, 
as long as the sequence is unique in the respective genome and a PAM is present immediately 
adjacent to the targeted site (107).  
Unfortunately, depending on the gRNA sequence, partial sequence homologies of a given gRNA 
throughout the genome will occur. Right from the start the extent of off-target binding/cleavage 
events was one of the major concerns regarding any genome engineering tool (100). Various 
studies indicate that off-target effects for the CRISPR/Cas9 system vary in frequency. In 2014, 
Sander and Joung reported that it is difficult to predict the off-target sites and their influence 
on the host, especially since it is not completely understood why some sites are cleaved whereas 
others are not (107). Either way, researchers aim for reducing off-target effects of 
CRISPR/dCas9, which is extraordinarily important particularly for medical applications 
(100,107).  
A simple approach to reduce off-target effects may be to lower the amount of gRNA and Cas9, 
which is expressed in the host. It seems, that the reduction of an off-target effect also leads to 
lower efficiency of the on-target engineering. Hence, this approach is only partially promising 
(107). Therefore, a more complex approach was envisioned – optimization of the gRNA. Many 
(web-based) computer tools for targeted gRNA design have been established, which allows one 
to find a/multiple gRNA(s) fitting exactly to the users’ requirements (132,133). Theoretically, 
these computer-based tools work well, but they do not always live up to the expectations, so 
that researchers have to repeat experiments with a different gRNA setup (99). Another 
approach to decrease off-target effects is to use a gRNA shortened at the 5´end of their 
complementarity region. In 2014 Fu et al. demonstrated that a truncated gRNA with only 17 or 
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18 nucleotides of complementarity generally functions as efficient as full-length gRNAs. At the 
same time the off-target mutagenic effects are reduced and the sensitivity to mismatches at the 
gRNA:DNA interference is increased (134). 
In addition to the optimization of gRNA, Cas9 can be modified to not only achieve better off-
target rates, but also to expand the field of applications. To increase specificity, Le Cong et al. 
engineered Cas9 in a way, that the nuclease was converted into a nickase (129). As mentioned 
above Cas9 cleaves the DNA using a RuvC-like domain together with an HNH nuclease domain, 
leading to a DSB inducing either NHEJ or HDR. Le Cong et al. performed an aspartate-to-alanine 
substitution (D10A) in the RuvC-like domain to only nick one DNA strand. Alternatively, to 
achieve a Cas9 nickase a H840A substitution of the HNH domain is possible. Nicked DNA is 
typically repaired by either seamless or high-fidelity HDR (105,129). In order to achieve a DSB, 
two nickases targeting opposite DNA strands can be used together with two gRNAs, each 
targeting one side of the DNA strand. The gRNAs bind in a distance of 4 to 100 bp, leading to 
efficient indel mutations or HDR events in the presence of a donor template (135–137). Since 
it is unlikely that two off-target nicks will occur close enough to cause a DSB, this double nickase 
setup lowers off-target effects drastically. However, it was shown by several studies, that 
monomeric nickases themselves can induce indel mutations at certain genomic loci (135–137). 
A system, where both nickase monomers are strictly co-dependent on each other to induce 
genome engineering activity, may solve this problem (107). Accordingly, Cas9 nickases do not 
only reduce off-target effects, but also allow specific nicking of the DNA and, in a dimer-
approach increase the occurrence of HDR, while decreasing the one of NHEJ. 
Another approach to optimize off-target effects, is the genetic modification of wildtype Cas9 
towards a high fidelity enzyme (97). In 2015, the first variants of high fidelity Cas9 
endonucleases were published. By rational mutagenesis and structure-guided protein 
engineering, Slaymaker et al. were able to improve the specificity of Streptococcus pyogenes Cas9 
(SpCas9) to an “enhanced specificity” SpCas9 (eSpCas9). It could be demonstrated by targeted 
deep sequencing and unbiased whole-genome off-target analysis that eSpCas9 variants reduce 
off-target effects while maintaining a robust on-target cleavage (138). Even more promising is 
the evolved Cas9 (evoCas9) variant, published 2018 by Casini et al. With the help of a yeast-
based assay that enabled simultaneous evaluation of on- and off-target activity, they screened 
for random mutations in SpCas9. Afterwards they combined four promising mutations into 
evoCas9. EvoCas9 was demonstrated to maintain near wild type on-target efficiency, while off-
target effects are dramatically decreased even in comparison to other rationally designed Cas9 
variants like eSpCas9. Even in a long-time experiment over 40 h, nearly no off-target effects 
were detected (139). These enhanced Cas9 variants provide promising high-fidelity enzymes, 
which allows genome engineering with high specificity and nearly no off-target effects. 
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Despite all the advantages of CRISPR, the main disadvantage is still that the target site must 
always have an appropriate PAM sequence (105). As a result, not every DSB can be made with 
the desired precision. Thus, Kleinstiver et al. demonstrated, that SpCas9 can be modified to 
specifically recognize altered PAM sequences. Alternatively they describe two smaller-sized 
Cas9 orthologues from Streptococcus thermophilus and Staphylococcus aureus, both efficiently 
working in bacteria and human cells and recognizing altered PAM sequences (121). Other 
orthogonal Cas9 proteins recognize gRNAs with different Cas9-binding modules (140). The 
usage of Cas9 proteins which recognize altered PAM sequences or gRNAs will expand the 
options for specific targeting and allows one to switch between distinct programs by controlling 
the expression of the Cas9 proteins targeted (for an example see 2.5) (5). 
 
2.4.4. Using inactive Cas9 variants for targeted transcription repression or activation 
CRISPR/Cas9 systems are not only a promising tool in terms of genetic modification, but also 
for genetic regulation of cells by robust and precise targeting of genes for expression or 
repression. To achieve this aim, a catalytically dead Cas9 (dCas9) was established, containing 
a silencing mutation (like D10A and H841A) in both nuclease domains of Cas9 (105,141). Qi 
et al. demonstrated in 2013, that a dCas9 can form a complex with a co-expressed gRNA to 
specifically recognize and bind DNA. This complex can modify the transcription of an arbitrary 
gene without causing genetic modifications of the target sequence (141). Hence, with 
CRISPR/dCas9 a platform was generated, allowing RNA-guided DNA recognition and 
regulation. 
The first system established on this platform was called CRISPR interference (CRISPRi). With 
the help of a specific gRNA, dCas9 binds to a target gene. The complex sterically blocks 
transcription with an up to 1000-fold repression. Multiple gRNAs can be used in parallel to 
simultaneously silence multiple genes. Furthermore, CRISPRi can be used to knock down 
endogenous genes in bacteria, as well as gene expression in mammalian cells (141). The 
repression effect can even be enhanced by fusing a transcription repressor like KRAB to Cas9 
(106). Target gene repression or knock-down is highly specific; off-target effects have not been 
reported (106,141). Therefore, it is not surprising, that already in 2013, a system called CRISPR 
activation (CRISPRa) was published. By fusion of transcription activators like VP16 to Cas9, 
targeted gene expression could be achieved in multiple organisms, among them the yeast 
S. cerevisiae and human cells (106,135).  
CRISPRi and CRISPRa can be used for multiplexed control of endogenous and synthetic genes, 
simply by implementing multiple gRNAs, where the respective dCas9-effector fusions are 
constrained to only one direction of regulation for all targeted loci which is either activation or 
repression. To overcome those limitations Zalatan et al. invented a strategy, where the gRNA 
  
Introduction   25 
overtakes both, target specificity and regulatory function (5). Mali et al. demonstrated in 2013, 
that a sgRNA can be extended with a MS2 hairpin loop to recruit an activator to a reporter gene 
in human cells (135). Zalatan et al. expanded this strategy and, with the help of different hairpin 
loops, directed three orthogonal RNA-binding modules, which are fused to activators or 
repressors to reporter genes in S. cerevisiae and in human cells (Figure 10). They demonstrated 
that the RNA-binding modules can be used in parallel, without influencing each other. This 
allowed the successful regulation of multiple genes at the same time to build a highly branched 
biosynthetic pathway in yeast (5).  
 
 
Figure 10 Comparison of regular CRISPR (left) and multi-domain scaffolding RNAs (right). 
Left: Repression or activation is regulated by dCas9 only. The gRNA only encodes the locus of action. Right: Repression 
and activation of target gene transcription is mediated due to dCas9 and scRNA directed regulation. Hence, the 
scRNA encodes both, locus and action. (Figure adapted after (5)) 
 
In summary, the CRISPR/dCas9-scRNA system provides a reversible and straightforward 
method for the simultaneous ON/OFF regulation of multiply genes and therefore, the design of 
complex switching programs and pathways. Due to the modular character and the simple 
application, the CRISPR/dCas9-scRNA system can serve as a basic toolbox to design complex 
switches, as illustrated in this work.  
 
2.4.5. Further applications for and with CRISPR systems 
Like active CRISPR/Cas9, catalytically inactive CRISPR/dCas9 systems only require a dCas9 
protein and guide RNAs, which makes them highly flexible and designable. Furthermore, dCas9 
can be fused to multiple effector proteins. For example, the fusion of a dCas9 or Cas9 nickase 
to base editors like the cytidine deaminase APOBEC1, allows precise integration of point 
mutations (142,143). This is especially useful for medical applications, where accuracy is 
absolutely critical (144).  
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Another possibility is to fuse the epigenetic modifier like the catalytic core domain of the human 
acetyltransferase p300 (145) or the catalytic domain of the DNA methyltransferase 3A 
(DNMT3A) (146) to dCas9. These fusions allow one to alter gene expression without inducing 
a DSB due to epigenetic modifications such as histone acetylation. Since the epigenetic 
modifiers are specific for a particular chromatin and DNA modification, among others they 
allow for the identification of the effects of a single epigenetic marker (146). This specificity is 
also their main disadvantage, since they can only be used cell-type and context-dependent (97).  
A third application for CRIPSR is to fuse an inactive dCas9 to a fluorescent marker like GFP to 
enable live cell imaging. Researches successfully turned dCas9 into a customizable DNA labeler, 
allowing among others the visualization of repetitive or nonrepetitive genomic sequences, 
telomere length change or movement/the dynamics of gene loci (147).  
A field, which was revolutionized trough the possibilities of CRISPR/Cas were genome wide 
screenings (148). Due to large gRNA libraries, large-scale forward genetic screening is possible. 
This is especially important for the genome-wide studying of diseases or phenotypes, for which 
the underlying genetic cause is not known (149,150). The goal of those genetic screens is to 
generate a large population of cells containing multiple mutations or knock-outs in a targeted 
set of genes. Researches then use these cells to identify the genetic perturbations that result in 
a desired phenotype (68,151).  
 
2.5. Complex genetic circuits based on CRISPR systems 
Collectively, the described techniques and applications establish the CRISPR platform as a 
powerful tool for modular, scalable, orthogonal, highly specific and practical genome 
engineering. Some highly complex control systems have already been published, demonstrating 
the possibilities of CRIPSR to solve problems that previously seemed unsolvable. This paragraph 
will give two examples for genome engineering tools that solve such problems in the yeast 
S. cerevisiae. 
The first problem concerns production of cell factories. Cell factories come to use, when 
environmentally damaging petro-chemistry productions are to be replaced or when natural 
bioproduction is not possible (151). Nowadays, the design and establishment of cell factories 
needs rather extensive multi-step metabolic engineering. Hence a tool is needed, which 
simplifies and speeds up the generation of cell factories (31). In 2017 Vanegas et al. published 
a CRISPR tool called SWITCH solving the problem at least partially. Due to the integration of 
two CRISPR tools, one for genetic engineering and one for pathway control, SWITCH allows to 
iteratively alternate between a genetic engineering state and a pathway control state. They 
build a whole pathway by integration of the necessary genes in engineering cycles. Each 
engineering cycle is performed by a different CasX species (151). As the first step of an 
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engineering cycle, the casX genes are integrated into one of the specific loci (152) in the 
specially designed yeast expression strain. During step two linear parts are combined and 
integrated into the genome by gRNA mediated genetic engineering. In a third step, by addition 
of a target gRNA plasmid, the casX cassette is either eliminated or by addition of a template 
replaced by a dcasX or dcasX-effector cassette. Both possibilities are carried out by recombination 
trough CasX itself. In the fourth and last step, a new gRNA directs the dCas9/dCas9-effector to 
a target gene for up- or down-regulation. This cycle can be repeated by the usage of another 
casX/dcasX variants. Therefore, the simple and scalable genome engineering towards a 
functional cell factory has been established (151). 
The second problem concerns the building of novel decision-making regulatory networks (153). 
It remains difficult to design and implement complex synthetic circuits in eukaryotes, due to 
arbitrarily interconnections, transcriptionally leaky components or the fact, that mainly 
analogue response mechanisms are used (154). In 2017, Gander et al. established a CRIPSR-
based system, that allowed the construction of digital genetic circuits of great complexity as 
quickly and easily as an electric circuit would be. Therefore, they developed a set of low-
variability genetic parts, that have the same programmable input and output signals (same 
molecular type), as in electronics, allowing them to be wired together. Their system is based on 
dCas9-Mxi1 NOR gates (154). Mxi1 is a chromatin remodelling repression domain that recruits 
histone deacetylases (155,156). By fusion of Mxi1 to dCas9, a NOR gate with inducible strong 
repression was achieved showing minimal leakage. The gRNA inputs were directly converted 
into gRNA outputs, creating a digital output signal. Since the input and output both are gRNAs, 
multiple NOR gates can be wired together to build large genetic circuits. Hence, Gander et al. 
were able to combine up to seven gRNAs, including repression cascades with up to seven layers. 
The experimental setup was combined with intense modeling that allowed the authors to 
predict the circuits behaviors (154). This combination of modeling and experimental research 
is a perfect example for a successful SynBio application. Based on this conclusion, it can be 
confirmed that the design and implementation of complex genetic switches according to the 
idea of SynBio is a really promising approach to solve problems in both areas, basic research 
and medical applications. 
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2.6. Objective 
Targeted genome engineering and gene regulation play a key role for basic research and 
industrial applications. Multiple setups have already been established for e.g. synthetic 
production of bio-derived materials in the yeast S. cerevisiae (2,3). Nevertheless, there still is a 
great need for well-defined switching systems and modular genetic circuits in S. cerevisiae. The 
presented work aims to characterize various switches and to assemble them into a modular 
toolbox. A three component CIRPSR/dCas9 system (5) should be tested to determine whether 
it is suitable as a basic route for genetic regulation (Figure 11). The genes should be genomically 
integrated into the yeast S. cerevisiae either by simple HR (94–97) or with the help of the 
method CasEMBLR (99). If the method CasEMBLR turns out to be successful, it should be 
established in the lab for future genomic integrations.  
For targeted gene regulation, the three components of the genetically integrated CRIPSR/dCas9 
complex should be individually and independently expressible. It was aimed to use different 
inducible expression strategies based on different induction mechanisms. As part of this work, 
three different switches should be tested. The selected switches are either inducible by the 
carbon source galactose (56), the antibiotic doxycycline (74), or the steroid hormone β-
estradiol (45). Promising switches should be combined into an AND gate. Both, the switches 
and the AND gates should be analyzed regarding their basal activity, expression levels and dose-
dependency. Selected AND gates should be further analyzed with the help of collaborations 
through a model and single-cell microfluidic measurements (4). In addition, a positive 
feedback-loop should be implemented, which allows the inducer-independent cell growth after 
a short induction phase. 
When successfully expressed, the three CIRSPR/dCas9 components should form a functional 
complex and bind specifically to the desired binding region. For simple detection via flow 
cytometry, the fluorophore Venus should be utilized as reporter gene. In addition, a setup 
should be implemented, that allows the verifiable gene expression of virtually every gene of 
interest. It was aimed to implement the ribosomal skipping peptide T2A (157), which after 
CRIPSR/dCas9-mediated expression of the GOI also enables the expression of the fluorophore 
tGFP. As a proof-of-concept two well-detectable GOIs should be used for a GOI-T2A-tGFP setup. 
The different reporter gene setups should be characterized in combination with the switches 
and AND gates. In order to demonstrate functionality, targeted gene expression of a reporter 
gene should be verified. 
This work can be seen as a proof-of-concept study for the development and characterization of 
a new toolbox for yeast. 
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Figure 11 Generation of genetic switches and assembly to genetic circuits.  
The target switches will be implemented on DNA level. Therefore, the established DNA will be transformed into 
S. cerevisiae cells.  The switches are based on a three component CRISPR/dCas9 system, which will be expressed either 
constitutively or inducible by various inducers. After all three components are expressed, they will build a complex 
for targeted binding to the binding region. The transcription activator will enable expression of one or more reporter 
genes. 
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3.1. Microorganisms 
For this study the following microorganisms were utilized.  
 
E. coli strains with the genotype described in Table 1 were used. 
Table 1 Purchased bacterial strains. 
Bacterial strains  
E. coli DH5α F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG Φ80dlacZΔM15 
Δ(lacZYA-argF)U169, hdR17(rK- mK+), λ– 
Top10 mcrA, Δ(mrr-hdRMS-mcrBC), Phi80lacZ(del)M15, ΔlacX74, deoR, recA1, 
araD139, Δ(ara-leu)7697, galU, galK, rpsL(SmR), endA1, nupG 
 
S. cerevisiae strains received from the Zalatan lab (University of Washington) (5) are described 
in Table 2. S. cerevisiae strains generated in this study are described in Table 3.  
Table 2 Purchased yeast strains. 
S. cerevisiae strains  
SO992 (W303 derivate) MATa ura3 leu2 trp1 his3 can1R ade 
cSLQ.sc002 SO992 HO::rtTA-msn2_hphR 
cSLQ.sc003 cSLQ.Sc002 trp1::pTET07-Venus 
yJZC02 cSLQ.Sc002 trp1::pTET01-Venus 
yJZC03 cSLQ.Sc002 trp1::pTET02-Venus 
yJZC04 cSLQ.Sc002 trp1::pTET03-Venus 
 
Table 3 Yeast strains generated in this study.  
Name Integrated genes Origin 
Ssw, 1x tetO trp1::TET01-Venus leu2::MCP-VP64_Gal10-dCas9, scRNA (plasmid)  yJZC02 
Ssw, 2x tetO trp2::TET01-Venus leu2::MCP-VP64_Gal10-dCas9, scRNA (plasmid)  yJZC03 
Ssw, 3x tetO trp3::TET01-Venus leu2::MCP-VP64_Gal10-dCas9, scRNA (plasmid)  yJZC04 
Ssw, 7x tetO trp7::TET01-Venus leu2::MCP-VP64_Gal10-dCas9, scRNA (plasmid)  cSLQ.sc003 
dC-VP64, 1x tetO trp1::TET01-Venus leu2::dCas9-VP64, gRNA (plasmid)  yJZC02 
dC-VP64, 1x tetO trp1::TET02-Venus leu2::dCas9-VP64, gRNA (plasmid)  yJZC03 
dC-VP64, 1x tetO trp1::TET03-Venus leu2::dCas9-VP64, gRNA (plasmid)  yJZC04 
dC-VP64, 1x tetO trp1::TET07-Venus leu2::dCas9-VP64, gRNA (plasmid)  cSLQ.sc003 
AND, 3x tetO ade2::lexA-MCP-VP64_Gal10-dCas9 his3::TET03-Venus_lexA-ER-B112, 
scRNA (plasmid)  
cSLQ.sc002 
AND, 7x tetO ade2::lexA-MCP-VP64_Gal10-dCas9 his3::TET07-Venus_lexA-ER-B112, 
scRNA (plasmid)  
cSLQ.sc002 
AND, GO ade2::lexA-MCP-VP64 Gal10-dCas9 his3::TET07-app8-Goase-T2A-tGFP_ 
lexA-ER-B112, scRNA (plasmid)  
cSLQ.sc002 
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AND, vNAR ade2::lexA-MCP-VP64 Gal10-dCas9 his3::TET07-app8-vNAR-His-Tag-T2A-
tGFP lexA-ER-B112, scRNA (plasmid)  
cSLQ.sc002 
AND, GO, pFL ade2::lexA-MCP-VP64 Gal10-dCas9 his3::TET07-app8-Goase-T2A-tGFP_ 
lexA-ER-B112, scRNA (plasmid), pFL (plasmid)  
AND, GO 
Ubi, wt ade2::lexA-MCP-VP64 Gal10-dCas9 his3::TET07-UbiY-tGFP_ lexA-ER-B112  cSLQ.sc002 
Ubi, pJZC588 ade2::lexA-MCP-VP64 Gal10-dCas9 his3::TET07-UbiY-tGFP_ lexA-ER-
B112, scRNA (plasmid) 
cSLQ.sc002 
Ubi, pJZC588 + 
AH019 
ade2::lexA-MCP-VP64 Gal10-dCas9 his3::TET07-UbiY-tGFP_ lexA-ER-
B112, scRNA (plasmid), pFL (plasmid)  
cSLQ.sc002 
 
3.2. Plasmids 
3.2.1. Plasmids for genomic integration into the yeast genome 
The plasmids pFRP880 (#58437) (45), pJZC519(#62278) and pJZC638 (#62283, 3.2.1) (5) 
were received from addgene. These plasmids were designed for genetic integration into the 
yeast genome and do not contain a yeast origin of replication (ori). Instead the plasmids 
maintain a homology region, which is necessary for the integration by homologous 
recombination. For genomic integration the plasmids were digested with restriction enzymes. 
The utilized enzymes, and their digestion sites are marked in the plasmid cards. All plasmids 
are E. coli – S. cerevisiae shuttle vectors, which mediate ampicillin resistance in the bacterial 
host.  
 
Figure 12 Plasmid map of pFRP880. 
The plasmid pFRP880 contains the following genes: His homology: region for homologous recombination into the 
yeast genome, His3p: selectable marker, f1 ori: origin of replication in T7 phage, E.coli lexA gene: bacterial LexA 
DNA-binding protein (88), ER: hormone-binding domain of the human estrogen receptor (47), haB112: 
transcriptional activation domain (91), CYC1: terminator sequence, ColE1 origin: origin of replication in E. coli, AmpR: 
gene for β-lactamase, mediating ampicillin resistance in E. coli. The plasmid has to be digested for genomic 
integration at PacI/KpnI: digestion sites for homologous recombination after linearization.  
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Figure 13 Plasmid map of pJZC519 (#62278) and pJZC638 (#62283). 
The plasmids pJZC519 (A) and pJZC638 (B) both contain the following genes: LEU2 UTR homology: regions for 
homologous recombination into the yeast genome, LEU2: selectable marker, dCas9: catalytically inactive Cas9 
S. Pyogenes with mutations in the RuvC1 and HNH domains to render it catalytically inactive (105,141), NLS: Nuclear 
localization signal, Tadh1: strong terminator derived from C. albicans, f1 ori: origin of replication in T7 phage, AmpR: 
gene for β-lactamase, mediating ampicillin Amp) resistance in E. coli, ColE1 origin: origin of replication in E. coli. 
Plasmid pJZC518 contains TDH3: strong constitutive promoter, in front of the dCas9 gene, which is genetically fused 
to VP64: transcriptional activation domain, derived from the Large T antigen. Plasmid pJZC638 contains a ADH1: 
strong constitutive promotor, controlling MCP: bacteriophage coat protein binding the scRNA MS2 stem loop, that 
is genetically fused (135) to VP64: transcriptional activation domain, derived from the Large T antigen. MCP-VP64 is 
terminated by the Eno2t: strong terminator. The plasmid also contains the dCas9 under control of pGal10: Galactose 
inducible promotor. Both plasmids have to be digested for genomic integration at PmeI: digestion sites for 
homologous recombination after linearization. 
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3.2.2. CEN/ARS-plasmids for gRNA/scRNA delivery 
The plasmid pJZC523 (#62320), pJZC588 (#62315) and pJZC625 (#62321) (5) were received 
from addgene. The plasmids are E. coli – S. cerevisiae shuttle vectors. They contain the CEN/ARS 
motif as yeast origin, the gene for uracil prototrophy in yeast cells and the AmpR gene to mediate 
ampicillin resistance in the bacterial host.  
 
 
Figure 14 Plasmids cards for gRNA/scRNA plasmids. 
All plasmids, namely pJZC523 (A), pJZC588 (B) and pJZC625 (C) contain the following genes: tetO gRNA: 20 bp long 
binding region to the tet Operator, gRNA scaffold: gRNA with stem loop for dCas9 binding, f1 ori: origin of 
replication in T7 phage, AmpR: gene for β-lactamase, mediating ampicillin resistance in E. coli, CEN/ARS: 
autonomously replicating sequence (ARS) and yeast centromere. URA3: selection marker. ColE1 origin: origin of 
replication in E. coli. The plasmid pJZC523 an pJZC588 also contained the genes: SNR52 promotor: minimal RNA 
polymerase III promotor for yeast cells, SUP4 terminator: terminator with a T7GT6 sequence for RNA polymerase III. 
The plasmid pJZC588 also contained the gene: 2xms2_ds6: two copies of the MS2 stem loop (wt, f6) for MCP binding 
(5). The plasmid pJZC625 also contained the genes: ADH1: strong constitutive promotor for RNA polymerase II, HH 
and HDV: self-cleaving ribozymes (158), 1xms2: one copy of the MS2 stem loop (wt) for MCP binding (135), Tadh1: 
strong terminator derived from C. Albicans for RNA polymerase II.  
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3.2.3. Plasmids needed for genomic integration by CasEMBLR 
The plasmids p414_Cas9, p425-αAde_gRNA and p425-αHis3_2_gRNA (99) were received from 
the Süß lab (TU Darmstadt). All three plasmids are E. coli – S. cerevisiae shuttle vectors. 
 
Figure 15 Plasmid map of CasEMBLR plasmids. 
All plasmids, namely p414_Cas9 (A), p425-αAde_gRNA (B) and p425-αHis3_2_gRNA (C) contain the E. coli genes: 
AmpR: gene for β-lactamase, mediating ampicillin resistance in E. coli. ColE1 origin: origin of replication in E. coli, f1 
ori: origin of replication in T7 phage. p414_Cas9 also contained the yeast genes: CEN/ARS: autonomously replicating 
sequence (ARS) and yeast centromere (CEN), TEF1: strong constitutive promotor for RNA, Cas9: catalytically active 
Cas9, NLS: Nuclear localization signal peptide derived from the Large T antigen, CYC1: terminator sequence, TRP1: 
selection marker. The plasmids p425-αAde_gRNA (B) and p425-αHis3_2_gRNA also contained the yeast genes: LEU: 
selection marker, f1 ori: origin of replication in T7 phage, SNR52 promotor: minimal RNA polymerase III promotor 
for yeast cells (159), αAde or αHis3_2 gRNA: 20 bp long binding region to a sequence encoded on the ade2 gene or 
his3 gene in the yeast genome (99), gRNA scaffold: gRNA with stem loop for dCas9 binding (105,106), SUP4 
terminator: terminator with a T7GT6 sequence (159), ColE1 origin: origin of replication in E. coli, AmpR: gene for β-
lactamase, mediating ampicillin resistance in E. coli, 2µ ori: origin of replication in yeast. 
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3.2.4. Additional plasmids utilized for part amplification 
For the construction of plasmids and gene constructs, different genes of interest were amplified 
from certain plasmids. Those plasmids are listed in Table 4. The plasmids pJZC532 and 
pSLQ1119 were kindly provided by the Zalatan lab. The plasmid pFRP793 (#58434) was 
received from addgene.  
Table 4 Plasmids used for GOI part amplification. 
Name Gene of interest 
pFRP793 4x lexA 
pJZC532 3x tetO 
pSLQ1119 7x tetO 
pYD_Leu_app8 app8 
pET22b GOase 
PCT_2A-GFP T2A-tGFP 
pJZC588/lexA 4x lexA in scRNA backbone 
pAH013 4x lexA_scRNA with ribozymes 
 
3.2.5. Plasmids generated in this study 
The plasmids in this chapter are E. coli – S. cerevisiae shuttle vectors. For the genomic integration 
into both CasEMBLR loci at the same time, the plasmid pAH006 (5.2) was generated by ligation 
of the p425-αAde_gRNA and the αHis3_2 gRNA during this study.  
 
Figure 16 Plasmid map of pAH006. 
The plasmid pAH006 contains the following genes: LEU: selection marker, f1 ori: origin of replication in T7 phage, 
SNR52 promotor: minimal RNA polymerase III promotor for yeast cells, αAde and αHis3_2 gRNA: 20 bp long binding 
region to a sequence encoded on the ade2 gene or his3 gene in the yeast genome, gRNA scaffold: gRNA with stem 
loop for dCas9 binding, SUP4 terminator: terminator with a T7GT6 sequence, ColE1 origin: origin of replication in E. 
coli, AmpR: gene for β-lactamase, mediating ampicillin resistance in E. coli, 2µ ori: origin of replication in yeast. 
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In order to achieve inducibility by ES without the necessity of genetic integration (5.5), the hTF 
LexA-ER-B112 was integrated on a plasmid named pAH015.  
Figure 17 Plasmid map of pAH015. 
The plasmid pAH015 contains the following genes: ColE1 origin: origin of replication in E. coli, AmpR: gene for β-
lactamase, mediating ampicillin resistance in E. coli, 2µ ori: origin of replication in yeast, LEU: selection marker, f1 ori: 
origin of replication in T7 phage, E.coli lexA gene: bacterial LexA DNA-binding protein, ER: hormone-binding domain 
of the human estrogen receptor, haB112: transcriptional activation domain, CYC1: terminator sequence. 
 
The plasmid pAH019 contains the genes for a positive feedback loop (5.4).  
 
Figure 18 Plasmid map of pAH019. 
The plasmid pAH019 contains the following genes: ColE1 origin: origin of replication in E. coli, AmpR: gene for β-
lactamase, mediating ampicillin resistance in E. coli, 2µ ori: origin of replication in yeast, TRP1: selection marker, tetO: 
binding region for scRNA from the Tet-systems (5,58,74), dCas9: catalytically inactive Cas9 S. Pyogenes with 
mutations in the RuvC1 and HNH domains to render it catalytically inactive, NLS: Nuclear localization signal.  
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The plasmid pAH021 contains the genes for an ES inducible scRNA flanked by the ribozymes 
HH and HDV (5.5).  The plasmid is a E. coli – S. cerevisiae shuttle vector. 
 
Figure 19 Plasmid map of pAH021. 
The plasmid pAH021 contains the following genes: lexA: binding region for the hTF LexA-ER-B112 (45), HH and HDV: 
self-cleaving ribozymes, tetO gRNA: 20 bp long binding region to the tet Operator, gRNA scaffold: gRNA with stem 
loop for dCas9 binding, 2xms2_ds6: two copies of the MS2 stem loop (wt, f6) for MCP binding, Tadh1: strong 
terminator derived from C. Albicans for RNA polymerase II, ColE1 origin: origin of replication in E. coli, AmpR: gene 
for β-lactamase, mediating ampicillin resistance in E. coli, CEN/ARS: autonomously replicating sequence (ARS) and 
yeast centromere. URA3: selection marker.  
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The plasmids pAH024, pAH025 and pAH026 contain the genes for an ES inducible scRNA, that 
is either unflanked, flanked by the ribozyme HH or flanked by the ribozyme HDV (5.5). All 
three plasmids are E. coli – S. cerevisiae shuttle vectors. 
 
 
Figure 20 Plasmid maps of lexA_scRNA plasmids with different ribozyme setups. 
All plasmids, namely pAH024, pAH025 and pAH026 contain the following genes: lexA: binding region for the hTF 
LexA-ER-B112, tetO gRNA: 20 bp long binding region to the tet Operator, gRNA scaffold: gRNA with stem loop for 
dCas9 binding, ms2 stem loop: MS2 stem loop for MCP binding, Tadh1: strong terminator derived from C. Albicans 
for RNA polymerase II, ColE1 origin: origin of replication in E. coli, AmpR: gene for β-lactamase, mediating ampicillin 
resistance in E. coli, CEN/ARS: autonomously replicating sequence (ARS) and yeast centromere. URA3: selection 
marker. Depending on the plasmid no ribozyme, only HH or only HDV are present (HH and HDV: self-cleaving 
ribozymes).  
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3.3. Standard DNA Ladder 
DNA size standards 
The utilized protein and DNA size standards are listed in Figure 21. 
 
 
Figure 21 Protein and DNA size standards. 
(A) For SDS PAGE, the Blue Prestained Protein Standard, Broad Range (11-190 kDa) (NEB) was utilized. For 1 % 
agarose gels either the 2-Log DNA Ladder (NEB) (B) or the 1kb DNA-ladder (vwr) (C) were utilized. For 3 % agarose 
gels the Ultra Low Range DNA-Leiter II, peqGOLD (vwr) was utilized.  
 
3.4. Oligonucleotides 
The utilized oligonucleotides are listed in Table 5. Oligonucleotides were designed using the 
SnapGene software (GSL Biotech) and synthesized by Sigma-Aldrich. Oligonucleotides used for 
part amplification are marked with a P, oligonucleotides used for colony PCR are marked with 
a C, oligonucleotides used for sequencing are marked with a S and oligonucleotides used for 
RNA analysis are marked with a R. 
 
Table 5 List of Oligonucleotides received by Sigma Aldrich. 
Name Sequence Use 
A1 GGCATACGATGGAAGAGGTAACTTCGTTGTAAAGAATAAGGAAATGATTC
CGGAAGCTTTGGAAGTACTGAAGGATCGTC 
P 
A3 CTTGAAACTTGAAAACACCGAGTTGATAACCCACACAATTATAAGCAAAG P 
A4 ATTGTACCCCCTTTGCTTATAATTGTGTGGGTTATCAACTCGGTGTTTTC P 
A5 GTTATCCTCCTCGCCCTTGCTCACGCACATCATGGTTGTTTATGTTCGGA P 
A6 TCACATCACATCCGAACATAAACAACCATGATGTGCGTGAGCAAGGGCGA P 
A7 TTTTATTGTCAGTACTGATTATAATTGGCCTTATTGCTCAGCGGTGGCAG P 
A10 AAATGAGCTTCAAATTGAGAAGTGACGCAAGCATCAATGGTATAATGTCCA
GAGTTGTGAGGCCTTGGGGCAATTTCGTT 
P 
   
40   Material 
A11 GGAAGTACTGAAGGATCGTCCTTTGTACGCCGAAAAATGGGCACCATTTA
CTAAAGAATTCGGCCAGTGAATTGTAATAC 
P 
A12 TGGGCATCTCGAGAGACATTGTATATGAGAGATATCGAATTCCTGCAG P 
A13 GGATCCCCCGGGCTGCAGGAATTCGATATCTCTCATATACAATGTCTCTC P 
A15 AGACGGTAATACTAGATGCTGA C 
A18 ACATACAGAGCACATGCTCT C 
A20 GGCCTTGGGGCAATTTCGTTAATAAGCAATTCCCCTGTTTCTAAATAGAAC
ATTTCCACACCCACACAATTATAAGCAAA 
P 
A25 AGACTATATTTCTTTTCGAGCTCCCTAG C 
A26 AGAAAAGAAAAGTGGGTAGTATGGCTTC C 
A27 AGAAGCCATACTACCCACTTTTCTTTTC C 
A28 TGCATTATGCAATAGACAGCACGAG C 
Cas1 AGCCACGCGGCTCAAAAGAA C 
Cas2 TGCGCAACAGATCTTCTCTG C 
Cas8 CTGATAGGGAGTGGTAAAGGGCCCGGTACCAACGACATTACTATATATAT P 
Cas9 TTCCTATATTATATATATAGTAATGTCGTTGGTACCGGGCCCTTTACCAC P 
Cas10 GATGGCCAGTCCGATAGAATACTTCTTGTCCTCGAGCATCCCGAATTGAT P 
Cas11 AATTACCCGGATCAATTCGGGATGCTCGAGGACAAGAAGTATTCTATCGG P 
Cas12 ATTAACCCTCACTAAAGGGAACAAAAGCTGCACACAATTATAAGCAAAGG P 
Cas13 GATTGTACCCCCTTTGCTTATAATTGTGTGCAGCTTTTGTTCCCTTTAGT P 
Cas14 GCAAATTTCGTCAAAAATGCTAAGAAATAGAGACGAAAGGGCCTCGTGAT P 
Cas15 AAATAGGCGTATCACGAGGCCCTTTCGTCTCTATTTCTTAGCATTTTTGA P 
dCAS_fw_Colony PCR TGACGAGTACAAGGTGCCCT C 
fw_gene-gene_lexA FP CCAGGCAACAAGAGGTGTTT C 
fw_genomic int._leu-
dCas Plasmid 
GTGGAAGCTGAAACGCAAGG C 
fw_lexA+scRNA_ 
ColonyPCR 
TTCTTTTCGAGCTCCCTAGG C 
fw_lexA+scRNA_ 
ColonyPCR 
TTCTTTTCGAGCTCCCTAGG C, S 
gRNA_fw_Colony PCR GCTCTTCCTGCTCTCAGGTA C 
gRNA_rv_Colony PCR TAGCGGCTTAACTGTGCCCT C 
gRNA5 GCGCGCGTCGACTCTTTGAAAAGATAATG P 
gRNA6 GCGCGCAAGCTTAGACATAAAAAACAAAAAAAGCACCACCGAC P 
gRNA7 CCCAGTCACGACGTTGTAAAACG C, S 
gRNA8 GGAAACAGCTATGACCATG C 
H1 CGATCTTCCCAGAAAAAGAGGCAGAAGCAGTAGCAGAACAGGCCACACAA
TCGCAAGTGATTAACGTCCACACAGGTATA 
P 
H2 TTAACGTCCACACAGGTATAGGGTTTCTGGACCATATGATACATGCTCTGG
CCAAGCATTGGTACCGGGCCCTTTACCAC 
P 
H3 TTAACGTCCACACAGGTATAGGGTTTCTGGACCATATGATACATGCTCTGG
CCAAGCATTGGTACCCGGGCCCTTAATTCGC 
P 
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H6 AAGGCGCAAATCCTGATCCAAACCTTTTTACTCCACGCACGGCCCCTAGGG
CCTCTTTAAGAGTGTAAACTGCGAACCTT 
P 
H7 CGACAACTGCGTACGGCCTGTTCGAAAGATCTACCACCGCTCTGGAAAGT
GCCTCATCCAAAGGCGCAAATCCTGATCCA 
P 
H8 TCCAATTCGCCCTATAGGCGGCCGCTGTTTCGCCAACCAAGTATTTCGG P 
H9 GTTCAGGCACTCCGAAATACTTGGTTGGCGCGCCTATAGGGCGAATTGGA P 
H10 CCCGTTCCTCCATCTCTTTT C 
H11 TGCCAGGTATCGTTTGAACA C 
H12 ACCTTCACCGGAGACAGAAA C 
H14 CGATCCAGTTGCTGAAAGAA C 
H16 AACTGCAGTAAAAAATTGAAGGAAATCTCATCTCGAGCATCCCGAATTGAT P 
H17 AATTACCCGGATCAATTCGGGATGCTCGAGATGAGATTTCCTTCAATTTT P 
H18 CATATGACGACCTTCGATATGGCCGCTGCTTCTTTTATCGAGTTGATACCC P 
H19 AAAGAAGAAGGGGTACAACTCGATAAAAGAAGCAGCGGCCATATCGAAGG P 
H29 TGTCGGTGTTTGTTCAAGCCGTGCGGCCATTCTTTTATCGAGTTGTACCC P 
H30 AAAGAAGAAGGGGTACAACTCGATAAAAGAATGGCCGCACGGCTTGAACA P 
H33 GCCGCAGGTCAGCAGGCTGCCGCGGCCCTCCTGAGTAACGCGAATCGTCG P 
H34 AGTGTGGCTTCGACGATTCGCGTTACTCAGGAGGGCCGCGGCAGCCTGCT P 
H35 GCGGTGGAGCTCCAATTCGCCCTATAGGCGAATTCTCTTAGGATTCGATT P 
H36 GATGAATGTGAATCGAATCCTAAGAGAATTCGCCTATAGGGCGAATTGGA P 
H41 TGCCGCGGCCCTCGTGGTGGTGGTGGTGGTGTTTCACAGTCAGAATGGTC
C 
P 
H42 TCTGACTGTGAAACACCACCACCACCACCACGAGGGCCGCGGCAGCCTGC
T 
P 
H43 AGACACGCAAACACAAATACACACAC C 
H44 ACCATTCAGGGTGCCGGTAATAC C 
lexA FP 7 CGCGTGTACGCATGTAACAT C 
lexA FP 8 GAGGTGTGGAGACAAATGGT S 
lexA FP 13 TCCTTCTAGTGTAGCCGTAG C 
lexA lo1 CCTTATTTTAACTTGCTATTTCTAGCTCTAAAACTATCAGTGATAGAGAAA
AGTGATATCGAATTCCTGCAG 
P 
lexA up GAATTGTAATACGACTCACTATAGGGCGAATTGGAGCTCACTCGGCGGCC
GCAATAATATATAAACCTGTA 
P 
oAH003 TCATAACTGCAAAGTACACA C 
oAH004 CTGAATCAAAGAGGAGAGCT C, S 
oAH005 GTTTTGGGACGCTCGAAGGCTTTAATTTGCTGTGCTGCAAGGCGATTAAG P 
oAH006 ATTAACCCTCACTAAAGGGAACAAAAGCTGAATTCAGAAACTTTGACAAA P 
oAH007 CAGCTTTTGTTCCCTTTAGT C 
oAH007 CAGCTTTTGTTCCCTTTAGT C 
oAH009 AACTAAAAAACTGTATTATAAGTAAATGCATCATGTAATTAGTTATGTCA P 
oAH010 CGTTACCCAACTTAATCGCCTTGCAGCACAGCAAATTAAAGCCTTCGAGC P 
oAH011 GTGGTCTCTACAGGATCTGA S 
oAH019 CTGATGAGTCCGTGAGGACG R 
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oAH020 ACTTTTCTCTATCACTGATAGTTTTAGAGCT R 
oAH021 AAAAGCACATGGGTGATCCT R 
oAH022 GTCCCATTCGCCATGCC R 
oAH025 CTTCTATACTAGTGGATCCCCCGGGCTGCAACTTTTCTCTATCACTGATA P 
oAH026 TATAATTTAGCTATTTGCTTAGAGCTCCACGGGAAGACTCCCCAGTGACT P 
oAH027 CTTCTATACTAGTGGATCCCCCGGGCTGCAGGAAAAGTCTGATGAGTCCG P 
oAH028 TAATTTAGCTATTTGCTTAGAGCTCCACCGAAAAGCACATGGGTGATCCT P 
oAH029 ATAATTTAGCTATTTGCTTAGAGCTCCACCGAGCTCCACCGCGGTGGCGG P 
oAH031 CGCACTCACGTAAACACTTA C, S 
oAH066 TTTACCAGTTAAAGTTTTAACGAAAATCTGCTCGAGCATCCCGAATTGAT P 
oAH067 AATTACCCGGATCAATTCGGGATGCTCGAGCAGATTTTCGTTAAAACTTT P 
oAH068 GGGTGCCGGTAATACGACATTCAATTTCCATTGATCTCTGCATTAAAGAGT P 
oAH069 GCCTTGGCAGACTCTTTAATGCAGAGATCAATGGAAATTGAATGTCGTAT P 
rv_copynumber_dCas-
dCas Plasmid 
GGTTCTCTTCAAAGAGCTGG C 
rv_gene-gene_lexA FP TTATCGTTGCCCGGCAGATC C 
rv_genomic int._leu-
dCas Plasmid 
ATATGCGTCAGGCGACCTCT C 
rv_lexA+scRNA_ 
ColonyPCR 
GGGAACGCCTGGTATCTTTA C, S 
scRNA31 TACAGAATAGCAGAATGGGC C 
scRNA32 CTTGCTATTTCTAGCTCTAA C 
scRNA33 TCTATACTAGTGGATCCCCCGGGCTGCAGGAAAAGTCTGATGAGTCCGTG P 
scRNA34 ATTAACCCTCACTAAAGGGAACAAAAGCTGAATTCAGAAACTTTGACAAA P 
204 ura3_in CAGCCTGCTTTTCTGTAACG R 
205 ura3_out GGAAGAGATGAAGGTTACG R 
 
3.5. Enzymes and Proteins 
The utilized enzymes and polymerases are listed in Table 6. 
Table 6 List of enzymes and polymerases used in this study. 
Name Supplier 
Anti-Mouse IgG (whole molecule)-Alkaline 
Phosphatase antibody (from goat) 
Sigma Aldrich 
ApaI New England Biolabs 
HindIII-HF New England Biolabs 
KpnI  New England Biolabs 
M-MuLV reverse transcriptase New England Biolabs 
monoclonal Penta-His antibody (from mouse) Quiagen 
OneTaq® New England Biolabs 
Phusion® High-Fidelity DNA Polymerase New England Biolabs 
PacI New England Biolabs 
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PmeI New England Biolabs 
Q5® High-Fidelity DNA Polymerase New England Biolabs 
SalI-HF New England Biolabs 
T4 DNA Ligase New England Biolabs 
Taq DNA polymerase New England Biolabs 
TURBODNase Life Technologies, USA 
TURBODNase buffer Life Technologies, USA 
 
3.6. Kits for DNA preparation 
The utilized kits are listed in Table 7 
Table 7 Kits for DNA preparation utilized in this work.  
Name Supplier 
PureYield™ Plasmid Midiprep System Kit Promega 
PureYield™ Plasmid Miniprep System Kit Promega 
Wizard® SV Gel and PCR-Clean up System Promega 
Zymoprep™ Yeast Plasmid Miniprep II Zymoresearch 
Frozen-EZ Yeast Transformation II Kit ™ Zymoresearch 
 
3.7. Cultivation media 
The utilized cultivation media are listed in Table 8. The cultivation media for yeast and bacteria 
was sterilized for 20 min at 121 °C. In cases where agar plates were prepared, 1.5 % (w/v) agar-
agar powder was added. When required, antibiotics were added after sterilisation. The 
ingredients were solubilized in 9/10 of the total volume and autoclaved for all utilized yeast 
media. Glucose/galactose, yeast nitrogen base and amino acids were solubilised in 1/10 of the 
total volume, sterile filtrated and added afterwards. The amino acid drop-out powder was 
mixed according to the requirements for the drop-out media or plates (Table 9). 
Table 8 Composition of cultivation media. 
Media Substances 
Double concentrated Yeast Tryptone (dYT) 
medium 
1.0 % (w/v) yeast extract 
1.6 % (w/v) tryptone 
0.5 % (w/v) sodium chloride 
1 L ddH2O 
SD media 2.0 % (w/v) glucose 
0.5 % (w/v) ammonium sulfate 
0.17 % (w/v) Yeast Nitrogen Base 
0.13 % (w/v) amino acid powder containing all aa 
0.54 % (w/v) Na2HPO4 
0.86 %(w/v) NaH2PO4 × H2O 
SD drop-out media 2.0 % (w/v) glucose 
   
44   Material 
0.5 % (w/v) ammonium sulfate 
0.17 % (w/v) Yeast Nitrogen Base 
0.13 % (w/v) amino acid drop-out powder 
0.54 % (w/v) Na2HPO4 
0.86 %(w/v) NaH2PO4 × H2O 
SG drop-out media 2.0 % (w/v) galactose 
0.5 % (w/v) ammonium sulfate 
0.17 % (w/v) DifcoTM Yeast Nitrogen Base 
0.13 % (w/v) amino acid drop-out powder 
0.54 % (w/v) Na2HPO4 
0.86 % (w/v) NaH2PO4 × H2O 
YPD 2.0 % (w/v) glucose 
2.0 % (w/v) Trypton 
1.0 % (w/v) Yeast extract 
 
Table 9 Composition of amino acid drop-out powder. 
Substance Concentration for drop out powder 
Adenine hemisulfate 40 mg/L 
L-Arginine 20 mg/L 
L-Aspartic acid 100 mg/L 
L-Glutamic acid 100 mg/L 
L-Histidine 20 mg/L 
L-Leucine 60 mg/L 
L-Lysine 30 mg/L 
L-Methionine 20 mg/L 
L-Phenylalanine 50 mg/L 
L-Serine 375 mg/L 
L-Threonine 200 mg/L 
L-Tryptophan 40 mg/L 
L-Tyrosine 30 mg/L 
L-Valine 150 mg/L 
Uracil 20 mg/L 
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3.8. Buffers and Solutions 
The utilized buffer and solutions are listed in Table 10. 
Table 10 Buffers and Solutions used in this work. 
Name Composition 
A  
AE buffer 
Ammonium acetate solution 
Ampicillin stock solution (1000x) 
AP buffer 
APS stock solution  
50 mM NaAc, pH 5.3, 10 mM EDTA 
7 M ammonium acetate 
100 mg/mL ampicillin (sodium salt) 
100 mM TrisHCl (pH 9.1), 50 mM MgCl2 100 mM NaCl  
10 % APS 
B  
Buffer E 1.2 g/L Tris, 92.4 g/L Saccharose, 0.2 g/L MgCl2  
C  
Chloramphenicol stock (1000x) 
Coomassie Brilliant Blue staining  
 
Coomassie destaining solution 1  
Coomassie destaining solution 2  
25 mg/ml chloramphenicol in 96 % ethanol 
10 % (v/v) solution acetic acid, 40 % (v/v) methanol, 0.25 % (w/v) 
Coomassie Brilliant Blue R250 
10 % (v/v) Acetic acid, 25 % (v/v) Isopropanol 
10 % (v/v) Acetic acid 
D  
DNA-loading dye (6x) 
 
10 mM Tris-HCl (pH 7.6), 0.03 % (w/v) bromo-phenol blue, 0.03% 
(w/v) xylene cyanol FF, 60 mM EDTA 
I  
IMAC buffer A 
IMAC buffer B 
50 mM Tris-HCl (pH 7.5), 600 mM NaCl, 10 mM Imidazol 
50 mM Tris-HCl (pH 7.5), 600 mM NaCl, 1 mM Imidazol 
N  
Native PAGE sample buffer (2x) 
Native PAGE running buffer 
Native western blot - buffer A 
Native western blot - buffer B 
Native western blot - buffer C 
Native western blot - Chloronaphthol 
62.5 mM Tris-HCl pH 6.8, 25 % glycerin, 1 % Bromophenol Blue 
25 mM Tris, 192 mM glycerin 
300 mM Tris, 5 % Methanol 
25 mM Tris, 5 % Methanol 
25 mM Tris, 40 mM 6-aminocaproic acid, 5 % Methanol 
3 mg/mL 4-CN in Ethanol 
P  
Phosphate buffered saline (PBS) 
PBS-B  
PBS-T 
PBS-TM  
140 mM NaCl, 10 mM KCl, 6.4 mM Na2HPO4, 2 mM K2PO4 
0.1 % (w/v) BSA in 1x PBS 
0.05 % (v/v) Tween® 20 in 1xPBS 
5 % (w/v) milk powder in 1x PBS-T 
S  
SDS-PAGE Running buffer  50 mM Tris-HCl pH 8.8, 190 mM glycerin; 1 g/L SDS 
T  
TAE buffer (50x) 
Tris-HCl 
2M Tris-HCl, 1 M acetic acid (conc.), 50 mM EDTA, pH 8.0 
1 M Tris, pH 8 with HCl 
W  
Western blot transfer buffer 25 mM Tris, 192 mM Glycin, 20 % Methanol 
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3.9. Chemicals 
The utilized chemicals are listed in Table 11. 
Table 11 List of chemicals used in this work. 
Name Supplier 
A  
α-D(+) glucose 
α-D(+) galactose 
Acrylamide/Bisacrylamide (37,5:1) 
Agar-Agar, Kobe I 
Agarose 
Ammonium acetate  
Ammonium sulfate 
Ammonium persulfate (APS) 
Ampicillin (sodium salt) 
Carl Roth GmbH & Co. KG 
Carl Roth GmbH & Co. KG 
Carl Roth GmbH & Co. KG 
Carl Roth GmbH & Co. KG 
Carl Roth GmbH & Co. KG 
Carl Roth GmbH & Co. KG 
Carl Roth GmbH & Co. KG 
Merck Millipore  
Carl Roth GmbH & Co. KG 
B  
Bacto™ Casamino Acids 
β-Estradiol 
β-Mercaptoethanol  
Bromophenol blue 
5-bromo-4-chloro-3'-indolyphosphate (BCIP) 
BD (Becton, Dickinson and Company) 
Sigma-Aldrich Co. LLC 
Carl Roth GmbH & Co. KG 
Carl Roth GmbH & Co. KG 
Carl Roth GmbH & Co. KG 
C  
Chloramphenicol 
Coomassie Brilliant Blue-R250 and G-250  
CutSmart®-Buffer (10x) 
Carl Roth GmbH & Co. KG 
Carl Roth GmbH & Co. KG 
New England Biolabs 
D  
Difco™ Yeast Nitrogen Base  
Dimethyl sulfoxide (DMSO) 
Dithiothreitol (DTT) 
dNTP mix 
Doxycycline hydrochloride 
Dry milk powder (DMP) 
BD (Becton, Dickinson and Company) 
Carl Roth GmbH & Co. KG 
Carl Roth GmbH & Co. KG 
New England Biolabs  
Sigma-Aldrich Co. LLC. 
Carl Roth GmbH & Co. KG 
E  
EDTA 
Ethanol 
Carl Roth GmbH & Co. KG 
Carl Roth GmbH & Co. KG 
G  
Glycerin Carl Roth GmbH & Co. KG 
H  
HCl (conc., 37%) 
HD Green Plus DNA stain 
Horseradish peroxidase 
Carl Roth GmbH & Co. KGintas 
Intas-Science-Imaging Instruments GmbH 
Merck Millipore 
I  
Isopropanol Carl Roth GmbH & Co. KG 
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M  
Magnesium chloride 
Methanol 
milk powder 
Carl Roth GmbH & Co. KG 
Thermo Fisher Scientific Inc.  
Carl Roth GmbH & Co. KG 
N  
Nitro blue tetrazolium chloride (NBT) Carl Roth GmbH & Co. KG 
P  
Phenol (Roti Aqua Phenol) 
Phenol/Chloroform/Isoamyl alcohol, 25:24:1 (PCI) 
5X Phusion HF buffer 
Carl Roth GmbH & Co. KG 
Carl Roth GmbH & Co. KG 
New England Biolabs 
S  
Sodium chloride 
Sodium dodecyl sulfate (SDS) 
Carl Roth GmbH & Co. KG 
Carl Roth GmbH & Co. KG 
R  
Random Hexamer (RHX) Sigma-Aldrich Co. LLC. 
T  
Tetramethylethylenediamine (TEMED) 
ThermoPol buffer (10x) 
Tris(hydroxymethyl)aminomethan (Tris) 
Tryptone/Peptone 
Tween®20  
Sigma-Aldrich Co. LLC. 
New England Biolabs 
Carl Roth GmbH & Co. KG 
Carl Roth GmbH & Co. KG 
Carl Roth GmbH & Co. KG 
Y  
Yeast extract Carl Roth GmbH & Co. KG 
 
3.10.  Equipment 
The utilized equipment is listed in Table 12. 
Table 12 List of equipment used in this work. 
Equipment Model Supplier 
A   
AccuriTM 
Adhensive foil 
ÄKTA Purification System 
Amicon® Ultra-15 centrifugal 
filter units 
Autoclave 
Autoclave 
C6 Flow Cytometer 
 
 
MWCO 3 kDa  
 
HAST 4-5-6 
V-150 
BD (Becton, Dickinson and Company) 
VWR 
Amersham Pharmacia Biotech 
Merck Millipore 
 
Zirbus Technologies 
Systec 
C   
Centrifuge 
Centrifuge 
Centrifuge 
Centrifuge 
Countertop centrifuge 
Biofuge pico 
Multifuge 3L-R 
6K15 
Centrifuge 5427 R 
ScanSpeed mini 
Heraeus 
Heraeus 
Sigma-Aldrich 
Eppendorf 
Eppendorf 
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Countertop centrifuge 
Cover slides 
centrifuge 5415 D 
20 x 60 mm 
Eppendorf 
Carl Roth GmbH & Co. KG 
E   
Electrophoresis Power Supply 
Electrophoresis Power Supply 
Electroporation device 
Electroporation vials 
301 and 601 
250/2.5 
Gene Pulser Xcell 
 
Amersham, Pharmacia Biotech 
Bio-Rad 
Biorad 
Biorad 
F   
FACS 
FACS tubes 
FACS Laser 
FACS Laser 
Falcon™ tubes 
Filter (sterile filter) 
Freezer (-80°C) 
Freezer (-20°C) 
Influx 
5 mL 
Sapphire 
56CLC100 
15 and 50 mL 
20 µm pore size 
VIP™ Series 
Economic Froster 
BD (Becton, Dickinson and Company) 
BD (Becton, Dickinson and Company) 
Coherent 
CVI Melles Griot 
Sarstedt 
Millipore 
Sanyo 
Bosch 
G   
Glassware 
Gloves (latex and nitrile) 
Gel analysis software 
Gel chambers 
Gel chambers 
Gel documentation UV 
 
 
Gel Jet Imager 
 
HU10 
GelDoc-It® 310 imaging system 
Schott; VWR; Merck KGaA 
B. Braun 
INTAS 
Hoefer 
Scie-Plas 
UVP INTAS 
H   
Heating block 
HisTrap HP column 
Thermomixer compact Eppendorf  
GE 
I   
Ice machine 
Ice machine  
IMAC-column 
Incubator (shaker) 
Incubator 
Incubator (shaker) 
Incubator (shaker) 
Incubator (shaker) 
SP125 AS 
AF80 
 
Certomat BS-1 
Incucell 
WiseCube® 
G25 
Titramax 1000 and Incubator 1000 
NordCap 
Scotsman 
Quiagen GmbH 
Sartorius 
Medcenter Einrichuntgen GmbH 
WISD Laboratory Instruments 
New Brunswick Scientific Co. 
Heidolph 
M   
Magnetic stirrer  
Microfluidic Microscope 
Microfluidic camera 
Microfluidic light source 
Microscope slides  
Microwave 
IKAMAK RCT  
Eclipse TI 
ORCA Flash4.0 
SpectraX 
76 × 26 mm  
Micro700 
IKA-Labortechnik  
Nikon 
Hamamatsu 
Lumencor 
Carl Roth GmbH & Co. KG  
Hitachi 
N   
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Nanodrop 
Nanodrop 
nitrocellulose membrane 
Biospec Nano™ 
ND-1000 Spekrtophotometer 
0.48 µm 
Shimadzu Europe GmbH 
PeqLab 
Amershan™ Protran™ 
P   
Parafilm "M" laboratory film 
Paper towels 
Paper towels, green 
PCR machine 
PCR machine 
PCR tubes 
Petri dishes 
pH meter 
Photometer 
Pipetting controller 
Protein-Blotting device  
Kimwipes 
 
Mastercycler standard 
T100™ Thermal Cycler 
Multiply®-µStrip 
PYPF 
BioPhotometer 
Pipetus R Standard 
Trans-Blot® Turbo™ Transfer System 
Pechiney Plastic Packaging 
Kimberley-Clark 
Sarstedt 
Eppendorf 
Bio-Rad 
Sarstedt 
Sarstedt 
Sartorius 
Eppendorf 
Hirschmann Laborgeräte 
Biorad 
R   
Reaction tubes 1.5 and 2 mL Sarstedt 
S   
Sterile workbench 
Sterile workbench 
Unihood 
Safe2020 
Clean Air Technik B.V. 
Thermo Fisher Scientific Inc.  
T   
Tecan reader INFINITE Tecan M-1000 Tecan 
U   
UV cuvettes  Sarstedt 
V   
Vortex Eurolab Merck 
 
3.11. Computer Software 
The utilized software is listed in Table 13. 
Table 13 Computer software utilized in this work. 
Name Supplier 
ApE  Tangient LLC 
BD FACS Software v1.0 BD (Becton, Dickinson and Company) 
Fiji Fiji team 
Flowing software (version 2.5.1)  Turku Centre for Biotechnology of Turku 
Inkscape The Inkscape Project 
Mathematica II software Wolfram 
Matlab The MathWorks, Inc 
Microsoft Office Standard 2019 Microsoft Corporation 
SnapGene software  GSL Biotech 
T-Coffee European Bioinformatics Institute (EMBL-EBI) 
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 Methods 
4.1. Microbiological methods 
4.1.1. Cultivation and storage of E. coli cells 
E. coli cells were grown either in liquid dYT media or on dYT agar plates. E. coli cells were 
incubated at 37 °C for up to 24 h and stored a 4 °C. Liquid E. coli cultures were shaken at 
180 rpm. The optical density was controlled spectrophotometrically at OD600. For long term 
storage the cell suspension was stored at -80 °C after addition of 10 % DMSO (v/v).  
 
4.1.2. Generation and transformation of electrocompetent E. coli cells  
Two different strains were used for E. coli transformation: DH5α or TOP10 (preferred for large 
plasmids >8000 bp). Therefore, 50 mL dYT media were inoculated with cells of an overnight 
culture towards an OD600 of 0.1 and grown at 37 °C until an OD600 of 0.5-0.7 was reached. 
Subsequently the cell suspension was transferred into a 50 mL Falcon™ tube and centrifuged 
at 4000 rpm at 4 °C for 10 min. Afterwards the cells were washed with decreasing volumes of 
ice-cold ddH2O (50 mL, 20 mL, 10 mL) and the pellet was suspended in 1 mL ice-cold ddH2O. 
For transformation 100 µL of the prepared cell suspension were incubated with 0.1 – 3 µg DNA 
for up to 10 min on ice. 1µL was used for bacterial plasmid DNA and 3 µL were used for yeast 
plasmid DNA. The transformation was performed in a pre-chilled electroporation cuvette via 
electroporation at room temperature for 4 ms at 200 Ω, 2.5 kV and 25 µF. 1 mL dYT media was 
immediately added. Following the cell suspension was transferred to a new reaction tube and 
incubation was performed at 37 °C for 1 h. After incubation, cells were transferred to dYT plates 
containing the corresponding antibiotics and incubated overnight at 37 °C. 
 
4.1.3. Isolation of plasmid DNA from E. coli  
For isolation of plasmid DNA from E. coli, cells were grown shaking at 37 °C overnight. The 
PureYield™ Plasmid Miniprep System Kit (Promega) was used for the isolation of plasmid DNA 
out of 5 mL of the fresh E. coli cultures, whereas the PureYield™ Plasmid Midiprep System Kit 
(Promega) was used for 50 mL E. coli culture. The concentration of the isolated plasmid DNA 
was measured at 260 nm using the BioSpec Nano™ photometer (Shimadzu). The plasmid DNA 
storage temperature was -20 °C.  
 
4.1.4. Cultivation and storage of Saccharomyces cerevisiae cells 
Cultivation of S. cerevisiae was performed in liquid YPD or SD media at 30 °C and 180 rpm until 
an appropriate optical density was reached. Cultivation on YPD agar plates or SD agar plates 
was performed for 48 h at 30 °C. In case of short-term storage cells were kept at 4 °C. For long-
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term storage cells were pelleted for 5 min at 4000 rpm, suspended in PBS, mixed 1:1 with 
50 % glycerol (v/v) and stored at -80 °C. 
 
4.1.5. Generation and transformation of electrocompetent S. cerevisiae cells  
Cells of an overnight culture of the corresponding strain were used to inoculate 50 mL of YPD 
or SD drop-out media towards an OD600 of 0.3. Cells were grown at 30 °C until they reached an 
OD600 of 1.3-1.5 and were subsequently incubated with 500 µL of 0.39 g/mL DTT dissolved in 
Tris-HCl for 15 min at 30 °C and 180 rpm. Afterwards the cell suspension was transferred into 
a 50 mL Falcon™ tube and centrifuged at 4000 rpm at 4 °C for 5 min. The cells were washed 
with decreasing volumes of ice-cold buffer E (40 mL, 15 mL, 1 mL). After the final centrifugation 
step, the pellet was suspended in 1 mL of ice-cold buffer E. 100 µL of the prepared cell 
suspension were used for each transformation. Cells were incubated with 0.5 – 2 µg DNA for 
up to 10 min on ice. Transformation was performed via electroporation in a pre-chilled 
electroporation cuvette at room temperature for 4 ms at 200 Ω, 2.5 kV and 25 µF. Subsequently, 
1 mL of YPD media was added and the cell suspension was transferred to a new reaction tube. 
Cells were grown at 30 °C for 1 h, transferred to the corresponding SD drop-out-plates and 
incubated for 48 – 120 h at 30 °C.  
 
4.1.6. Generation and transformation of chemo competent S. cerevisiae cells  
Chemo competent cells were obtained, following the instructions of the Frozen-EZ Yeast 
Transformation II Kit™ from Zymoresearch. Therefore, cells of an overnight culture of the 
corresponding strain were used to inoculate 15 mL of YPD or SD media towards an OD600 of 
0.3. All transformation steps were performed following the manual. 5 µL of precipitated DNA 
were added for transformation. Cells were grown for two hours after transformation. 
Afterwards the samples were centrifuged to remove most of the supernatant. Cells were 
suspended in the remaining supernatant, transferred to the corresponding SD drop-out-plates 
and incubated for 48 – 120 h at 30 °C.  
 
4.1.7. Gap repair by HR in S. cerevisiae for plasmid generation  
Gap repair is a fast and efficient method that uses the capacity of S. cerevisiae to perform 
homologous recombination in order to assemble recombinant DNA fragments or parts in vivo. 
For most gap repair approaches a plasmid backbone carrying an ori and selection marker is 
assembled with one or more linear DNA fragments (160). 
In this work, gap repair was used to assemble various plasmids (3.2.5). Therefore, the DNA 
fragments were amplified by PCR and purified using the Wizard® SV Gel and PCR-Clean up 
System (Promega). The DNA concentration was determined at 260 nm using the 
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BioSpec Nano™ photometer (Shimadzu) and 4 pM of each insert fragment was mixed with 1 µg 
backbone DNA., which was concentrated by ammonium acetate-ethanol precipitation (0) and 
resuspended in 5 µl of ddH2O. For transformation the chemical competent cSLQ.sc002 cells 
(4.1.6) were used. After transformation the cells were grown on the corresponding SD drop-
out agar plates at 30 °C for 48 h. 
 
4.1.8. Isolation of plasmid DNA from S. cerevisiae cells 
For isolation of plasmid DNA from S. cerevisiae, cells were grown shaking at 30 °C overnight. 
Usually, 2 mL of the fresh yeast culture were used for the isolation of plasmid DNA with the 
Zymoprep™ Yeast Plasmid Miniprep II Kit (Zymoresearch). 3 µL of the isolated plasmid DNA 
were directly used for transformation into freshly prepared electrocompetent E. coli cells. The 
remaining plasmid DNA was stored at -20 °C. 
 
4.2. Molecular biological methods 
4.2.1. Polymerase chain reaction (PCR) 
When the amplification or modification of DNA in vitro was demanded, polymerase chain 
reaction (PCR) was accomplished (161). For DNA amplification the commercially available 
Phusion® High-Fidelity DNA Polymerase (New England Biolabs), Q5® High-Fidelity DNA 
Polymerase (New England Biolabs) or Taq/OneTaq® DNA polymerase (New England Biolabs) 
were used. A representative reaction mixture for each polymerase can be seen in Table 14. 
Primers were ordered in a concentration of 0.025 µmole from Sigma Aldrich in form of powder. 
The protocol for the PCR reactions regarding the utilized polymerase are listed in Table 15. The 
annealing temperature was adjusted to the primers according to the Tm calculator from 
New England Biolabs (162). 
Table 14 Reaction mixtures for PCR utilized in this work, depending on polymerase. 
Substance Phusion® Q5® Taq/OneTaq® 
Template DNA (1ng-1µg) 1 µL 1 µL 1 µL 
Primer forward (10 µM) 2.5 µL 2.5 µL 1 µL 
Primer reverse (10 µM) 2.5 µL 2.5 µL 1 µL 
dNTP-Mix (10 mM) 1 µL 1 µL 1 µL 
Reaction buffer (5x) 10 µL 10 µL 10 µL 
Polymerase 0.5 µL 0.5 µL 0,25 µL 
ddH2O 33 µL 33 µL 36 µL 
Total volume 50 µL 50 µL 50 µL 
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Table 15 Protocol for a standard PCR prepared with Phusion® HF DNA Polymerase, Q5® High-Fidelity DNA 
Polymerase or Taq/OneTaq® DNA polymerase DNA polymerase. 
 Phusion®   Q5®   Taq/OneTaq®   
Step Temperature Duration Temperature Duration Temperature Duration Repeats 
Initial 
denaturation 
98 °C 30 sec 98 °C 30 sec 94 °C 30 sec 1 
Denaturation 98 °C 10 sec 98 °C 10 sec 94 °C 30 sec 30 
Annealing 45-72 °C 30 sec 50-72 °C 30 sec 45-68 °C 30 sec 30 
Elongation 72 °C 15-30 
sec/kb 
72 °C 20-30 
sec/kb 
68 °C 1 min/kb 30 
Final 
Extension 
72 °C 5-10 min 72 °C 2 min 68 °C 5 min 1 
Hold 10 °C ∞ 10 °C ∞ 10 °C ∞  
 
RT PCR 
Roof tile PCR was performed, when 120 bp were added to one side of a DNA part in order to 
allow in vivo assembly and genomic integration by CasEMBLR (2.4.2) (99). Since the efficiency 
and accuracy of PCR is reduced due to the usage of relatively long primers, the 120 bp were 
added in a two-step PCR with an elongation of 60 bp each round. In the first step, the inner 
primers were diluted 1/10 and only 10 cycles of denaturation, annealing and elongation were 
performed. The second step was performed immediately, using the PCR mix of step one. The 
outer primers were added undiluted and 30 cycles were run for denaturation, annealing and 
elongation. Either Phusion® High-Fidelity DNA Polymerase (New England Biolabs) or 
Q5® High-Fidelity DNA Polymerase (New England Biolabs) were used as polymerase.  
 
Colony PCR 
Colony PCR was performed to verify correct transformation. For S. cerevisiae colony PCR, fresh 
yeast colonies were used. Cell material of a single colony was added with a pipette tip into a 
PCR tube filled with 20 µL of 0,02 M NaOH. To break the cells and release the DNA for following 
amplification, the cell suspension was heated for 20 min at 98 °C. For E. Coli colony PCR cell 
material of a single colony was added with a pipette tip into a PCR tube filled with 10 µL of 
ddH2O and boiled for 10 min. After boiling, 1 µL of the boiled cell suspension served as template 
for the colony PCR and was added to the premixed PCR mixture. The commercially available 
OneTaq® DNA polymerase (New England Biolabs) was used as polymerase.  
 
4.2.2. Restriction digestion  
Restriction digestion was prepared for two reasons, first to verify the correct size of a plasmid 
and second to linearize a plasmid for cloning experiments. The digestion mixtures can be found 
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in Table 16 named as small digestion mixture for simple size validation or pre-experiments and 
large digestion mixture for actual cloning experiments. The digestion was accomplished for one 
to four hours at 37 °C. 
For further usage the enzymes were heat inactivated at 65 °C or 80 °C, if possible. The digested 
plasmids were purified using the Wizard® SV Gel and PCR-Clean up System (Promega) (4.2.5). 
Table 16 Mixtures for restriction digestion utilized in this work. 
Substance Small digestion mixture Large digestion mixture 
Plasmid DNA 2 µL 20 µg 
Buffer (CutSmart®-Buffer (1x)) 2 µL 5 µL 
Restriction enzyme 0.5 µL 2 µL 
(Restriction enzyme 2) (0.5 µL) (2 µL) 
ddH2O Add to 20 µL add to 50 µL 
 
4.2.3. DNA Ligation 
For ligation, two DNA fragments were used that were digested with the required restriction 
enzymes. The amounts of the backbone and the insert used for ligation were estimated via 
agarose gel. The insert was used at a five times higher concentration than the backbone. For 
ligation, the T4 DNA ligase was used as described in Table 17. Ligation was performed at room 
temperature for at least 30 min. The DNA was purified by ammonium acetate-ethanol 
precipitation (0) and suspended in 20 µL ddH2O. 5 µL of this DNA suspension were directly 
used for transformation into freshly made competent E. coli cells. The remaining DNA 
suspension was stored at -20 °C. 
Table 17 Ligation mixture for two fragment ligation with T4 DNA ligase.  
Substance Volume 
Backbone ~ 4 µL 
Insert ~ 4 µL 
T4-DNA-Ligase buffer (10 x) 2 µL 
Wasser 10 µL 
T4-DNA-Ligase 0,5 µL 
 
4.2.4. Ammonium acetate-ethanol precipitation of DNA 
Ammonium acetate-ethanol precipitation was performed for DNA purification after ligation and 
DNA concentration. Therefore, the DNA solution was mixed with 1/10 volume of 7 M 
ammonium acetate and three times the volume of DNA + ammonium acetate of 99% ethanol. 
Precipitation was performed at -20 °C for at least 1 h or ideally overnight. The mixture was 
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centrifuged at 13000 rpm for at least 20 min at 4 °C. The supernatant was carefully removed 
and the pellet dried at 37 °C for at least 10 min to remove remaining ethanol. The precipitated 
DNA was dissolved in 20 µL ddH2O for ligation purification and in 5 µL for concentration.  
 
4.2.5. Clean-up of DNA 
After PCR amplification or restriction digestion the DNA was purified using the Wizard® SV 
Gel and PCR-Clean up System (Promega). Purification was accomplished according to the user 
manual. After purification the eluation was performed using 55 µL of nuclease-free water. The 
concentration of the purified DNA was measured at 260 nm using the BioSpec Nano™ 
photometer (Shimadzu). The DNA was either directly used for transformation or stored 
at -20 °C. 
 
4.2.6. Agarose gel electrophoresis 
A solution of 1 % to 3 % agarose (w/v) in 1x TAE-buffer was prepared depending on the size 
of the DNA fragment analysed. To perform agarose gel electrophoresis, 5 µL of HD Green Plus 
DNA stain Master Mix (intas) were added to 20 mL of the agarose solution. DNA samples were 
mixed with DNA-loading dye (6x) (not necessary for prestained OneTaq® Quick-Load® Buffer) 
and applied to the polymerized gel. If not described differently, 2.5 µL of the 2-log DNA ladder 
(New England Biolabs) was used as size standard. Electrophoresis was carried out for 20-40 min 
at 115 V. The gel was analysed using the GelDoc-It® 310 imaging system (UVP) or a gel 
documentation system from INTAS. 
 
4.2.7. Sequencing of DNA 
For precise analysis of DNA, isolated plasmids or PCR amplified DNA was sent to Sequence 
Laboratories (SeqLab) in Göttingen. Therefore, 12 µL DNA with a concentration of at least 
80 ng/µL was mixed with 3 µL of a selected primer. The oligonucleotides used for sequencing 
are listed in 3.4. 
 
4.2.8. Generation of parts for CasEMBLR 
The generation of DNA parts was performed for the in vivo assembly by CasEMBLR (2.4.2) (99). 
For plasmid preparation, the E. coli strains DH5α or TOP10 were used. These plasmids were used 
for part amplification via PCR, which was performed following the manufacturer’s instructions 
using either Q5®High-Fidelity DNA Polymerase or Phusion® High-Fidelity DNA Polymerase (New 
England Biolabs.) (4.2.1). To allow assembly and integration via homologous 
recombination in vivo PCR was used to create 30 bp overlaps to the ends of each part in case of 
combination with another part and 120 bp in case of combination with the yeast genome. In 
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case 120 bp should be added by PCR, RT PCR was performed (4.2.1). All utilized 
oligonucleotides are listed in 3.4. The correct DNA part size was confirmed by agarose gel 
electrophoresis, followed by purification using Wizard® SV Gel and PCR Clean-Up System 
(Promega). To perform in vivo one-step assembly and genomic integration via homologous 
recombination, 4 pM of each part were mixed. For large parts, 1 µg DNA was used instead. For 
CasEMBLR integration into one locus, 2 µg of the corresponding gRNA plasmid was used, 
whereas for integration in multiple loci 1 µg of each gRNA plasmid were added. Plasmids are 
listed in 3.2.3. The mixture of DNA parts and CasEMBLR plasmids was concentrated by 
ammonium acetate-ethanol precipitation (0) of DNA and resuspended in 5 µl of ddH2O. 
 
4.3. RNA-related techniques  
4.3.1. RNA-Isolation from yeast cells 
For RNA extraction from yeast cells, the corresponding strains were grown over night in YPD 
or SD drop-out media. These cells were used to inoculate 5 mL of YPD, SD drop-out media or 
induction media (see 3.7) for RNA extraction. After growth for 20 h, the cells were incubated 
on ice for 5 min, before they were harvested by centrifugation at 4000 xg for 5 min. All following 
centrifugation steps were performed at 4 °C. The supernatant was removed, the pellet was 
resuspended in 400 µL AE buffer and transferred into a new 1.5 mL reaction tube. 40 µL of a 
10 % SDS solution were added and the sample vigorously mixed. 400 µL phenol were added 
subsequently and the samples mixed vigorously followed by incubation at 65 °C and vigorous 
mixing. The samples were put on ice for 10 min, before they were centrifuged at 13000 x g for 
10 min. The liquid phase was transferred into a new tube and 400 µL PCI was added. The 
samples were vigorously mixed and incubated at room temperature for 5 min. The phases were 
separated by centrifugation at 13.000 x g for 10 min. The liquid phase was transferred into a 
new 1.5 mL reaction tube. To precipitate the nucleic acids, 40 µL of a 3 M Sodium acetate 
solution (pH 5.3) and 1 mL 100 % EtOH were added and mixed by inverting several times. The 
nucleic acids were sedimented by centrifugation at 13.000 x g for 10 min and the pellet washed 
with 500 µL 70 % EtOH. The pellet was dried for 5 min at room temperature, before it was 
suspended in 35 µL of ddH2O. Afterwards the DNA/RNA concentration was measured by 
ND-1000 Spectrophotometer.  
According to the measured concentrations, a working solution of 10 µg in 40 µL ddH20 was 
prepared. For digestion of DNA, 4 µL TURBO-DNase buffer and 2 µL TURBO-DNase (New 
England Biolab) were added. After incubation at 37 °C for 30 min, 2 µL TURBO-DNase were 
added followed by further incubation at 37 °C for 30 min. For enzyme removal 4 µL of a 3M 
Sodium acetate solution (pH 6.5) and 100 µL 100 % EtOH were added for precipitation. The 
samples were stored at -20 °C for at least 30 min and subsequently sedimented at 17.000 xg. 
  
Methods   57 
The supernatant was removed and the pellet washed with 500 µL 70 % EtOH. Afterwards the 
pellet was dried at room temperature for 5 min and suspended in 20 µL ddH2O and the RNA 
concentration measured by ND-1000 Spectrophotometer. The concentration was adjusted to 
100 ng/µL. For quality control, 500 ng RNA were applied on a 3 % agarose gel. The prepared 
RNA was stored at -20 °C. 
 
4.3.2. cDNA synthesis 
For RNA into cDNA transcription, 10 µg of the isolated RNA (see 4.3.1) were mixed with 4 µL 
dNTPs (10 nmol), 1 µL Hexamer (RHX, 0,2 µg) and 2 µL ddH2O. The mixture was heated to 
65 °C for 5 min, before 2 µL of the corresponding buffer was added and the sample incubated 
at 25 °C for 2 min. Afterwards 1 µL of the reverse transcriptase M-MuLV (New England Biolabs) 
was added. The sample was incubated at 25 °C for 10 min, followed by an incubation at 42 °C 
for 60 min. The enzyme was inactivated at 68 °C for 10 min. For the reverse transcription a 
thermo cycler was utilized. The synthesized cDNA was used as template for a PCR using 
Taq polymerase (New England Biolabs) (see 4.2.1). 
 
4.4. Cell biological techniques  
4.4.1. Induction of reporter gene expression  
The induction of the reporter gene constructs was performed in two different set ups, single 
sample analysis after growth in a flask/tube or multiple sample analysis in a 96-deep-well plate, 
both described below. The induction media was adapted to the utilized strain and the 
experimental setup. The induction media is described in the corresponding results paragraph. 
The sample fluorescence was measured by AccuriTM C6 (BD) with a 488 nm laser and the filter 
options 533/30 or by FACS (BD) with a 488 nm laser and the filter options 533/40. The data 
was processed using either Accuri™ software (BD) for measurements performed with AccuriTM 
C6 (BD) (163) or the software Flowing software (version 2.5.1, Turku Centre for Biotechnology 
of Turku) for measurements performed with FACS (BD). Afterwards the data analysis was 
performed using Microsoft Excel (Microsoft) or Mathematica II software (Wolfram).  
 
4.4.2. Single sample analysis after growth in a tube/flask 
An overnight culture of the strain of interest was grown in 3-5 mL medium in a tube or 50 mL 
in a flask, respectively. The OD600 was measured photometrically and 3-5 mL/50 mL of induction 
media were inoculated towards an OD600 of 1 in a new tube or flask. The inoculated medium 
was selected depending on the experimental setup. The samples were incubated for 20 h at 
25 °C and 180 rpm. For analysis 300-500 µL of the cell suspension were used. If necessary, the 
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cell suspension was centrifuged and cells and supernatant were stored and analyzed separately. 
Both, cells and supernatant were stored separately at 4 °C. 
 
4.4.3. Multiple sample analysis in a 96-deep-well plate 
For comparison of multiple samples, the incubation and induction were performed in a 96-
deep-well plate. For incubation 500 µL of the desired medium was inoculated in a 96-deep-well 
plate. The cells were grown overnight at 30 °C using a plate incubator (Titramaxx 1000 and 
Incubator 1000 by Heidolph). For induction, most experiments were performed in biological 
triplicates. Therefore 450 µL of the selected medium was mixed with 50 µL of the overnight 
cultures. The induction was performed at 25 °C for 20 h and 1000 rpm. If necessary, the cell 
suspension was centrifuged and cells/supernatant were stored and analyzed separately.  
 
4.4.4. Data collection for time dependent measurements 
For time dependent measurements, induction was performed using a 50 ml Falcon™ tube. 
Therefore, 10 mL of the induction medium were inoculated with yeast cells as described above. 
The samples were grown at 25°C for 48 h. After each hour 200 µl of cells were transferred into 
a new reaction tube. The cell suspension was centrifuged at 13000 rpm, the supernatant was 
separated for ABTS assay (4.5.7) and the cells suspended in 500 µL PBS for flow cytometry 
measurement. In order to retain the total volume, 200 µl of the induction medium were 
replaced after each measurement.  
 
4.5. Biochemical and -physical methods  
4.5.1. Preparation of GOase and vNAR 
Both reporter genes were secreted to the medium. Hence, after growth and induction the cell 
suspension was centrifuged at 3000 rpm for 5 min. The supernatant and the cells got separated 
and were stored separately. For verification of GOase and vNAR, the experimental setup is 
described in 4.5.2 and 4.5.3. For further experiments, the experimental setups described in 4.4 
were used.  
 
4.5.2. GOase purification using Viva flow 
For GOase verification, the enzyme was purified. Therefore, cells were grown overnight in a 
50 ml flask in SD drop-out medium at 30 °C. After growth cells were inoculated to a cell density 
of OD600 of 1 in 1000 ml SG-ura drop-out medium. The induction was completed by addition of 
1000 µl of a 1 mM ES stock solution. Cells were induced at 25 °C for 20 h. The expression of 
the GOase-tGFP construct was checked by tGFP verification via flow cytometry. The cells were 
precipitated by centrifugation at 3000 rpm for 5 min. The supernatant was transferred into a 
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fresh flask and concentrated to 25 ml using a Vivaflow 200, 10.000 MWCO Hydrosart laboratory 
crossflow cassette (Sartorius). The purified and concentrated supernatant was stored at 4 °C. 
Meanwhile, the cell pellet was resuspended in PBS and disrupted using a cell disrupter 
(Constant systems LTD). The cell debris was removed by centrifugation and the suspension 
stored at 4 °C. Both supernatant and cell debris were analyzed using SDS-PAGE (4.5.4) as well 
as ABTS assay (4.5.7).  
 
4.5.3. vNAR purification using IMAC  
For vNAR verification, the shark antibody was purified. Therefore, cells were grown overnight 
in a 50 ml flask in SD drop-out medium at 30 °C. After growth cells were inoculated to a cell 
density of OD600 of 1 in 500 ml SG-ura drop-out medium. The induction was completed by 
addition of 500 µl of a 1 mM ES stock solution. Cells were induced at 30 °C for 20 h. The 
expression of the vNAR-tGFP construct was checked by tGFP verification via flow cytometry. 
The cells were precipitated by centrifugation at 3000 rpm for 5 min. The supernatant was 
transferred into a fresh flask and concentrated to 3 mL using Amicon Ultra-15 Centrifugal Filter 
Units (MWCO 3 kDa, Merck Millipore). Meanwhile, the cell pellet was resuspended in IMAC 
buffer A (10 mM imidazole) and disrupted using a cell disrupter (Constant systems LTD). The 
cell debris was removed by centrifugation.  
The His-tagged vNAR was isolated by immobilized metal affinity chromatography (IMAC). 
IMAC allows the simple and efficient purification of proteins recombinantly fused to a 
hexahistidine affinity tag (6xHis-Tag). Purification is performed by the metal chelating agent 
nitrilotriacetic acid (NTA), which is coupled to the column matrix (164).  
For IMAC 30 mL of the cell-lysate were applied to a 1 mL HisTrap HP column (GE), which was 
washed with 10 column volumes of buffer A. For elution, a linear gradient of 0-100 % IMAC 
buffer B (1 M imidazole) was applied over 20 column volumes. Fractions of 1 mL were collected 
and stored at 4 °C until further analysis by SDS-PAGE and Western-blot analysis.  
 
4.5.4. SDS polyacrylamide gel electrophoresis 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) allows to separate 
denatured proteins in an electric field depending on their molecular weight. Hence, this method 
was used to verify the presence and correct size of GOase and vNAR. SDS-PAGE was performed 
as described in (165). 
For SDS PAGE, the protein samples were mixed with 17% volume of the 5x loading dye. The 
loading dye contained the reducing agent β-mercaptoethanol, which results in the disruption 
of protein disulphide bonds. The samples were denatured at 95 °C for 5 min. The SDS PAGE 
gel was prepared as a 15 % (w/v) SDS PAGE gel (Table 18), placed in an electrophoresis 
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chamber and covered with loading buffer, before 15 µL of each sample were applied. 5 µL of 
the Blue Prestained Protein Standard, Broad Range (11-190 kDa, New England Biolab) were 
applied as marker. Electrophoresis was performed at 40 mA for 1 h. To visualize the proteins, 
the SDS PAGE gels were stained with Coomassie (4.5.5). 
Table 18 Mixture of 15 % SDS PAGE gel (w/v), consisting of separation and stacking gel.  
Volumes are calculated for five gels. 
Stock solution Separation gel Stacking gel 
30 % (w/v) acrylamid, 0,8 % bisacrylamid 18 mL 2.4 mL 
4x separation gel buffer  9 mL - 
4x stacking gel buffer  - 3.6 mL 
Water 9 mL 8.4 mL 
APS-Stock 10 % (w/v)  270 µL 129.6 µL 
TEMED 13.5 µL 10.8µL 
 
4.5.5. Protein Coomassie staining  
To visualize protein, SDS gels were stained with Coomassie staining solution containing 
Coomassie Brilliant Blue R-250 and G-250. The gel was placed in a small bowl, doused with the 
Coomassie solution and heated in a microwave for dyeing. To remove nonspecific staining, 
decolorization was carried out with a solution out of 10 % (v/v) acetic acid, 25 % (v/v) 
isopropanol. The gel was heated up again und destaining solution 1 was replaced with 
destaining solution 2 containing 10% (v/v) acetic acid in distilled water. The gel remained in 
this solution until background staining was sufficiently removed. 
 
4.5.6. Western-blot analysis 
Western-blot analysis is performed in order to visualize specific proteins. Therefore, SDS PAGE 
is used to separate the proteins, before being transferred to a nitrocellulose membrane. The 
protein on the membrane can be detected by a specific antibody, which either is directly labelled 
by an enzyme or a fluorescent tag, or can be recognized by a second visualization antibody. 
When labelled to an antibody-alkaline phosphatase (AP), the complex can be visualized by a 
mixture of Nitro-blue tetrazolium (NBT) and 5-bromo-4-chloro-3'-indolyphosphate (BCIP), 
which leads to an insoluble black-purple precipitate. This technique was utilized for vNAR 
detection.  
After SDS-PAGE of selected fractions, the proteins were blotted onto a nitrocellulose membrane 
(Semi-dry Western Blot). Therefore, 12 Whatman filter papers were pre-wetted with Western 
blot transfer buffer. The SDS gel and the nitrocellulose membrane were also pre-wetted with 
Western blot transfer buffer for 5 min. The components were arranged on a semidry blotting 
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chamber in the following order: 6x Whatman filter papers, nitrocellulose membrane, SDS gel, 
6x Whatman filter papers. The blot was run for 45 min at 12 V and 300 mA. 
Afterwards, the membrane was washed with ddH2O and blocked with 1.5% milk powder 
solution (PBS-TM) for 1 h at room temperature. The membrane was washed with PBS-T for 10 
min. Afterwards incubation with constant shaking was performed with the primary antibody 
for 1 h. The membrane was washed three times in PBS-T for 10 min, followed by incubation 
with the second antibody for 1 h. The membrane was washed another three times with PBS-T 
for 10 min and afterwards equilibrated in AP buffer. For detection 50 µl NBT and 75 µl BCIP 
were added into the AP buffer and shaken constantly until the desired color intensity was 
reached. The membrane was washed with ddH2O several times to stop the reaction.  
 
4.5.7. ABTS assay  
In order to verify GOase, ABTS (2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)) assay 
can be used to demonstrate its activity. GOase uses galactose as a substrate and oxidizes it, 
which leads to the production of H2O2. The coenzyme horse radish peroxidase (HRP) reduces 
H2O2 to H2O. ABTS serves as electron acceptor and receives the electrons generated by HRP. 
This results in the green-colored radical cation ABTS•+, which allows to measure an absorption 
shift (166–168).  
For the ABTS assay, cleared supernatant was utilized. The samples were diluted 1:10 in PBS. 
180 µL of the solution were mixed with 10 µl HRP (0.1 mg/ml), 10 µl ABTS (10 mM) and 
10 µl galactose as substrate (1 M). After 5 min the absorption of ABTS and ABTS•+ was 
measured at 405 nm with the INFINITE Tecan M-1000 (Tecan) reader. The absorption data was 
exported to and analyzed with MS Excel (Microsoft). 
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 Results and Discussion 
Multiple switches based on antibiotics like tetracycline, metabolists like glucose or steroid 
hormones like β-estradiol have been successfully established. All of those switches have their 
own specific advantages and disadvantages (46,57,74). In order to allow tightly controlled and 
targeted gene expression, this work delivers a strategy to combine different switches to a 
functional gate or circuit.  
 
5.1. Implementation and characterization of a galactose dependent CRISPR/dCas9-
based switch 
5.1.1. Construction of the reporter gene setup 
The basis for the different setups is a three component CRISPR/dCas9 system, which was 
already demonstrated to allow the targeted gene expression control in the yeast S. cerevisiae 
(5). For functional gene expression, three CRISPR/dCas9 components have to be implemented 
into the yeast cells:  
• a dCas9 of type II from S. pyogenes 
• an effector protein fused to a transcriptional activator 
• a scRNA containing a hairpin loop for recruitment of the effector protein 
This setup was chosen because of the high expression rates of a reporter gene and the 
modularity demonstrated by Zalatan et al. (5). According to their data, the combination of 
bacteriophage coat protein MS2 (MCP) fused to the transcription activator VP64 as effector 
protein and a scRNA containing two different MCP recruitment motifs delivers the highest 
expression levels. The utilized scRNA contained a mixed hairpin construct out of a MS2 wildtype 
hairpin and an aptamer hairpin named f6 (2x MS2 [WT + f6]) (5,169) (Figure 22). 
 
 
Figure 22 Structure of the utilized scRNA. 
The scRNA is assembled from three subunits, the 20 bp long target binding site, the 76 bp long dCas9 recruiting 
hairpin and the 29 bp long MCP recruiting hairpins. Two different MCP recruitment hairpins are used, the MS2 
wildtype hairpin and an aptamer hairpin named f6. (Figure adapted after (4))  
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Additionally, besides the CRISPR/dCas9 components, the implementation of a reporter gene 
construct is necessary. Following the setup of Zalatan et al., a tetO sequence was used for scRNA 
binding and the yellow fluorophore Venus as reporter. The use of tetO as a binding sequence 
brings a crucial advantage. With the implementation of a Tet-On System, the testing of the 
inducibility of the reporter construct will be enabled. In total five strains were kindly provided 
by Jesse Zalatan containing the reporter gene Venus placed behind different tetO copy numbers. 
For the generation of the yeast strains, the rtTA-msn2_hphR gene was genetically integrated 
into the HO gene of the yeast strain SO992. The obtained clone was named cSLQ.sc002 and 
subsequently transformed with the reporter gene constructs, containing Venus as the reporter 
gene placed behind 1x, 2x, 3x and 7x tetO copies. The constructs were genomically integrated 
into the trp1 locus, leading to the provided strains yJZC02 (1x tetO), yJZC03 (2x tetO), yJZC04 
(3x tetO) and cSLQ.sc003 (7x tetO) (5).  
 
5.1.2. Examination of the general inducibility of the reporter gene setup 
As a first step, the newly constructed strains were tested for inducibility of the reporter 
constructs with the help of the implemented Tet-On system. Doxycycline is added to the growth 
medium, resulting in the binding of the constitutively expressed rtTA to dox and subsequently 
tetO, which induces Venus gene expression (74). This allows direct Venus fluorescence 
detection by flow cytometry (Figure 23A).  
For the experiment, the strains cSLQ.Sc003, yJZC02, yJZC03 and yJZC04 were inoculated and 
induced in a 96-deep-well plate. The experiment was carried out according to paragraph 4.4.3. 
Cells were grown in full SD medium. Induction was performed using 100 µg/mL dox following 
a protocol for doxycycline-dependent target gene expression (170). Additionally, untreated 
samples were prepared as controls. For each sample triplicates were applied. Deviating from 
the protocol, induction was only performed for 4-5 h. Venus fluorescence was directly measured 
using BD Accuri™ C6 (BD). For analysis the Accuri™ software (BD) was used. A gate excluding 
cell debris and contaminations was applied (data not shown). The average of the mean 
fluorescence and the standard deviation of the gated triplets were calculated using Microsoft 
Excel (Microsoft) (Figure 23B).  
SD medium was measured as a blank and did not show any fluorescence, as expected. Hence, 
this control could be neglected for future experiments. Analysis of the samples showed that the 
fluorescence increased according to the tetO copy numbers. For 7x tetO copy numbers, the 
fluorescence slightly decreased in comparison to 3x tetO copy numbers. This can be explained 
by Supplementary Figure 50, showing a decreased total number of induced cells for 7x tetO 
copy numbers. Due to the dox induction, it was demonstrated, that all reporter constructs are 
functional. Even though the Tet systems generally suffer from a high basal activity (73), it was 
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demonstrated, that in the absence of an inducer all switches were relatively tightly regulated. 
A low basal activity was crucial for further applications, since it was aimed to combine the 
CIRPSR/dCas9 platform with multiple switches to a tightly regulated toolbox. For the purposes 
of this work, the tetO-generated leakiness is acceptable and the approach can be used as a 
platform. 
 
 
Figure 23 Verification of the functionality of the reporter gene constructs. 
(A) Logic gate for the doxycycline induction of the Tet-On system. (B) The induction of the reporter gene constructs 
was successful. The expression range strongly depends on the tetO copy number. The fluorescence was measured 
with the 488 nm laser of BD Accuri™ C6 [533/30]. Error bars indicate the standard deviation of the biological 
triplicates. 
 
5.1.3. Construction of a galactose-inducible switch 
After demonstrating the general inducibility of the reporter constructs, the next objective was 
to implement and characterize a switch. Zalatan et al. implemented a galactose dependent 
switch in their approach by bringing dCas9 under the control of the Gal10 promoter (Figure 
24A). This chapter describes the building of a galactose-dependent switch and its 
characterization regarding suitability as part of complex genetic circuits. 
To build a galactose-dependent CRISPR/dCas9-based single switch (Ssw), the three 
CRISPR/dCas9 components were integrated into the strains cSLQ.Sc003, yJZC02, yJZC03 and 
yJZC04, which already contained the tetO-Venus reporter gene constructs in the trp1 gene. A 
type II dCas9 derived from S. pyogenes was placed behind the Gal10 promoter, whereas 
MCP-VP64 and scRNA were expressed continuously (Figure 24B). MCP-VP64 was expressed by 
the strong constitutive Adh1 promoter. The scRNA was expressed by the constitutive snoRNA 
SNR52 promoter and contained a terminator from the 3′ region of the yeast SUP4 gene (159). 
Unless stated differently, this setup was retained for the following experiments. All plasmids 
with genes for the CRISPR/dCas9 complex were obtained from addgene (3.2). 
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Figure 24 Schematic and genetic overview of the galactose-dependent single switch. 
(A) Schematic overview and (B) logic gate for the single switch (Ssw). Both showing, that MCP-VP64 and the scRNA 
are continuously expressed, whereas the dCas9 is inducible by galactose. When all components are expressed, they 
bind to tetO and induce Venus expression. (C) Genomic overview for the Ssw including homologous flanks for 
genomic integration as well as the gene combinations, that were genomically integrated. 
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The pGAL-dCas9 and the effector protein fusion MCP-VP64 were genomically integrated, 
whereas the scRNA was transformed as a CEN/ARS plasmid (Figure 24C). Hence in a first 
transformation step, dCas9 and MCP-VP64 genes were integrated into the genome. It was 
decided for genomic integration, since genetic networks based on plasmids can be unstable 
(171). Thus, most metabolic engineering efforts for complex, multistep pathways rely on 
genomic integration (172). Traditionally genomic integration of heterologous genes into yeast 
is performed via integration into an integrative plasmid and subsequent integration of the 
plasmid into the genome (173). One option is to integrate the entire plasmid into the 
chromosome. Therefore, the vector only needs to be linearized to be integrated by a single 
cross-over event (174). It is possible, that this method results in multiple integrations or tandem 
duplication of the integration site (175). Hence, a second option is preferred, where the 
backbone is removed before integration. On those plasmids, the marker and the GOI are flanked 
by homologous sequences for the up- and downstream region of the integration site. To 
integrate the construct of upstream flank-marker-GOI-downstream flank, the plasmid needs to 
be double digested with two enzymes (173,175). 
This backbone-free integration method was used for the integration of the MCP-VP64 and 
GAL-dCas9 genes. The plasmid pJZC638 contained both genes between leu2 homology flanks. 
The plasmid was digested with the enzyme PmeI, which did cut directly outside of both 
homology flanks. The digestion was controlled by agarose gel electrophoresis and subsequently 
purified using the Wizard® SV Gel and PCR-Clean up System (Promega). The protocols can be 
found in (4.2.5). The digested DNA was integrated into the strains cSLQ.Sc003, yJZC02, yJZC03 
and yJZC04 via electroporation (4.1.5). Selection was performed using SD-leu drop-out-plates. 
Due to the high effort of genetic integration for the cells, cells were grown for up to 120 h. 
Correct integration was verified by colony PCR (cPCR) using the oligonucleotides fw_genomic 
int._leu-dCas Plasmid, rv_genomic int._leu-dCas Plasmid, dCAS_fw_Colony PCR and rv_copy 
number_dCas-dCas Plasmid (3.4) (data not shown, but can be found in (176)). 
In order to establish a functional CRISPR/dCas9 platform, the scRNA was added to the dCas9 
and MCP-VP64 containing yeast cells. Therefore, the scRNA containing plasmid pJZC588 was 
obtained from addgene. The utilized shuffle plasmid pJZC588 contains the 
(2x MS2 [WT + f6])-scRNA under control of the constitutive snoRNA SNR52 promoter. The 
plasmid pJZC588 is a shuttle vector containing both, the genes for reproduction in E. coli as 
well as for stable expression in S. cerevisiae. Therefore, it contains the auxotrophic marker for 
ura3 (177) and a CEN6_ARS4 origin of replication (ori). The CEN6_ARS4 ori consist of an 
autonomously replicating sequence (ARS) and yeast centromere (CEN) and is a low copy ori, 
that allows relatively stable expression of a target gene (178).  
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In a second transformation step, the scRNA was genomically integrated with this plasmid. 
Transformation was performed via electroporation into the positively tested dCas9/MCP-VP64 
clones. Selection was performed using SD-ura drop-out-plates. Cells were grown for 48 h and 
correct integration was verified by cPCR using the oligonucleotides gRNA_fw_Colony PCR and 
gRNA_rv_Colony PCR (3.4) (data not shown, but can be found in (176)).  
As a control, the classical two component CRISPR/dCas9 system was integrated into the yeast 
strains as well. This allowed for the comparative analysis with the three components 
CRISPR/dCas9 system especially for the efficiency of transcriptional activation. For a functional 
complex a dCas9, which was fused to a transcription activator, and a gRNA targeting tetO were 
required. For dCas9-VP64 integration, the plasmid pJZC519 was used. The plasmid contained 
a gene for type II dCas9 derived from S. pyogenes, which was fused to the transcription activator 
VP64 and placed between leu2 homology flanks. For backbone-free genome integration the 
plasmid was digested with PmeI. The digestion was controlled by agarose gel electrophoresis 
and subsequently purified using the Wizard® SV Gel and PCR-Clean up System (Promega). The 
digested DNA was integrated via electroporation into the strains cSLQ.Sc003, yJZC02, yJZC03 
and yJZC04 already containing the tetO-Venus reporter gene constructs in the trp1 gene. 
Selection was performed using SD-leu drop-out-plates. Cells were grown for up to 120 h and 
correct integration was verified by cPCR using the oligonucleotides fw_genomic int._leu-dCas 
Plasmid, rv_genomic int._leu-dCas Plasmid, dCAS_fw_Colony PCR and rv_copynumber_dCas-
dCas Plasmid (3.4) (data not shown, but can be found in (176)). 
In a second transformation step, the CEN/ARS plasmid pJZC523 was transformed into the 
positively tested dCas9-VP64 strains. The plasmid is a shuttle plasmid containing a gRNA under 
control of the constitutive snoRNA SNR52 promoter, guiding the dCas9-VP64 to the tetO target 
site. The plasmid pJZC523 contained the auxotrophic marker ura3 for selection. The 
transformation was performed via electroporation. Selection was performed using SD-ura drop-
out-plates. Cells were grown for 48 h and the correct integration was verified by cPCR using 
the oligonucleotides gRNA_fw_Colony PCR and gRNA_rv_Colony PCR (3.4) (data not shown, 
but can be found in (176)).  
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To sum up, the following transformations were performed: 
Table 19 Summary of the transformed clones for Ssw and control strains. 
Name Integrated genes Origin 
Ssw, 1x tetO trp1::TET01-Venus leu2::MCP-VP64_Gal10-dCas9, scRNA (plasmid)  yJZC02 
Ssw, 2x tetO trp2::TET01-Venus leu2::MCP-VP64_Gal10-dCas9, scRNA (plasmid)  yJZC03 
Ssw, 3x tetO trp3::TET01-Venus leu2::MCP-VP64_Gal10-dCas9, scRNA (plasmid)  yJZC04 
Ssw, 7x tetO trp7::TET01-Venus leu2::MCP-VP64_Gal10-dCas9, scRNA (plasmid)  cSLQ.sc003 
dC-VP64, 1x tetO trp1::TET01-Venus leu2::dCas9-VP64, gRNA (plasmid)  yJZC02 
dC-VP64, 2x tetO trp1::TET02-Venus leu2::dCas9-VP64, gRNA (plasmid)  yJZC03 
dC-VP64, 3x tetO trp1::TET03-Venus leu2::dCas9-VP64, gRNA (plasmid)  yJZC04 
dC-VP64, 7x tetO trp1::TET07-Venus leu2::dCas9-VP64, gRNA (plasmid)  cSLQ.sc003 
 
At least one clone was achieved for every transformation. For each strain a positively tested 
clone was cultivated and subsequently stored at -80 °C. 
 
5.1.4. Function and inducibility of the utilized CRISPR/dCas9 approach and the Ssw 
As demonstrated before, induction of Venus expression in the utilized tetO strains is possible 
due to addition of doxycycline. The successful integration of CRISPR genes will additionally 
enable the targeted gene expression of Venus by the two and three component CIRPSR/dCas9 
systems. The CRISPR/dCas9 associated reporter gene expression as well as the galactose 
dependent reporter gene expression of the Ssw are examined in this chapter. 
All strains described in Table 19 were inoculated and induced in flasks. The experiment was 
carried out according to paragraph 4.4.2. Cells were grown in -ura drop-out medium. The 
dC-VP64 clones were inoculated in SD medium only, whereas the Ssw clones were inoculated 
in both SD and SG medium. This setup allowed the comparison of induced and uninduced 
single switch cells. Strains only containing the MCP-VP64_pGald-Cas9 or dCas9-VP64 gene 
respectively were inoculated in SD medium. Additionally, the strain Ssw, 7x tetO was induced 
with 100 µg/mL dox in SD medium as positive control and the cSLQ.sc002 strain was inoculated 
in SD medium as negative control. Venus fluorescence was measured via Accuri™ (BD). An 
overlay histogram (A) and a single histogram for each tetO copy number (B) is shown in 
Supplementary Figure 51. For the comparative analysis of both approaches, the Accuri™ 
software (BD) was used. A gate including only fluorescent cells was applied. For the successful 
and comparable application of a gate, only 5 % of the cells of the negative control were included 
(Supplementary Figure 51). If not stated differently, this strategy was used for all gates applied. 
The mean fluorescence of the cells in the gate was compared in a diagram using Microsoft Excel 
(Microsoft) (Figure 25). 
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The samples dC_VP64, 1x, 2x and 3x tetO did not show any significant fluorescence. The sample 
dC_VP64, 7x tetO showed a slight increase in fluorescence, demonstrating the general 
functionality of the two component CRIPSR/dCas9 system. In comparison, the fluorescence 
expression achieved with the Ssw strains was distinctly higher. Already for Ssw, 1x tetO a 
significant fluorescence was detected. The fluorescence increased exponentially with the tetO 
copy number. Thus, fluorescence of Ssw, 3x tetO already increased around 20-fold in 
comparison to Ssw, 2x tetO, whereas the fluorescence of Ssw, 7x tetO increased around 40-fold. 
The florescence of the positive control 7x tetO, SD + dox was 20-fold lower than the 
corresponding fluorescence of the fluorescence of Ssw, 7x tetO, but around 2.5-fold stronger 
than the fluorescence of dC_VP64, 7x tetO. The fluorescence of the negative control was in 
range of the strains only containing the MCP-VP64_pGald-Cas9 or dCas9-VP64 gene respectively 
and the Ssw samples grown in SD only. In comparison to that, the fluorescence of the Ssw, 7x 
tetO was slightly increased. 
 
 
Figure 25 Relative fluorescence depending on the integrated CRISPR/dCas9 system and the tetO copy number. 
Four different samples are shown for each of the tetO strains; 7x tetO, 3x tetO, 2x tetO and 1x tetO. Clones called 
wt contained only the dCas9 genes and are shown in grey; cells for the construct 519_523/dC-VP64 in orange; cells 
for the construct 638_588/Ssw grown in SD-ura drop-out medium in dark grey and induced with SG-ura drop-out 
medium in dark red. As controls cells of the strain Ssw, 7x tetO induced with 100 µg/mL dox in SD-ura drop-out 
medium are shown in green and in blue the cells of the strain cSLQ.sc002 = negative control, not containing any 
reporter or CRISPR genes. 
  
The observation that the fluorescence increases with the number of tetO boxes can easily be 
explained. The increased number of scRNA binding sites exponentially increases the likelihood 
of MCP-VP64 binding and subsequent associated transcriptional activation. Moreover, it is 
possible that several scRNA/dCas9/MCP-VP64 complexes bind to the tetO binding sites 
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simultaneously. This finding fits the common practice to increase the copy number of a binding 
site, when high transcription rates are desired (45,79). 
Interestingly, the induced Ssw, 1x tetO and dC_VP64, 7x tetO show approximately the same 
fluorescence. Thus, it can be stated that the three-component system activates transcription 
much stronger than the classical two-component system. A simple explanation is, that MCP 
binds to its RNA target as a dimer (179). Hence, for each scRNA hairpin loop, two MCP-VP64 
are recruited, which allows the recruitment of up to four MCP-VP64 molecules per scRNA 
molecule. This effect strongly enhances the transcription activation, making the Ssw setup the 
perfect tool for high expression rates (5).  
 
5.1.5. Leakiness of the galactose switch 
An unfortunate side effect is that the basal activity also increases with the copy number of tetO. 
Further analysis was performed in order to verify the functionality of the approach for further 
circuit design. Therefore, the strain Ssw, 7x tetO, showing the highest basal activity, was 
inoculated in a flask and induced with SD and SG medium, respectively. As negative control 
the 7x tetO strain only containing the MCP-VP64_pGald-Cas9 genes was inoculated in SD 
medium. Venus fluorescence was measured via Accuri™ (BD) and the Accuri™ software (BD) 
was used for analysis. The resulting histograms are shown in Figure 26. A gate was applied 
covering only cells that were showing fluorescence.  
For the negative control, only a few cells were fluorescent, whereas for the galactose induced 
strain nearly all cells were fluorescent. Both results demonstrate, that the induction worked as 
intended. Furthermore, 34 % of the cells grown in SD medium were fluorescent. These results 
emphasize, that the galactose inducible Ssw system has the disadvantage of high basal activity. 
Due to the biological background (2.2.1.), a certain leakiness must be expected for galactose 
dependent promoters (57).  
To sum up, the three-component CRISPR/Cas9 system allows the functional expression of the 
reporter gene Venus. Transcription activation thereby strongly depends on the copy number of 
tetO. In the Ssw setup, the addition of galactose allows targeted activation of transcription with 
the only necessity of a galactose dependent promoter in front of a GOI. Hence, beside the 
achieved high expression rates, the main advantage of the galactose switch is its simplicity. 
However, with an increase of transcriptional activation, the basal activity increases as well. 
Thus, the main disadvantage of the galactose switch is its natural leakiness.  
 
  
Results and Discussion   71 
 
Figure 26 Leakiness of the Ssw, 7x tetO depending on the induction medium. 
The Ssw, 7x tetO was either grown in SD (red) or induced by growth in SG (yellow). For comparison the 7x tetO clone 
only containing the MCP-VP64_pGald-Cas9 gene was grown in SD (black). For each strain a histogram is given, 
showing the fluorescence for Venus measured by FACS with a 488 nm laser and the filter options 530/540. An overlay 
histogram was prepared. A gate was implemented containing 5 % of the wild type cells. The percentage of cells in 
the gate is shown as a diagram. 
 
5.2. A hormonal transcription factor for a tight and dose-dependent AND gate 
The aim of this thesis is to combine various genetic switches in order to remove disadvantages, 
while maintaining advantages. Furthermore, the goal of the following chapter is the addition 
of a second switch to the Ssw system, allowing the tight regulation of the whole genetic 
network, while maintaining the high expression rates of the galactose switch. Additionally, the 
second switch should enable the concentration-dependent induction of expression of the gene 
of interest. According to Ottoz et al., their ES-inducible approach allows both, the tight and 
dose-dependent induction of a target GOI (45). Hence, the implementation of this approach 
into the galactose-dependent three-component CRIPSR/dCas9 system, to achieve a functional, 
tightly regulated and dose-dependent AND gate, was investigated and is described below.  
 
5.2.1. Function of the hTF LexA-ER-B112 
In order to establish a modular platform based on the three component CRISPR/dCas9 system, 
that is precisely tunable at low induction levels as well as tightly regulated, an ES-dependent 
switch, based on a heterologous transcription factor, was utilized. This heterologous 
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transcription factor consists of the bacterial LexA DNA-binding protein (92), the ES-binding 
domain of the human estrogen receptor (ER) (46,47,92) and the short unstructured acidic 
peptide B112 as activation domain (AD) (91,92) (Figure 27). In the absence of ES, the hTF is 
located in the cytoplasm and is bound to Hsp90 (47) and other molecular chaperone 
components like a p23 monomer (180). This complex represses the ER’s transcriptional 
regulatory activities, while it maintains a receptor conformation that is able to bind ES with a 
high affinity (181). After addition of ES, the hormone diffuses through the cell membrane, binds 
to the hTF and the Hsp90 complex is released (46). The hTF-ES complex localizes to the 
nucleus, where it binds to lexA and strongly activates transcription through the activation 
domain B112 (45).  
 
 
 
Figure 27 Induction of LexA-ER-B112 fusion protein transcription activation by ES.  
The fusion protein containing the LexA binding domain, the human estrogenic receptor ER and the transcription 
activator B112 are bound to Hsp90 in absence of ES. After addition of ES Hp90 is displaced and is able to enter the 
nucleus, where it binds to the lexA boxes preceding the MCP-VP64 gene. The gene is transcribed to mRNA, transits 
from the nucleus to the cytoplasm and is translated into a functional fusion protein. (Figure adapted after (4)) 
 
5.2.2. Construction of an AND gate with a single and double reporter system 
In order to achieve a double switchable AND gate, MCP-VP64 was brought under the control of 
ES, whereas dCas9 remained under the control of galactose (Figure 28A). The scRNA was 
constitutively expressed from the constitutive snoRNA SNR52 promoter. By combining the 
sensitive LexA based ES tunability with the modularity and low basal activity of CRISPR/dCas9 
and the high expression levels of galactose promoters, an AND gate was designed depending 
on both galactose and ES. 
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Three different reporter gene setups were implemented (Figure 28B). For a single reporter 
setup, the successfully tested tetO-Venus setup was chosen (AND). As demonstrated before, this 
allows the direct and simple measurement of the reporter gene by flow cytometry. With regard 
to possible biotechnological applications, the aim was to establish an approach that enables the 
tight regulation of biologically relevant, but not directly detectable GOIs. Therefore, two double 
reporter setups were chosen, combining either the enzyme galactose oxidase (GOase) or the 
variable domain of new antigen receptors (vNAR) from sharks with a T2A-tGFP (green 
fluorophore turbo GFP). 
After Grzeschik et al. the usage of T2A allows the monitoring of the expression of secreted or 
cell surface displayed proteins. Therefore, the fluorescence of a T2A coupled tGFP is measured, 
which remains in the cell cytoplasm (157). In general, picornaviral 2A peptides allow the 
generation of multiple proteins from one mRNA transcript by ribosomal skipping (182,183). 
For this work, the 18 amino acid T2A sequence derived from the Thosea asigna virus was 
utilized. Compared to other 2A variants, the T2A sequence results in the most efficient cleavage 
(184). Thus, once a GFP fluorescence can be detected, it is indicative of GOI expression. To 
investigate, whether the T2A-tGFP expression monitoring works, the double reporter systems 
were constructed as GOase-T2A-tGFP (AND, GO) and vNAR-T2A-tGFP (AND, vNAR) (Figure 
28C). Due to the secretion signal app8 (185), the utilized GOase from Fusarium spec. as well as 
the vNAR were secreted in the medium, while the green fluorophore turbo GFP remained in the 
cell after ribosomal skipping.  
In addition to the indirect measurement of tGFP fluorescence via flow cytometry, the properties 
of GOase allowed the direct measurement of the enzyme’s expression. GOase mediates the 
oxidative conversion of D-galactose to D-galactohexodialdose, which leads to the side 
production of hydrogen peroxide (186,187). This hydrogen peroxide formation can be 
determined quantitatively by ABTS (2,2'-azinobis-(3-ethylbenzthiazoline-6-sulphonic acid) 
assay. When hydrogen peroxide is produced due to the GOase reaction, it oxidizes ABTS to 
produce a radical cation (ABTS•+) (166,167). This shift can be photometrically measured and 
the absorption can be compared in order to detect samples containing active GOase (4).  
The AND, vNAR setup contained an anti-Matuzumab vNAR, which is a shark derived antibody 
domain. In order to examine different purification strategies, the vNAR was expanded with a 
C-terminal hexahistidine tag (vNAR-6His) that can be used for protein detection by western 
blot analysis. This setup should allow vNAR purification by IMAC chromatography followed by 
detection via ELISA assay (188). The reporter genes were genetically implemented after 7x tetO. 
The single reporter setup was additionally implemented after 3x tetO.  
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5.2.3. CasEMBLR for efficient genomic integration  
The need of genomic integration of multiple genes required a method that is more efficient and 
less time consuming than genome integration by homologues recombination (HR). As described 
in (2.4.2), CasEMBLR should deliver a tool for the simple assembly and efficient integration of 
multiple parts into up to three genomic loci (99). To achieve a functional CasEMBLR 
integration, only an active Cas9 and a gRNA, which is targeting the integration locus, need to 
be integrated into a host strain. All CasEMBLR constructs were kindly provided by the Süß lab 
(TU Darmstadt). 
In order to implement an ES- and galactose-dependent AND switch, the fusion protein 
MCP-VP64 was genetically placed behind four lexA boxes and the dCas9 was placed behind the 
PGAL10. Both genes were integrated into the ade2 locus. All reporter constructs described in 5.2.2 
were integrated into the his3 locus. To achieve a functionals ES-inducible switch, the 
LexA-ER-B112 hTF was implemented into the his3 locus as well. The assembled genes are 
described in Figure 28C. 
For the assembling the HR capacity of S. cerevisiae was used. To allow the successful assembly 
and integration via HR in vivo, 30 bp overlaps were added to the ends of each part when 
combined with another part and 120 bp when combined with the yeast genome. For the plasmid 
preparation, the E. coli strain DH5α or TOP10 were used. Those plasmids were used as 
templates for the desired parts. To amplify the parts with the required flanks, PCR was 
performed following the manufacturer’s instructions using either Q5®High-Fidelity DNA 
Polymerase or Phusion® High-Fidelity DNA Polymerase (New England Biolabs, Inc.) (4.2.1). All 
parts used for the construction of the AND gate are listed in Table 20, of the AND, GO in Table 
21 and of the AND, vNAR in Table 22. 
Table 20 Parts utilized for the construction of the AND switch with 3x/7x tetO. 
Parts Method fw rv Template Size [bp] c [ng/µL]  pmol/µL  
Ade2 PCR, Q5 A4 A5 pJZC638 530 68.7  0.39   
Ade3 PCR, Q5 A6 A7 pJZC625 840 87.6  0.32   
Ade5 PCR, Q5 A1, A11 A12 pFRP793 590 20.45  0.11   
Ade6 PCR, Phu A13 A3 pJZC638 7350 80.46  0.03   
His1B2 RT PCR, Q5 H1, H2 H8 pJZC532 2100 85.27  0.12   
His1B3 RT PCR, Q5 H1, H3 H8 pSLQ1119 2500 50.3  0.06   
His2 RT PCR, Q5 H9 H6, H7 pFRP880 3100 42.7  0.04   
pAH006 - - - - - 237.42 - 
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Figure 28 Schematic and genetic overview of the AND gate. 
(A) Schematic overview and (B) logic gate for the AND gate. Both showing, that MCP-VP64 is inducible by ES and 
dCas9 is inducible by galactose, whereas the scRNA stays constitutively expressed. Only when all components are 
expressed, they bind to tetO and induce reporter gene expression. (B) Three different reporter gene setups were 
tested. First the AND gate with Venus as a single reporter gene. Second GOase and tGFP in a double reporter setup 
(AND, GO). Third a vNAR and tGFP also in a double reporter setup (AND, vNAR). (C) Genomic overview for the AND 
gates including homologous flanks for genomic integration as well as the reporter gene combinations, that were 
genomically integrated. 
 
Table 21 Parts utilized for the construction of the AND, GO switch. 
Fragment Method fw rv Template Size [bp] c [ng/µL]  pmol/µL  
Ade1 RT PCR, Phu A1, A11 A12 pJZC793 590 67.34 0.35 
Ade2 RT PCR, Phu A13 A20, A10 pJZC638 7451 84.58 0.03 
His2 PCR, Q5 H17 H18 pYD_Leu_app8 315 38.33 0.37 
His6 RT PCR, Q5 H1, H3 H16 pSLQ1119 895 230.42 0.78 
His14 PCR, Q5 H19 H33 pET22b 2007 120.29 0.18 
His15 PCR, Q5 H34 H35 PCT_2A-GFP 1110 39.36 0.11 
His16 PCR, Q5 H36 H6, H7 pFRP880 3063 116.22 0.11 
gRNA (H) - - - - - 64.88 - 
gRNA (A) - - - - - 80.17 - 
 
Table 22 Parts utilized for the construction of the AND, vNAR switch. 
Fragment Method fw rv Template Size [bp] c [ng/µL]  pmol/µL  
A1 RT PCR, Phu A1, A11 A12 pFRP793 590 70.68 0.36 
A2 RT PCR, Phu A13 A20, A10 pJZC638 7451 74.33 0.03 
H6 RT PCR, Q5 H1, H3 H16 pSLQ1119 895 68.69 0.23 
H11 PCR, Q5 H17 H29 pYD_Leu_app8 315 48.59 0.47 
H16 PCR, Q5 H36 H6, H7 pFRP880 3063 20.75 0.02 
H20 PCR, Q5 H30 H41 pvNAR 403 135.87 1.02 
H21 PCR, Q5 H42 H35 PCT_2A-GFP 1111 120.87 0.33 
gRNA (H)    pA6 7612 93 0.04 
gRNA (A)    p425-antiAde 7233 122.73 0.05 
 
For the genetic integration, the strain cSLQ.Sc002 was utilized, especially since cSLQ.Sc002 
does not contain reporter or CRISPR genes. Due to the high amount of desired DNA, 
electroporation would be difficult to perform. Hence, for CasEMBLR cells were made chemo 
competent using the Frozen-EZ Yeast Transformation II Kit (Zymo Research). The chemo 
competent cells were transformed with 2 µg of the Cas9 encoding plasmid p414 (99)(4.1.6). 
Transformants were selected by SD-trp agar plates and integration was checked by colony PCR 
using the oligonucleotides Cas1 and Cas2 (data not shown). The positively tested 
cSLQ.Sc002_p414 clones were picked, made chemo-competent again and frozen at -80 °C for 
the following chromosomal integrations.  
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For transformation 4 picomoles of each part were mixed with 1 µg of the corresponding gRNA 
plasmid. An exception was made for very large parts, e.g. the part encoding for dCas9. For these 
parts, 0.5 µg of DNA were used. After amplification, the correct size of the constructs was 
verified by agarose gel electroporation. The DNA was purified using the Wizard® SV Gel and 
PCR-Clean up System (Promega). The parts and plasmid(s) were precipitated and suspended in 
5 µL nuclease free water (0). The utilized parts and plasmids for the genomic integrations as 
well as the concentrations used for precipitation, can be found in Table 23 for the AND gate, 
Table 24 for AND, GO and Table 25 for AND, vNAR.  
Table 23 Used concentrations and parts for 3x/7x tetO AND gate transformation. 
Part for 4 pmol [µL] for 1 µg [µL] Use [µL] T2B T2C total V total [µL] 
Ade2 10,18 14,56 10 X X 2 20 
Ade3 12,66 11,42 13 X X 2 26 
Ade5 38,08 48,90 40 X X 2 80 
Ade6 120,58 12,43 13 X X 2 26 
His1B2 32,51 11,73 12 X  1 12 
His1B3 65,61 19,88 20  X 1 20 
His2 95,83 23,42 25 X X 2 50 
pAH006 - 4,21 5 X X 2 10 
 
Table 24 Used concentrations and parts for the AND, GO transformation. 
Part for 4 pmol [µL] for 1 µg [µL] Use [µL] T2B T2C total V total [µL] 
Ade1 11.57   10 X   1 10 
Ade2 116.28 11.82 13 X  1 13 
His2 10.85   11   X 1 11 
His6 5.13  5  X 1 5 
His14 22.02   22   X 1 22 
His15 37.23  38  X 1 38 
His16 34.79 8.60 10   X 1 10 
gRNA (H)  15.41 15  X 1 15 
gRNA (A)  12.47 15 X  1 15 
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Table 25 Used concentrations and parts for the AND, vNAR transformation. 
Part for 4 pmol [µL] for 1 µg [µL] Use [µL] T2B T2C total V total [µL] 
A1 11.02 14.15 11 X  1 11 
A2  13.45 17 X  1 17 
H6 17.20 14.56 20  X 1 20 
H11 8.56 20.58 9  X 1 9 
H16  48.19 40  X 1 40 
H20 3.92 7.36 4  X 1 4 
H21 12.13 8.27 12  X 1 12 
gRNA (H)  10.75 15  X 1 15 
gRNA (A)  8.15 9 X  1 9 
 
For the AND switch, a one-step integration for both, the reporter genes as well as the 
CRISPR/dCas9 gene was performed. In order to enable the integration in two loci, ade2 and 
his3, during the same transformation step, a new gRNA plasmid was generated. This new gRNA 
plasmid pAH006 contained a gRNA for both loci and was constructed from the backbone of 
p425-αAde_gRNA. All utilized parts are listed in Table 26. The plasmid was obtained by ligation 
of the fragments gRNA1 and gRNA3a with T4 DNA Ligase (NEB) and produced in the E. coli 
strain DH5α. The plasmid was prepared using the PureYield™ Plasmid Miniprep System Kit 
(Promega) and the correct sequence was verified by cPCR using the oligonucleotides gRNA7 
and gRNA8 as well as by sequencing using the oligonucleotide gRNA7 (data not shown).  
Table 26 Fragments utilized for the construction of pAH006 and the concentration used. 
Fragment Method fw rv Template Size [bp] c [ng/µL] 
gRNA1 digestion SalI HindIII p425-αAde 7233 estimated 
gRNA3 PCR, Q5 gRNA5 gRNA6 p425-αHis 390 47.75 
gRNA3a digestion SalI HindIII gRNA3 390 estimated 
 
After the successful generation of pAH006, one-step integration for the AND switch was 
performed using the chemo-competent cSLQ.Sc002_p414 cells. After transformation, cells were 
plated on SD-trp-leu drop-out agar plates and grown for up to 120 h. Correct part assembly and 
correct genomic integration was verified by cPCR. For verification of correct integration into 
the ade2 locus the oligonucleotides A15, A18 (correct integration into the genome), A25, A26, 
A27 and A28 (correct assembly) were used. To proof correct integration into the his3 locus the 
oligonucleotides H10, H11, H12, H14 (correct integration into the genome), fw_gene-
gene_lexA FP and rv_gene-gene_lexA FP (correct assembly) were used (data not shown). 
One-step transformation was demonstrated to be efficient. Almost all tested clones contained 
the target genes in the correct locus. However, only very few clones were obtained, which led 
to the decision for a two-step transformation. This two-step transformation was expected to be 
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as efficient regarding integration, but much more efficient regarding the obtained number of 
clones. Hence, the transformation for AND, GO and AND, vNAR were performed in a two-step 
transformation.  
In the first transformation step, the CRISPR genes were integrated into the ade2 locus of chemo-
competent cSLQ.Sc002_p414 cells. Cells were plated on SD-trp-leu drop-out agar plates and 
grown for up to 120 h. This order allowed to keep the total number of transformations as low 
as possible. Additionally, the integration into the ade2 locus allowed a red/white color 
screening. S. cerevisiae cells are normally white colored, but turn red when the ade2 mutation 
in the adenine biosynthetic pathway leads to the accumulation of a cell-limited red pigment 
(189,190). Hence, after the successful integration of the CRISPR parts into the ade2 locus, the 
colonies turned red. This effect allowed the easy selection of putative positively transformed 
clones. For these clones, the correct part assembly as well as correct genomic integration was 
verified by cPCR using the oligonucleotides A15, A18 (correct integration into the genome), 
A25, A26, A27 and A28 (correct assembly) (data not shown). In a second transformation step, 
the reporter genes were integrated into the his3 locus. Cells positively tested on the integration 
of the CRISPR genes were made chemo-competent and transformed with the reporter gene part 
and plasmid mix. After transformation cells were plated on SD-trp-leu drop-out agar plates and 
grown for up to 120 h. Correct part assembly as well as correct genomic integration was verified 
by cPCR using the oligonucleotides H10, H11, H12, H14 (correct integration into the genome), 
fw_gene-gene_lexA FP and rv_gene-gene_lexA FP (correct assembly) (data not shown). 
After successful genomic integration, the CasEMBLR plasmids were removed for both methods 
by growth in regular YPD medium and subsequent dilution of the culture to 5x105 cells/ml. For 
each strain, 100 µL of these cells were plated out on YPD agar plates and grown for 48 h. Single 
colonies were picked and transferred to YPD, SD-trp and SD-leu drop-out plates and grown for 
48 h. One clone per AND switch was selected for further experiments, that only grew on YPD. 
This plasmid-free clone was subsequently transformed with 2 µg of the scRNA plasmid pJZC588 
via electroporation. Cells were plated out on SD-ura drop-out agar plates and correct plasmid 
integration was verified by cPCR using the oligonucleotides gRNA_fw_Colony PCR and 
gRNA_rv_Colony PCR (data not shown). 
To sum up, at least one clone per switch setup was obtained (Table 27). The tool CasEMBLR 
has repeatedly proven its suitability for genomic engineering in S. cerevisiae. As described by 
Jakociunas et al. (99), it is indeed possible to simply and efficiently assemble different genes 
in vivo from DNA parts. However, integration into multiple loci at the same time has not proved 
as effective as promised by the authors. After the integration into two loci, the number of 
colonies was very low. Thus, a two-step transformation was preferred and is recommended as 
method of choice for integration into several loci. In conclusion, CasEMBLR provides a reliable 
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tool for genomic integration in S. cerevisiae with the huge advantage that the parts do not have 
to be assembled beforehand. 
Table 27 Summary of the transformed clones for the different AND gates. 
Name Integrated genes Origin 
AND, 3x tetO ade2::lexA-MCP-VP64_Gal10-dCas9 his3::TET03-Venus_lexA-ER-B112, 
scRNA (plasmid)  
cSLQ.sc002 
AND, 7x tetO ade2::lexA-MCP-VP64_Gal10-dCas9 his3::TET07-Venus_lexA-ER-B112, 
scRNA (plasmid)  
cSLQ.sc002 
AND, GO ade2::lexA-MCP-VP64 Gal10-dCas9 his3::TET07-app8-Goase-T2A-tGFP_ 
lexA-ER-B112, scRNA (plasmid)  
cSLQ.sc002 
AND, vNAR ade2::lexA-MCP-VP64 Gal10-dCas9 his3::TET07-app8-vNAR-His-Tag-
T2A-tGFP lexA-ER-B112, scRNA (plasmid)  
cSLQ.sc002 
 
5.2.4. Examination of the functionality of the AND gate 
After all transformations were successfully performed, the different switches were tested on 
their functionality and leakiness (5.2.4, 5.2.5 and 5.2.7), their tunability (5.2.6) and their time-
dependency (5.2.8). As a first experiment, the general functionality of the double-inducible 
setup was verified by induction of the single reporter AND gate. Therefore both, the AND switch 
with Venus placed behind 3x tetO and the AND switch with Venus placed behind 7x tetO were 
used for an induction experiment. Additionally, the Ssw, 7x tetO was used as positive control 
and the strain cSLQ.sc002 as negative control.  
The four strains were inoculated and induced in tubes following the protocol 4.4.2. The strain 
cSLQ.sc002 was grown in SD full medium, whereas the other strains were grown in -ura drop-
out medium. For the induction experiment, cells of the Ssw, 7x tetO strain were grown in SD 
medium as a control and in SG medium for induction. Cells of the AND gate strains were grown 
in SD, SD + ES and SG as controls and in SG + ES for induction.  
The utilized ES approach was adapted from Ottoz et al., who detected that their ES-inducible 
approach is fully activated between 500 nM and 2000 nM ES (45). The ES concentration used 
for induction was chosen according to their findings. In order to ensure that the ES 
concentration in the induction medium is high enough to allow target gene expression, cells 
were induced using 500 µM ES. Moreover, to verify that the reporter construct is functional 
both strains were induced with 100 µg/mL Dox in SD medium. Venus fluorescence was 
measured via FACS (BD). For the comparative analysis of the strains, the Flowing software 
(Turku Centre for Biotechnology of Turku) was used. The Ssw, 7x tetO and the AND, 7x tetO 
strains were compared in Figure 29A and the AND gate with the different tetO copy numbers 
in Figure 29B. The data of the dox experiments is not shown, but Venus expression was 
successful. 
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In the comparative overlay histogram of Figure 29A it is shown, that the AND switch setup is 
functional. When grown in SG + ES, the reporter Venus is strongly expressed. In comparison 
to the Ssw, 7x tetO, both strains have an equally strong Venus reporter gene expression. When 
grown in SG only the AND gate is tightly regulated, whereas growth in SD + ES results in a 
significant leakiness. Likewise, both tetO strains strongly express Venus, when induced with 
galactose and ES (Figure 29B). Both are tightly regulated in SD and SG, but are leaky upon 
addition of ES. There was little difference between the tetO copy numbers concerning the 
leakiness. In comparison, the rate of expression for 7x tetO was slightly higher. Therefore, for 
further experiments only the clone AND, 7x tetO was used.  
 
 
Figure 29 ES and galactose induction of the 3x tetO and 7x tetO AND switch. 
(A) First induction experiment for the 7x tetO AND switch grown in SG (grey), SD + 500 µM ES (black) and SG + 
500 µM ES (khaki). Additionally, the Ssw, 7x tetO was induced with SG (green). As NC the strain cSLQ.sc002 was 
grown in SD (dotted grey). 
 
To sum up, two requirements of the AND gate have already been met. First, the AND switch 
design can generally be stated as functional, since the setup allows the ES and galactose 
inducible expression of a reporter gene. Second, the expression levels match those of the single 
galactose switch. The third requirement of tight regulation is not fulfilled yet.  
The AND gate is tightly regulated in the presence of galactose only, but not in the presence of 
ES only. Even though, the disadvantage of high basal activity of the galactose switch seems to 
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be successfully compensated by the tight ES switch, the leakiness in the presence of ES was 
unexpected, since the ES system is described as being tightly regulated (45,46,191). 
Interestingly, it has been demonstrated, that in high concentrations ES can have a toxic effect 
on yeast cells (192,193). In comparison to the ES-induction concentrations of Ottoz et al., this 
induction experiment was carried out with up to 250x higher concentrations (Ottoz et al. max. 
2 µM, here 500 µM) (45).  
To elucidate, which role ES played in the high basal expression, another experiment was 
conducted. To this end, cells of the strain AND, 7x tetO were grown in SD medium with different 
ES concentrations. Measurement of the cell distribution was performed using FACS (BD) and 
analysis was performed using the Flowing software (Turku Centre for Biotechnology of Turku). 
The cell distribution was represented by the ratio of forward (FSC) to sideward (SSC) scatter 
and can be found in Supplementary Figure 52. Depending on the ES concentration, the cell 
distribution changed significantly. At a low ES concentration, the population of cells displayed 
a narrower fluorescence distribution compared to cells that were subjected to high ES 
concentration. It can therefore be assumed that a high ES concentration causes an increased 
mortality and fluorescence distribution of the cells. Therefore, significantly lower ES 
concentrations were used in future experiments. Furthermore, it can be assumed that the 
desired tight regulation of the AND gate can be achieved with comparable low ES 
concentrations of 100 nM and below. 
 
5.2.5. Examination of the functionality of the double reporter setup 
After having demonstrated, that the single reporter AND setup is functional, the next step was 
to demonstrate the functionality of the double-reporter setup as well. To this end, the AND and 
AND, GO setups were compared via fluorescence measurements (Figure 30).  
For the experiment cells were inoculated and induced in tubes following the protocol described 
in 4.4.2. All strains were grown in -ura drop-out medium. For the induction experiment, cells 
of the strains AND and AND, GO were grown in SD, SD + 100 nM ES as controls and SG + 
100 nM ES for induction. For comparison, the strain Ssw, 7x tetO was grown in SD as a control 
and SG for induction. All samples were prepared as biological triplicates. The Venus and tGFP 
fluorescence were measured via Accuri™ (BD). For analysis, cytometry data was exported as 
FCS 3.0 files and kindly processed by Johannes Falk using Mathematica 11 software (Wolfram). 
This setup allowed the direct comparison of basal activity and expression levels. The comparison 
of the leakiness and the fold activation of the Ssw, 7x tetO, the AND gate and AND, GO are 
shown in Figure 30.  
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Figure 30 Comparative induction of Ssw, 7x tetO AND and AND, GO. 
The AND gate and the AND, GO gate were grown in SD (black), SD + 100 nM ES (grey) and SG + 100 nM ES (red). 
Error bars indicate the standard deviation of the biological triplicates. The corresponding logic gate is shown at the 
bottom for all three setups. 
 
First, it can be stated that 100 nM ES are sufficient to achieve maximum induction. At an 
induction concentration of 100 nM ES, only a slight impact on cell distribution for the AND 
switch was detected (Supplementary Figure 52). Additionally, induction with 100 nM ES had 
no effect on cell growth of the AND strain and only a slight impact of the AND, GO strain 
(Supplementary Figure 53). Hence, for following experiments a concentration of 100 nM was 
set as the maximum ES induction concentration.  
In Figure 29 it was shown, that the expression level of the AND switch corresponds to that of 
the Ssw, 7x tetO, which was confirmed hereby. In comparison to these expression levels, the 
expression level of the double reporter AND, GO was slightly lower. This effect may be due to 
different fluorophore properties (Venus and tGFP), like slightly different excitation and 
emission wavelength (194), but at least partially may also be caused by the T2A setup. Due to 
the properties of ribosomal skipping, the transcript behind the T2A signal is not always 
completely translated (157). As a result, slightly less fluorophore is produced compared to a 
classical expression scheme lacking T2A. Nevertheless, the GOI-T2A-tGFP double reporter setup 
worked as intended.  
The basal activity for the strain AND, GO corresponds to the one of the single reporter AND 
gate for both SD and SD + ES. For both strains, the basal expression of cells grown in SD only 
is slightly lower, than when grown in SD + ES. Hence, the gate is still not completely tightly 
regulated. However, when compared to the Ssw, 7x tetO, the basal expression is significantly 
lower for all AND switch controls. Thus, by implementing the ES switch to build a double 
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switchable AND gate, it was possible to reduce the basal expression significantly. Even in the 
presence of the inducer ES, the switch is so tightly regulated, that the level of basal expression 
remains under the level of basal expression of Ssw, 7x tetO in SD only. A fold-activation of 
111-fold for the AND switch and 99-fold for the AND, GO were observed.  
 
5.2.6. Concentration-dependent analysis 
In the previous chapter, the general functionality of the single and double reporter setups was 
demonstrated. In this paragraph, a concentration-dependent induction experiment was 
performed. Therefore, the dose-dependent ES induction was examined for the AND, GO and 
AND, vNAR in Figure 31A. 
To compare the strains AND, GO and AND, vNAR, both strains were inoculated and induced in 
tubes following the protocol described in 4.4.3. For the controls, cells were grown in SD, SD + 
100 nM ES and SG medium. To verify dose-dependency, cells of both strains were induced in 
SG with the ES concentrations 1 nM, 10 nM and 100 nM. The tGFP fluorescence was measured 
via Accuri™ (BD). For analysis, cytometry data were exported as FCS 3.0 files and kindly 
processed by Johannes Falk using Mathematica 11 software (Wolfram). 
Both strains show a very similar ES concentration-dependent induction behavior. Even the 
sample, which was induced with only 1 nM ES, showed significant fluorescence. This is 
especially interesting, since the ES system published by Ottoz et al. containing the hTF 
LexA-ER-B112 showed first induction only around 30 nM ES (45). These results demonstrate, 
that the AND switch setup did not only enable a very sensitive induction, but also allows ES 
concentration-dependent induction.  
To verify those results and to gain more information about the dose-dependency, two further 
experiments were performed using the strains AND and AND, GO. First, a detailed ES 
dose-dependent experiment (Figure 31B), and second, a galactose dose-dependent experiment 
were performed (Figure 31C).  
For both experiments the same procedure was used as described in the paragraph above. For 
the first experiment induction was performed with SG and multiple concentrations of ES 
between 0.1 nM and 100 nM ES: 0.1 nM, 0.5 nM, 1 nM, 5 nM, 10 nM, 15 nM, 20 nM, 30 nM, 
50 nM, 100 nM. For the AND gate fluorescence could be detected beginning at 5 nM ES and a 
maximum fluorescence was reached at approximately 30 nM ES. For AND, GO an increase in 
fluorescence could already be measured at 0.1 nM ES reaching a maximum value at 20 nM 
concentration. Interestingly, for AND, GO maximum cellular fluorescence was reached at a 
lower ES concentration compared to AND, whereas the mean fluorescence signal was weaker. 
This leads to the assumption, that the double reporter design lead to an increased sensitivity, 
so the ES concentration resolution was refined at lower concentrations. In conclusion, the AND 
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gate setup in principle enables the fine adjustable expression of different GOI at low nanomolar 
ES concentration. 
 
 
Figure 31 Dose–response induction of the single and dual reporter gene setup. 
(A) Dose-response histograms of the AND, GO (left) and the AND, vNAR (right) gate. (B) Dose-Response histograms 
of the single-reporter system (top) and the dual reporter AND, GO setup (bottom). The black histogram indicates 
the control, where cells were grown in SD only, the gray histogram indicates, where cells were grown in SG without 
ES. (C) Test for Galactose tunability of the AND (top) and AND, GO clone (bottom). The clones were induced with a 
constant amount of ES, but different SG concentrations. 
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For the second experiment, induction was performed with 100 nM Es and different ratios of SD 
and SG. This experimental setup was performed in order to determine, whether a dose-
dependent galactose induction is also possible. Therefore, the cells were inoculated into 
medium with three different SD to SG ratios: 100/0, 50/50 and 0/100. For both strains no 
induction at 0 % SG, a smooth induction for 50 % SG and a strong induction at 100 % SG were 
detected (Figure 33C). Hence, dose-dependent galactose switching was demonstrated, but 
resulted in a fluorescence distribution of Venus and tGFP producing cells over a broad range 
rather than a distinct off/on switch. Switching with galactose was not further investigated.  
From these results, it can be summarized that not only the single reporter AND setup, but also 
the double reporter setups AND, GO and AND, vNAR are functional. At ES concentrations of 
100 nM all AND gates are tightly regulated, whereas a high fold-activation was achieved. Hence, 
the already fulfilled requirements for double-dependent functionality and high expression levels 
were also fulfilled. Additionally, the third requirement of tight regulation is fulfilled by 
adjustment of the applied ES concentration. Even the requirement for a concentration-
dependent AND gate is fulfilled, which was demonstrated in Figure 31. To sum up, four 
requirements for the AND gate design were fulfilled. In order to be certain about the 
functionality of the double-reporter setup, further experiments were performed to specifically 
verify the expression of GOase and vNAR. 
 
5.2.7. Verification of the expression of GOase and vNAR 
First, the expression of GOase had to be verified by SDS PAGE and ABTS assay. Therefore, the 
expression of reporter construct GOase-T2A-tGFP was induced in order to determine if GOase 
is actually secreted. GOase expression and purification were performed according to the 
protocol described in 4.5.1 and 4.5.2. Induction of GOase-T2A-tGFP expression was checked by 
flow cytometry (data not shown). After successful verification of tGFP fluorescence, the cells 
were precipitated and the supernatant was concentrated to 25 ml using a Vivaflow 200, 10.000 
MWCO Hydrosart laboratory crossflow cassette (Sartorius). Until further usage, the supernatant 
was stored at 4 °C. Meanwhile, the cell pellet was resuspended in 1x PBS, disrupted using a cell 
disrupter (Constant systems LTD) and cell debris was removed by centrifugation. Both 
supernatant and cell debris were analyzed using ABTS assay (Figure 32A) as well as SDS-PAGE 
(Figure 32B).  
For ABTS assay, 180 µl of cell suspension or supernatant (sample diluted 1:10 in PBS) were 
mixed with 10 µl Horseradish peroxidase (0.1 mg/ml), 10 µl ABTS (10 mM) and 10 µl galactose 
substrate (1 M). After 5 min the absorption of ABTS was measured at 405 nm with INFINITE 
Tecan M-1000 (Tecan). The absorption was exported to MS Excel (Microsoft) and the analysis 
was kindly performed by Johannes Falk using Mathematica 11 software (Wolfram). As negative 
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control supernatant of uninduced cells was used. ABTS assay revealed, that GOase was only 
present in the supernatant. This result was confirmed by SDS PAGE analysis of the concentrated 
supernatant. 
In a second setup, the concentration-dependent expression of GOase was examined (Figure 
32C). Therefore, the AND, GO strain was grown in tubes according to the protocol described in 
4.4.2. Cells were grown in SD, SD + 100 nM ES and SG for controls and in SG with ES 
concentrations of 1 nM, 10 nM and 100 nM for induction. After growth, cells and supernatant 
were separated by centrifugation. The supernatant was replaced and stored at 4 °C in a 96-well 
plate until analysis. Analysis was performed using ABTS assay. 0.25 % H2O2 were added as 
positive control. The error bars indicate the standard deviation of the biological triplicates, 
except for SG + 100nM ES, where only a duplicate was available. Even though ABTS assay is 
really sensitive, no GOase activity was detected for the negative controls. For the samples a 
dose dependent GOase expression was detected.  
 
 
Figure 32 Detection and verification of GOase activity. 
(A) Localization of GOase activity. ABTS assay of the GOase-tGFP reporter strain after induction of 1 l of yeast culture. 
The supernatant was concentrated by cross-flow filtration with a Viva flow 200, 10.000 MWCO Hydrosart (Sartorius) 
from 1 l to 50 ml. As negative control supernatant of uninduced cells was used. (B) SDS PAGE analysis of concentrated 
supernatant. M = Blue Prestained Protein Standard, Broad Range (NEB) and S = supernatant. (C) ABTS assay for 
determination of GOase activity in cell supernatants upon induction of gene expression at varying ES concentrations. 
H2O2: PC, 0.25 % H2O2 were added to the ABTS assay. Error bars indicate the standard deviation of the biological 
triplicates. For SG + 100nM ES only a duplicate was available. 
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Therefore, the results of the tGFP measurement were verified. Thus, the AND gate design allows 
the concentration-dependent expression of one or multiple reporter genes when combined with 
a T2A setup. 
Second, the expression of vNAR had to be verified by SDS PAGE, Western blot and ELISA. 
Therefore, vNAR expression and purification was performed according to the protocol described 
in 4.5.1 and 4.5.3. vNAR-tGFP expression was verified by flow cytometry (data not shown). 
After successful verification of tGFP fluorescence, the cells were precipitated and the 
supernatant was concentrated to 3 mL using Amicon Ultra-15 Centrifugal Filter Units (MWCO 
3 kDa, Merck Millipore). The cell pellet was suspended in IMAC buffer A, disrupted using a cell 
disrupter (Constant systems LTD) and cell debris was removed by centrifugation. For purification 
of the His-tagged vNAR construct, IMAC was used. During elution 1 mL fractions were collected 
and applied on SDS-PAGE. Gels were either stained with Coomassie Blue for visualization of 
the whole protein content (Figure 33A) or blotted onto nitrocellulose membrane (Semi-dry 
Western Blot) for specific immunostaining (Figure 33B). For western blot analysis, the 
membrane was blocked with 1.5% milk powder solution, and incubated with monoclonal Penta-
His antibody followed by Anti-Mouse IgG (whole molecule)-Alkaline Phosphatase antibody 
(Sigma Aldrich). Addition of the detection reagent resulted in a purple-black precipitate only in 
presence of alkaline phosphatase activity, which enabled indirect detection of His-tagged 
proteins. 
 
 
Figure 33 Purification and analysis of vNAR. 
(A) and (B) both show the results of the purification of the AND, vNAR cell lysate with immobilized metal ion affinity 
chromatography (IMAC). (A) Samples were collected and applied to on an SDS PAGE. (B) Western blot analysis of 
the samples, which were immunostained with α-His antibody (mouse) and anti-mouse IgG-AP (goat). L = filtrated cell 
lysate, W = IMAC wash, 1-5 = IMAC elution/peak fractions, + = PC vNAR His-tag. Expected sizes for the constructs are 
vNAR = 13.256 kDa, vNAR+app8 = 22.045 kDa, vNAR+T2A+tGFP=39,726 kDa, vNAR+app8+T2A+tGFP=48,512 kDa, 
tGFP=24,676 kDa. For SDS PAGE and Western blot Blue Prestained Protein Standard, Broad Range (NEB) was used.  
 
For SDS-PAGE multiple bands were detected for all samples. Hence, IMAC was not sufficient 
for complete purification of the vNAR construct. By contrast, Western blot was able to 
specifically detect the vNAR and a vNAR-app8 construct in two fractions. Thus, the expression 
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of vNAR was verified and the functionality of the double reporter AND, vNAR gate was 
demonstrated. However, the purified supernatant still contained to many other proteins in 
order to perform ELISA. ELISA was intended to demonstrate functionality and dose-dependency 
of the double-reporter setup. Both have already been demonstrated by fluorophore analysis of 
AND, GO and vNAR in Figure 30 and for GOase in Figure 32. Functionality has also been 
demonstrated by Western blot analysis. Hence, no further purification steps were performed for 
vNAR purification and ELISA detection was not further pursued. 
With this paragraph the specific expression of GOase and vNAR was demonstrated. Hence, the 
double reporter setup allows the expression and indirect verification of any GOI in the T2A 
setup. For complete characterization of the switching behavior, in a last experiment the time-
dependent induction of the single and double reporter setup was analyzed. Because of the 
simple and quick detection methods of GOase, for this experiments the AND, GOase strain was 
used. 
 
5.2.8. Time-dependent analysis 
Time-dependent analysis was performed to achieve information about the length of the time 
period needed, until the first reporter gene expression can be measured as well as how long it 
takes to reach maximum induction. For time-dependent measurement, the single reporter AND 
gate and the double reporter AND, GO gate were utilized. For both gates flow cytometry 
analysis was performed on cells incubated with 10 nM ES and galactose (Figure 34A+B) and 
additionally with 100 nM ES for the double reporter system (Figure 34C).  
For the time dependent measurements, the strains were inoculated and induced according to 
the protocol described in 4.4.4. Induction was performed using either 10 µL or 100 µL of a 
10 µM ES stock solution, leading to a concentration of 10 or 100 nM, respectively. After each 
hour 200 µL of the cell suspension were removed and replaced by 200 µL of SG medium 
containing 10 nM/100 nM ES. The extracted cell suspension was centrifuged and the cells were 
suspended in PBS for flow cytometry measurement. For the AND, GO samples the supernatant 
was used for ABTS. Data analysis was kindly performed by Johannes Falk using Mathematica 11 
software (Wolfram).  
A first increase of fluorescence was measured after approximately 6 h for the single reporter 
setup and after 2 h for the double reporter setup, regardless of the ES concentration. After 15 h 
both gates were fully activated and no further increase of the fluorescence was detected. In 
comparison, the fluorescence for both AND, GO concentrations increased approximately to the 
same extent, but for the higher concentration it has reached an overall higher maximum. The 
same effect was demonstrated for GOase activity. 
  
   
90   Results and Discussion 
 
Figure 34 Time-dependent measurement of gene expression for the dual reporter system. 
(A) Time dependent measurement of single reporter system. Induction was performed with 10 nM ES and galactose. 
(B) + (C) Time dependent measurement of gene expression for the dual reporter system. Induction was performed 
with 10 nM ES (B) or 100 nM ES (C) and galactose, (blue) time dependent measurement of GOA activity examined 
by ABTS assay, (red) time dependent measurement of tGFP by flow cytometry. The error bars indicate the standard 
deviation of the biological triplicates.  
 
GOase activity was determined by ABTS assay for AND, GO. For both induction concentrations, 
first GOase activity was observed after 6 h and continued to increase until the hour 23. As 
expected, GOase activity correlated well with cellular fluorescence. However, measurement of 
GOase activity was delayed for approximately 4 h. This delay may be explained by the different 
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synthesis pathways: cytoplasmic expression of tGFP versus secretion of GOase. For secretion, a 
protein has to pass through the endoplasmic reticulum and the Golgi apparatus prior to be 
packaged into secretory vesicles, which fuse with the plasma membrane to release the fully 
processed protein into the surrounding medium (195). This process takes time, which leads to 
a decreased detection. Additionally, GOase is with a size of 65 kDa (168) larger than tGFP with 
a size of 26 kDa (196). Since the time needed for protein folding among others depends on its 
length (197), GOase requires more time for folding so that the detection is delayed. 
Nevertheless, our data indicates that co-translation via T2A ribosomal skipping can be used as 
a tool to follow time-dependent expression of a GOI and to quantitate its accumulation.  
 
5.3. Further analysis of the AND gate by collaborations with other scientific fields 
This work has been performed in the context of synthetic biology, making numerous 
opportunities for collaboration with other scientific disciplines available. In the course of further 
analysis of the AND setup, it was decided to work together with two different disciplines. The 
collaborations included both, computer-based modeling conducted by Johannes Falk from the 
group of Prof. Drossel (Physics Department of TU Darmstadt) and microfluidic measurements 
carried out by Tim Prangemeier from the group of Prof. Koeppl (Department of Electrical 
Engineering and Information Technology at TU Darmstadt). The results of the collaborations 
have been published, hence some parts of the following section were taken and adapted from 
Hofmann et al. Additional material and methods also can be found in Hofmann et al. and in the 
dissertation of Johannes Falk (4,198). 
 
5.3.1. Mathematical modeling to rebuild the experimental setup 
In order to understand the underlying principles that account for the observed dose 
dependency, a minimalistic dynamical mathematical model was developed in collaboration 
with Johannes Falk. The model comprises three important processes:  
• the diffusion of the transcription factor (hTF)  
• the expression of mRNA regulated by the hTF 
• the degradation of the fluorescent reporter proteins Venus or tGFP 
The established minimal model allowed, to capture most biological processes while still being 
capable of covering all important results of the experiment. Based on different reaction 
equations, a model was generated based on two ordinary differential equations that describe 
the time dependent concentrations of the ES-hTF complex in the nucleus and the tGFP mRNA. 
The corresponding formulas and derivations can be found in (4). The concentration of ES in 
the medium was given by the experimental conditions and was held constant during the 
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experiment. To be able to compare the model and the data, a scaling factor was introduced. 
This scaling factor accounts for the translation process and additionally maps the number of 
fluorescent proteins to the measured fluorescence value. The obtained values can be found 
in (4). For the model it was taken into account, that two reporter systems based on different 
fluorescent proteins were used. The AND gate was simulated using the Stochastic Simulation 
Algorithm (199) of the Dizzy Software Package (200). 
 
 
Figure 35 Comparison of model data with the real data. 
(A) Comparison of the stochastic model (red histogram) with the experiment (black solid line) for AND, GO at an ES 
concentration of 5 nM. (B) Dose–response curves of single reporter (left) and double reporter (right) setup. Markers 
indicate experimental results; the solid line indicates the expectation according to the mathematical model. The blue 
band denotes the 90% confidence interval of the mean of the model. The standard-error bars of the experimental 
data are smaller than the markers.  
  
First results using the minimal model predicted maximum reporter gene expression of both, the 
single and double-reporter setups at a concentration above approximately 35 nM ES after 20 h 
of induction. An exemplary comparison between the experimental data and the data obtained 
from the stochastic model is given in Figure 35A. A detailed comparison for the single and 
double reporter setup can be found in (4). In Figure 35B the mean of the dose-respond 
histograms for AND and AND, GO are shown together with the fitted model. The model 
accurately predicted the fluorescence behavior of the AND gates. Thus, the established 
computational model could be used to obtain further results in silico. For example, it would be 
possible to exactly quantify the ES concentration that is necessary to reach a desired 
fluorescence or other target gene expression. In this context, it is important to note that the 
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model is by purpose not designed as a complex model that tries to capture all ongoing processes 
in full detail. The intention of the model is rather to describe universal principles that can lead 
to the observations made by the experimental data.  
In conclusion, the AND gate enables the fine adjustable expression of different GOI at low 
nanomolar ES concentration. Outside this rather small range GOI expression is broadly binary. 
 
5.3.2. Microfluidic enables time-lapse single-cell experiments 
After the concentration dependency had been examined more closely with the help of the 
mathematical model, the time-dependent induction was further analyzed using microfluidics. 
Flow cytometry, which was performed to gain the results shown above, can only provide 
snapshots into the distribution of fluorescence across a population of cells. Hence, to gain a 
deeper insight into dynamics of individual cells, time-lapse measurements were recorded for 
the dual reporter setup. Time-lapse single-cell experiments were carried out on a microfluidic 
chip using a platform inspired by ALCATRAS (201) in cooperation with Tim Prangemeier.  
For the experiments, cells of the AND, GO gate were utilized. Cells were grown over night and 
freshly inoculated into SD-ura medium. These cells were grown at 30 °C for 5 h before they 
were induced at t = 0 with SG-ura and 20 nM or 100 nM ES, respectively. Cells were loaded 
on the microfluidic chip and exposed to a controlled environment at 30 °C with continuous flow 
of the respective inducer medium. This continuous flow ensures that daughter cells are flushed 
away, while the mother cells are confined. For analysis a microscope image was recorded every 
10 min. The resulting single traces were extracted with a FiJi/Matlab script. The results can be 
seen in Figure 36. 
Distinctive differences were observed for single-cell traces of the two ES concentrations. For the 
relatively high induction concentration of 100 nM ES, the cells demonstrated a homogeneous 
dynamic without a phase shift. Already 7 h after induction the maximum fluorescence was 
reached, after 12 h the cells arrested their growth and no further budding events were detected. 
The production of tGFP stopped as well, leading to a rapid decrease of detected fluorescence. 
The main reasons for this decrease might be photobleaching and potential bleaching due to 
presence of protein damaging H2O2. The arrested cell growth might be the result of a 
combination of detrimental effects, such as metabolic overload and potential toxicity of GOase-
mediated generation of H2O2. In comparison, for the lower induction concentration of 20 nM 
ES, the cells behave more heterogeneously: some of the cells remained switched off and the 
cells that switch on, did so with an intermittent phase shift. For some cells even an oscillation 
between the off and on state was detected. Some of the cells reached an arrested state as well, 
while others remained budding and continuously increased the expressed fluorescence. Hence, 
the arrest of growth seemed to be dose dependent.  
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Figure 36 Microfluidic measurements for time-dependency. 
Single-cell traces from 30 cells, each for 100 nM ES (left) and 20 nM ES (right), respectively. Below are corresponding 
fluorescence microscope images of selected cells for a given time-point. The cells are trapped in micro-patterned traps 
in continuous flow. 
 
While there is no conclusive evidence as to a single cause, it is deemed to be a combination of 
metabolic overload, increased sensitivity of the AND gate to ES and also the production of 
potentially toxic H2O2. For further experiments, this may be a key limiting factor in protein 
production. However, it cannot be excluded, that the different growth conditions in the 
microfluidic device had an impact as well, since ES-dependent cell growth arrest was not 
detected upon bulk cell cultivation in 96-deep-well plates, tubes or flasks (Supplementary 
Figure 53).  
Nevertheless, in combination all three, the experimental results, mathematic modeling and 
microfluidic single cell measurements supported the finding of a tightly regulated AND gate 
with no measurable basal transcription activation. Since the AND gate was satisfactorily 
characterized, no further attempts were made to this purpose. 
 
5.4. A positive feedback loop allowing removal of galactose after first induction 
The AND switches presented in section 5.2 and 5.3 demonstrated the successful combination of 
three different systems to one tightly regulated and dose-dependent double switch setup. 
Namely as the basis for switch designs a three component CRISPR/dCas9 system was used, 
allowing a modular and complex gate design. As the first switch, the well-established galactose 
inducible promoter GAL, leading to high expression rates, and as the second switch the ES 
inducible complex, enabling a dose-dependent and tight regulation, were implemented. 
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Many positive features of each switch have been combined. Nevertheless, some disadvantages 
remained. One of the major disadvantages is that the required change from glucose to galactose 
triggers a change in metabolism. Because of the high consumption of energy for the cell 
metabolism, this change limits the energy for the production of the reporter/target proteins 
(202,203). Additionally, cell growth often is slowed down. Hence, it may be helpful to switch 
back to glucose medium after a short induction in galactose containing medium. In the 
following paragraph a positive feedback loop is described, that allows one to remove galactose 
from the medium after only a short induction time. The feedback loop further enabled 
significantly higher expression rate than the already high ones achieved with the previous 
setups. 
 
5.4.1. Construction of the positive feedback loop based on the AND, GO setup 
For the positive feedback loop, the well characterized AND, GO strain was utilized. Hence, MCP-
VP64 is under the control of ES and dCas9 is under the control of galactose, whereas the scRNA 
is constitutively expressed (Figure 37A). After induction with ES and galactose CRISPR/dCas9 
can bind to the tetO binding region, leading to the expression of GOase and tGFP (Figure 37B). 
As visualized in Figure 37A, only tGFP fluorescence was measured for evaluation of the 
feedback loop. It was already demonstrated in 5.2.5 and 5.2.7, that tGFP expression is 
analogous to that of GOase. Since no further preparation is needed for the detection of tGFP 
via flow cytometry, it was decided to only use tGFP fluorescence to analyze the feedback loop. 
Since cells of the AND, GO strain were utilized, no further integration of the CRIPSR/dCas9, 
reporter genes or scRNA was necessary. Therefore, only a gene allowing a positive feedback 
had to be designed, cloned and integrated into the AND, GO strain (Figure 37C).  
For the positive feedback loop design, a setup was chosen that allows for the quick switch back 
to glucose after a short addition of galactose, mainly because galactose induction leads to 
unwanted side effects like slow growth rates. For the utilized setup, dCas9 expression was under 
control of galactose. Once induced with galactose, dCas9 was intended to be continuously 
expressed without further addition of galactose. To this end, dCas9 was placed under the 
control of tetO. After induction, the CRISPR/dCas9 complex did not only bind to the tetO 
preceding tGFP, but also to the tetO preceding dCas9. As a consequence, dCas9 should be 
constitutively expressed and the addition of galactose would be no longer necessary. 
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Figure 37 Schematic and genetic overview of the positive feedback loop. 
(A) Schematic overview and (B) logic gate for the positive feedback loop. Both showing, that MCP-VP64 is inducible 
by ES and dCas9 is inducible by galactose, whereas the scRNA stays constitutively expressed. Only when all 
components are expressed, they bind to tetO and induce tGFP expression. Additionally, a dCas9 placed behind tetO 
as well, will be expressed. Thus, dCas9 will be produced without further induction and galactose can be removed. (B) 
The AND, GO setup was utilized for the feedback loop implementation. (C) Genomic overview for the feedback loop 
including homologous flanks for genomic integration as well as the reporter gene combination, that was genomically 
integrated. The tetO-dCas9 plasmid is shown as well.  
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To allow for the implementation of the feedback loop into different strains, the gene tetO-dCas9 
complex was integrated into a plasmid backbone. The backbone of p425 containing a 2µ ori 
was used and combined with a tetO sequence in front of dCas9 and a tryptophan auxotrophic 
marker amplified from the plasmid p414. To keep the cellular burden by overexpression of 
dCas9 as small as possible, only 3 copies of tetO were used. All utilized fragments, that were 
needed to build the new plasmid pAH019, are listed in Table 28.  
Table 28 Fragments and concentrations utilized for the construction of pAH019. 
Fragment Method fw rv Template Size [bp] c [ng/µL] Use [µL] 
fAH001 PCR, Phu Cas13 Cas14 p425_aAde 3676 15.75 50 
fAH002 PCR, Q5 Cas15 Cas8 p414 1016 36.52 20 
fAH004 PCR, Q5 Cas9 Cas10 pJZC532 377 54.53 20 
fAH005 PCR, Phu Cas11 Cas12 pJZC638 4973 70.02 50 
 
The fragments were combined by HR in yeast after PCR amplification with 30 bp overlaps on 
both ends of the fragment. A concentration of approximately 4 picomolar of the small fragments 
was mixed with 0.5 µg of the bigger fragments. The mixture was precipitated, suspended in 
5 µL of nuclease free water and subsequently used for transformation into chemo competent 
cSLQ.Sc002 cells prepared with the Frozen-EZ Yeast Transformation II Kit (Zymo Research). 
Cells were selected using SD-trp drop-out agar plates and were grown for 48 h. Correct plasmid 
assembly was verified by cPCR using the oligonucleotides oAH003 and oAH004. A correct clone 
was chosen and after growth overnight the plasmid was isolated using the Zymoprep™ Yeast 
Plasmid Miniprep II Kit (Zymoresearch). The isolated plasmid was subsequently transformed 
into freshly prepared competent E. coli cells. After transformation, selection was performed 
using dYT+Amp agar plates and cells were grown overnight. Correct transformation was 
checked by cPCR using the oligonucleotides oAH003 and oAH004 (data not shown). A correct 
clone was chosen and after growth overnight the plasmid was isolated using the PureYield™ 
Plasmid Miniprep System Kit (Promega). The correct plasmid sequence was verified by 
sequencing using the oligonucleotides lexA FP 8 and oAH004 (data not shown).  
After the successful generation of pAH019, transformation of the plasmid into electrocompetent 
AND, GO cells was performed. Cells were selected using SD-trp-ura drop-out agar plates and 
were grown for 48 h. Correct plasmid integration was verified by cPCR using the 
oligonucleotides oAH003 and oAH004 (data not show). The newly generated strain was named 
AND, GO, pFL (positive Feedback Loop). 
 
5.4.2. Examination of the functionality of the positive feedback loop 
After the general functionality of the positive feedback loop was demonstrated (data not 
shown), the positive feedback loop was tested in a setup, where the cells were precultured in 
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SD medium, induced for a fixed time span with galactose and ES and subsequently transferred 
back to SD medium containing ES.  
For the experiment cells of the strains AND, GO and AND, GO, pFL were utilized. Both strains 
were inoculated in 10 mL and induced in 96-deep-well plates according to the protocol 
described in 4.4.3. Cells containing the pFL were grown in -trp-ura drop-out medium, others in 
-ura drop-out medium. For every strain a cell suspension with an OD600 of 1was prepared and 
subsequently used for induction. 475 µL of this cell mixture were pipetted into a 96-deep-well 
plate and mixed with 25 µL of medium or an ES stock leading to a concentration of 10 nM ES. 
For control cells were grown in SD, SD + 10 nM ES or SG. Cells constantly grown in SG + 
10 nM ES were used as positive control. For induction cells were induced with SG + 10 nM ES. 
After 30 min or 120 min, respectively, 200 µL of each sample were transferred to a fresh 96-
well plate and stored at 4 °C until measurement. The remaining cells were centrifuged, 
suspended in 500 µL SD + 10 nM ES and further grown at 25 °C. After 20 h, again 200 µL of 
each sample were transferred to the 96-well plate and stored at 4 °C until measurement. The 
samples were refilled with the corresponding medium and further grown for 76 h. Again 200 µL 
of each sample were transferred to the 96-well plate. The tGFP fluorescence was directly 
measured with Accuri™ C6 (BD) using the 96-well plate. The mean fluorescence and the 
percentage of fluorescent cells were exported to Microsoft Excel (Microsoft). For each sample 
the percentage of fluorescent cells was compared (Figure 38, bright colors). For the comparison 
of the samples the mean fluorescence of the positive control (corresponding strain grown for 
20 h in medium containing both inducers, namely SG + 10 nM ES) was set to 100 % and the 
respective percentage fluorescence in comparison to the positive control was calculated for the 
controls and samples (Figure 38, light colors). All time-points were applied for the samples. For 
the controls data was only applied for growth of 20 h. No significant change was obtained for 
further growth (data not shown).   
For both samples, the PC was clearly induced with around 85 % of fluorescent cells and a strong 
mean fluorescence. The negative controls were tightly regulated for the AND, GO. For AND, 
GO, pFL the controls SD and SG showed a slight increase in the number of fluorescent cells, but 
not for the mean fluorescence. Hence, more cells did show basal activity, but only at a low level. 
For the negative control SD + ES a significant increase of both, mean fluorescence and 
percentage of fluorescent cells, can be detected for AND, GO, pFL. Once more, the mean 
fluorescence did not increase as much as the percentage of fluorescent cells. It can therefore be 
assumed that due to the incorporation of the feedback loop the threshold for untargeted gene 
expression has dropped, but the general basal fluorescence has not increased to a great extent. 
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Figure 38 Induction experiment for the positive feedback loop. 
For the experiment cells of the AND, GO (blue) and AND, GO, pFL (orange) were used. As negative controls cells 
were grown in SD, SD + 50 nM ES and SG. As positive control cells were grown in SG + 10 nM ES. For the samples cells 
were induced with 10 nM ES and galactose, with galactose being removed after 30 min and 120 min. For both, 
fluorescence was measured directly, after growth for 20 h and 96 h, respectively. For all controls and samples, the 
percentage of fluorescent cells (dark color) and mean fluorescence (light color) was applied.  
 
The same results were obtained for the samples, which were only briefly incubated with 
galactose and then directly provided for measurement. For induction with galactose for 30 min, 
nearly no fluorescent cells were detected for AND, GO, but some for AND, GO, pFL. For 
induction with galactose for 120 min, again nearly no fluorescent cells were detected for AND, 
GO, but more than 30 % of the cells already expressed tGFP for AND, GO, pFL.  
When induced with galactose for 30 min and grown for 20 h, a significant difference between 
the two strains was obtained. The fluorescent pFL cells were about twice the number of cells 
from AND, GO. Only 25 % of the AND GO cells showed fluorescence, whereas 55 % of the pFL 
did. These numbers remained roughly constant even after growth for 96 h. Only the mean 
fluorescence did increase between 20 h and 96 h of induction. For the AND, GO strain after 
20 h 40 % and after 96 h 55 % of the PC fluorescence were obtained. In comparison for the pFL 
strain 85 % were already obtained after 20 h of induction, whereas 120 % were obtained after 
96 h. Due to the integration of the pFL, the percentage of the mean fluorescence has therefore 
increased more than twice. 
When induced with galactose for 120 min, for both strains and both timepoints the number of 
cells showing fluorescence was roughly 60 %. After growth of 20 h, a percentage of 165 % mean 
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fluorescence for the pFL was obtained, which slightly decreased after further growth. Hence, 
the maximum fluorescence was reached after 20 h and according to the microfluidic 
measurements, cells seemed to have reached an arrested state and stopped the production of 
tGFP. The ratio of the fluorescence of AND, GO to pFL roughly doubled after growth for 20 h, 
which was similar to the previous result. After growth for 96 h the mean fluorescence of AND, 
GO slightly increased, but remained with 70 % under the fluorescence of the PC.  
To sum up, the implementation of a positive feedback loop led to an increase of number of 
fluorescent cells as well as the maximum fluorescence, especially when galactose induction was 
only performed for a short period. In detail, the implementation of the positive feedback loop 
resulted in an increased number of fluorescent cells for both, controls and samples. For the 
control SD+ES this may be explained by the leakiness of the galactose switch (57). As long as 
no ES is added, the ES switch tightly regulated the expression of the transcription activator 
complex MCP-VP64. Hence, even in the presence of dCas9 and scRNA, the CIRPSR/dCas9 can 
only bind to tetO, but did not activate tGFP or dCas9 expression. As soon as ES is added and 
the basal expression of the galactose switch has led to the expression of a few dCas9 molecules, 
the AND gate is able to constantly produce more dCas9. The two-hairpin design of the scRNA 
was already demonstrated to achieve high expression rates, hence it can be assumed that a 
significantly higher number of dCas9 molecules will be produced than it was the case with the 
galactose switch only. The induction of MCP-VP64 by ES thus triggered a chain reaction, which 
activated the reporter gene expression to a certain degree even without the addition of 
galactose.  
However, the same chain effect is responsible for a quick induction and the achievement of high 
induction values. Even though a short induction with galactose and subsequent growth in SD 
+ ES is sufficient for the AND, GO to achieve a certain degree of tGFP expression, the number 
of cells showing fluorescence and especially the achieved mean fluorescence are much weaker, 
than for AND, GO, pFL. The higher number of AND, GO, pFL cells that are fluorescent may be 
explained by the circumstances, that dCas9 is a relatively large protein and the galactose-
inducible switching behavior is rather slow. As a result, for AND, GO the short galactose 
induction may only be sufficient to induce synthesis of a few dCas9 proteins per cell. These in 
turn might be insufficient to promote full activation of the CRISPR system. In comparison, for 
the AND, GO, pFL already a single dCas9 molecule may be sufficient to produce more dCas9 
proteins and hence start the already described chain reaction.  
On the other hand, the significantly increased mean fluorescence is more difficult to explain. 
Upon positive feedback loop mediated overexpression of dCas9, a significant increase of 
maximum reporter gene expression was observed. Hence, the experimental results suggest, that 
dCas9 had been the limiting factor for the further increase of the expression rate. Earlier 
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research, however, does not support this hypothesis (106,204). Instead Jinek et al. 
demonstrated, that gRNA expression and/or assembly of the gRNA into Cas9 are the limiting 
factors of CRISPR/(d)Cas9 mediated gene expression (204). According to this idea, it is 
conceivable that due to the significantly higher number of dCas9 molecules achieved due to the 
integration and activation of the positive feedback loop, the assembly of the scRNA with dCas9 
is no longer a limiting factor. As a consequence, a significantly higher maximal expression of 
the reporter gene would be possible. To further investigate this hypothesis, another feedback 
approach was designed aimed at generating a fast degrading tGFP variant that would allow one 
to precisely investigate, at which time point how much tGFP is expressed. 
Nevertheless, the pFL was demonstrated to be functional and the anticipated requirements of a 
reduction of galactose induction to a short period as well as a high reporter gene expression 
rate were completely fulfilled. 
 
5.4.3. Construction of a positive feedback loop containing a fast-degrading tGFP 
With the clone AND, GO, pFL a positive feedback loop was established. Nevertheless, due to the 
long half-life of tGFP (196,205), a time-dependent induction of tGFP expression could not be 
measured. Hence, after tGFP has been first expressed, it will remain in the cell and after some 
time it cannot be easily determined whether further tGFP is produced. In order to solve this 
problem, tGFP should be combined with a protein degradation tag, leading to a fast degradation 
and more precise analysis of the feedback loop.  
A new clone was designed using CasEMBLR. Following the AND switch design, MCP-VP64 
expression was controlled by ES, dCas9 expression was controlled by galactose and scRNA was 
continuously expressed from a plasmid (Figure 39A). After induction with ES and galactose, 
the CRISPR/dCas9 system binds to the tetO binding region, leading to the expression of Ubi-
tGFP and dCas9 (Figure 39B). To achieve a fast degrading tGFP a degradation tag was fused to 
the N-terminus. It was decided to use Ubi-Y, which was classified as a medium strong 
degradation tag (206). Ubi-Y was already used in yeast, resulting in detectable levels of 
fluorescence only at high expression levels (42). Since the utilized AND gate results in high 
tGFP levels, the Ubi-Y tag was chosen to allow tGFP detection only when the reporter gene 
expression is strongly activated. This setup should also reduce the relatively high basal activity 
of the positive feedback loop design. As before, the CRISPR genes were integrated into the ade2 
locus, the reporter genes and the hTF in the his3 locus and tetO-dCas9 as well as the scRNA as 
a plasmid (Figure 39C). 
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Figure 39 Schematic and genetic overview of the positive feedback loop with a Ubi-tGFP. 
(A) Schematic overview and (B) logic gate for the positive feedback loop with a Ubi-tGFP. Both showing, that MCP-
VP64 is inducible by ES and dCas9 is inducible by galactose, whereas the scRNA stays constitutively expressed. Only 
when all components are expressed, they bind to tetO and induce Ubi-tGFP expression. Additionally, a dCas9 placed 
behind tetO, will be expressed. Thus, dCas9 will be produced without further induction and galactose can be 
removed. (B) The AND, GO setup was utilized for the feedback loop implementation. (C) Genomic overview for the 
feedback loop including homologous flanks for genomic integration as well as the reporter gene combination 
containing the Ubi-tGFP, that was genomically integrated. The tetO-dCas9 plasmid is shown as well.  
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In order to implement an ES- and galactose-dependent AND switch, the fusion protein MCP-
VP64 was genetically placed behind four lexA boxes. The dCas9 was placed behind the PGAL10 
and both genes were integrated into the ade2 locus. The 7x tetO-Ubi-Y-tGFP reporter and the 
LexA-ER-B112 hTF were integrated into the his3 locus. To amplify the parts with the required 
flanks, PCR was performed following the manufacturer’s instructions using either Q5® High-
Fidelity DNA Polymerase or Phusion® High-Fidelity DNA Polymerase (New England Biolabs, 
Inc.). All parts used for the construction of the Ubi-tGFP AND gate are listed in Table 29. After 
amplification, the correct size of the constructs was verified by agarose gel electrophoresis. The 
DNA was purified using the Wizard® SV Gel and PCR-Clean up System (Promega). 
Table 29 Parts utilized for the construction of the Ubi-tGFP AND gate. 
Part Method fw rv Template Size [bp] c [ng/µL]  pmol/µL  
fAH025 PCR, Q5 A1, A11 A12 pFRP793 590 22.00 0.11 
fAH027 RT PCR, Phu A13 A20, A10 pJZC638 6746 22.30 0.01 
fAH032 RT PCR, Phu H33 H6, H7 pFRP880 3063 39.46 0.04 
fAH048 PCR, Q5 H1, H3 oAH066 pSLQ.119 895 53.39 0.18 
fAH049 PCR, Q5 oAH067 oAH068 pYTK042 405 77.19 0.58 
fAH050 PCR, Q5 oAH069 H35 PCT_2A-GFP 1110 111.90 0.31 
gRNA (H) - - - - - 53 - 
gRNA (A) - - - - - 80.17 - 
 
For in vivo assembling of the parts, 4 picomoles of each part were mixed with 1 µg of the 
corresponding gRNA plasmid. An exception was made for very large parts. For these parts, 
0.5 µg of DNA were used. The parts and plasmid were precipitated and suspended in 5 µL 
nuclease free water (0). The utilized parts and plasmids for the genomic integrations as well as 
the concentrations used for precipitation, can be found in Table 30. 
Table 30 Used concentrations and parts for Ubi-tGFP AND gate transformation 
Part for 4 pmol [µL] for 1 µg [µL] Use [µL] T2B T2C total V total [µL] 
fAH025 35.40 15.26 35 X  1 35 
fAH027 399.31 26.09 22 X  1 22 
fAH032 102.46 25.34 25  X 1 25 
fAH048 22.13 18.73 22  X 1 22 
fAH049 6.93 12.96 7  X 1 7 
fAH050 13.09 8.94 13  X 1 13 
gRNA (H)  9.42 10  X 1 10 
gRNA (A)  12.47 15 X  1 15 
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For the genetic integration, the chemo competent strain cSLQ.Sc002_p414 was used for a two-
step CasEMBLR transformation. The ade2 parts were transformed, plated on SD-trp-leu drop-
out agar plates and grown for up to 120 h. After the successful integration of the CRISPR parts 
into the ade2 locus, the colonies turned red. For those cells, correct part assembly and correct 
genomic integration were verified by cPCR using the oligonucleotides A15, A18 (correct 
integration into the genome), A25, A26, A27 and A28 (correct assembly) (data not shown).  
In a second transformation step, the 7x tetO-Ubi-Y-tGFP reporter gene and the hTF were 
integrated into the his3 locus. Cells positively tested on the integration of the CRISPR genes 
were made chemo-competent and transformed with the parts for his3. Cells were plated on 
SD-trp-leu drop-out agar plates and grown for up to 120 h. Correct part assembly as well as 
correct genomic integration were verified by cPCR using the oligonucleotides H43, H44, H12, 
H14 (correct integration into the genome), fw_gene-gene_lexA FP and rv_gene-gene_lexA FP 
(correct assembly) (data not shown). The successful transformed clone was named Ubi, wt.  
After successful genomic integration, the CasEMBLR plasmids were removed as described in 
5.2.2. One plasmid-free clone per AND switch was selected for further experiments and 
subsequently transformed via electroporation with 2 µg of the scRNA plasmid pJZC588 (Ubi, 
scRNA) or 1 µg of both, pJZC588 and pAH019 (Ubi, pFL). Cells were plated out on SD-ura 
drop-out agar plates or SD-trp-ura drop-out agar plates and correct plasmid integration was 
verified by cPCR.  
 
5.4.4. Examination of the functionality of the Ubi-tGFP positive feedback loop 
In this chapter the general functionality and inducibility of the new setup was verified. 
Therefore, five clones were inoculated: the AND, GO gate; the AND, GO, pFL; the Ubi wt, 
containing the ES inducible MCP-VP64 and the galactose inducible dCas9, but no scRNA; the 
Ubi, scRNA, inserting the constitutively expressed tetO-binding scRNA; the Ubi, pFL, containing 
both, the scRNA and the positive feedback loop. 
All clones were inoculated in 10 mL and induced in a 96-deep-weel-plate following the protocol 
described in 4.4.3. Cells containing the pJZC588 and pFL were grown in -trp-ura drop-out 
medium, cells containing only pJZC588 in -ura drop-out medium and Ubi, wt in full SD. 
Induction was performed in biological triplicates in 96-deep-well plates. For every strain a cell 
suspension with an OD600 of 1 was prepared and subsequently used for induction. 475 µL of 
this cell mixture were pipetted into a 96-deep-well plate and mixed with 25 µL of medium or 
an ES stock leading to a concentration of 50 nM ES. For controls, cells were grown in SD and 
for induction in SG + 50 nM ES. After 20 h of growth at 25 °C, 200 µL of each sample was 
transferred to a 96-well plate and stored at 4 °C until measurement. The remaining sample 
volume was filled up to 450 µL with the corresponding medium and cells further grown for 
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24 h. Again 200 µL of each sample were transferred to the 96-well plate. The tGFP fluorescence 
was directly measured with Accuri™ C6 (BD) using the 96-well plate. The average of the mean 
fluorescence and the standard deviation of the gated triplets were calculated for 20 h (Figure 
40) and 48 h (Supplementary Figure 54) of induction using Microsoft Excel (Microsoft). 
 
 
Figure 40 Induction experiment for the positive Ubi-tGFP feedback loop. 
For the experiment cells of the AND, GO, AND, GO, pFL, Ubi wt (not containing a scRNA), Ubi, scRNA and Ubi, pFL 
were used. As negative control cells were grown in SD. As positive control cells were grown in SG + 10 nM ES for 24 h. 
Error bars indicate the standard deviation of the biological triplicates 
 
None of the new Ubi clones showed fluorescence at any time point, whether induced or not. 
The fluorescence of those samples corresponded to that of the non-induced AND, GO and AND, 
GO, pFL. Induction was generally successful, since AND, GO and AND, GO, pFL were strongly 
activated. It can be assumed, that the Ubi strains are either generally not inducible or, more 
likely, the Ubi-Y tag induces tGFP degradation so efficiently that the accumulation in the cell is 
negligible. For further experiments another degradation sequence could be considered such as 
the degradation domain of mouse ornithine decarboxylase that was already successfully used 
to reduce the half-life of tGFP (205,207). 
Nevertheless, this measurement demonstrated how strongly tGFP expression is increased by the 
positive feedback loop. As can be seen from Figure 42, the fluorescence of pFL is about 7x 
stronger than the one of the normal AND gate. Since with this experiment and the one described 
in 5.4.2, the criteria for the positive feedback loop are fulfilled, no further experiments with a 
less effective degradation tag were performed. 
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5.5. Transfer of the AND setup to achieve an inducible scRNA 
In the previous chapters it was shown, that both, the fusion protein MCP-VP64 as well as dCas9, 
are excellently suited for inducible expression. However, the inducible expression of the scRNA 
was not yet investigated. Therefore, this chapter deals with the design and implementation of 
an inducible scRNA into a functional CRISPR/dCas9 system. 
 
5.5.1. Self-cleaving ribozymes for a functional scRNA 
There is a major challenge for the design of an inducible scRNA switch: the scRNA gene has to 
be transcribed into a functional scRNA. Therefore, conventionally promoters transcribed by 
RNA polymerase III (pol III) like U3, U6 or SNR52 are used (103,129). The physiological 
function of RNA pol III is to transcribe small nuclear RNA genes such as U6 and U3 snRNA as 
well as ribosomal genes like 5S rRNA or tRNA (208). Hence, RNA pol III is optimally suited for 
the transcription of a gRNA or scRNA, respectively. However, there are multiple limitations to 
RNA III-based gene expression. Due to the constitutive and ubiquitous expression of U6 and U3 
snRNA genes, it is not possible to express a gene cell or tissue specific (158,208). Additionally, 
in many organisms those promoters have not been characterized yet, making it even more 
challenging to design a functional CRISPR system (158). RNA Pol III also has a limited capacity 
to yield long RNA transcripts, making it difficult to express larger genes. The most restraining 
limitation in the scope of this work was the limitation of tightly regulated inducible RNA pol III 
promoters (209–211). 
In comparison, for RNA polymerase II (pol II), which has the physiological function to transcribe 
the majority of mRNA, there are already multiple inducible promoters available. mRNAs 
expressed from these promoters undergo extensive processing and modification at both ends, 
like capping or polyadenylation (212). Additionally, mRNAs expressed by RNA pol II promoters 
are actively transported out of the nucleus into the cytoplasm. Since the CIRPSR complex has 
to form in the nucleus to be able to target the genomic DNA, this transport would lead to an 
unfunctional CRISPR system (158). 
To sum up, the utilized RNA pol III promoter SNR52 is sufficient for constitutive and cell/tissue 
unspecific expression, but does not allow inducible scRNA expression (Figure 41A). Instead 
inducible scRNA expression by RNA pol II promoters like the inducible lexA-minimal promoter 
region is generally possible, but will lead to the processing of the scRNA and its transport out 
of the nucleus, resulting in a non-functional scRNA (Figure 41B). Thus, the simple exchange of 
the RNA pol III promoter SNR52 by the RNA pol II lexA-minimal promoter region is not possible.  
Nevertheless, in 2014 Gao and Zhao demonstrated the successful transcription of a gRNA by 
the RNA pol II promoter Adh1 (158). To this end, they took advantage of the nuclease activity 
of ribozymes (213,214) and designed a setup, where the gRNA was genetically flanked by two 
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ribozymes resulting in the construct Ribozyme-gRNA-Ribozyme. They used a ribozyme of the 
type Hammerhead (HH) (215) at the 5’‐end of the gRNA and hepatitis delta virus (HDV) 
ribozyme (216) at the 3’‐end. After transcription the ribozymes undergo precise self-catalyzed 
cleavage, followed by the release of a functional gRNA (158). Following this setup, the design 
of a ribozyme flanked scRNA should allow the inducible expression by RNA pol II (Figure 41C). 
 
 
Figure 41 Promoter change leading to the recruitment of a different RNA polymerase. 
The different promoter setups are shown for (A) the RNA polymerase recruiting SNR52 promoter and (B) + (C) the 
RNA polymerase recruiting and ES inducible lexA minimal promoter. (A) results in a functional scRNA. (B) does not 
result in a functional scRNA. (C) results in a ribozyme flanked mRNA transcript, whom is subsequently cleaved off 
and a functional scRNA is achieved.  
 
5.5.2. Construction of a CRISPR/dCas9 system using a ribozyme flanked scRNA  
Following the design of Gao and Zhao, the HH ribozyme was placed at the 5’‐end and the HDV 
ribozyme at the 3’‐end of the tetO-binding scRNA. The HH-scRNA-HDV construct was expressed 
from the strong constitutive RNA pol II promoter Adh1. To find out, whether the ribozyme setup 
was applicable to the CRIPSR/dCas9 system and functional even when transcribed by 
RNA pol II, it was integrated into the galactose inducible Ssw, 7x tetO (Figure 42A). In this 
construct, dCas9 is inducible by galactose and both, MCP-VP64 and the scRNA as HH-scRNA-
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HDV construct, are constitutively expressed (Figure 42B). This setup does not only allow one 
to verify the functionality of scRNA expression by RNA pol II expression, but it also enables one 
to test, whether the construct leads to an enhanced leakiness or reduction of reporter gene 
expression. Furthermore, this setup could be used to test, whether the scRNA-ribozyme 
construct works with the galactose switch in order to build an AND switch in further 
experiments. As reporter gene the fluorophore Venus was used (Figure 42C). 
For the HH-scRNA-HDV construct, the plasmid pJZC625 was utilized (3.2) (5). The plasmid 
already contained the HH-scRNA-HDV construct under control of Adh1. Hence, pJZC625 could 
be used directly for transformation into the target strain Ssw, 7x tetO. For transformation, cells 
of the strain Ssw, 7x tetO were freshly inoculated and grown overnight. Cells were made 
electrocompetent and transformed with 2 µg of the plasmid pJZC625. After transformation, 
selection was performed using SD-ura drop-out agar plates. The cells were grown for 48 h at 
30 °C. Correct plasmid integration was verified by cPCR using the oligonucleotides scRNA31 
and scRNA32 (data not shown). One correct clone was cultivated and stored at -80 °C.  
 
5.5.3. Examination on the functionality of the ribozyme setup 
After successful transformation, the growth, induction and analysis of the Ssw, 7x tetO, HH-
scRNA-HDV strain was performed. As a control the Ssw, 7x tetO containing the plasmid 
pJZC588 was used. This plasmid contained the SNR52 promoter, constitutively expressing the 
scRNA trough RNA pol III. Cells of both strains were inoculated and induced in -ura drop-out 
medium in tubes according to the protocol described in 4.4.2. Both strains were grown in SD 
medium as a negative control and in SG for induction. The Venus fluorescence was measured 
via Accuri™ (BD) and analysis was performed using the Accuri™ software (BD). The resulting 
histograms were applied to Figure 43. 
For the Ssw, 7x tetO, HH-scRNA-HDV strain a clear Venus expression was obtained, when 
induced with SG. In comparison, no fluorescence was detected for the negative control. When 
compared with the strongly Venus expressing strain Ssw, 7x tetO, no significant difference was 
detected. In both cases, the expression pattern of the strains was very similar. When grown in 
SD only, both strains demonstrated the same basal expression. When grown in the galactose 
containing induction medium SG, the strains equally strong expressed Venus.  
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Figure 42 Schematic and genetic overview of the Ssw combined with a ribozyme flanked scRNA. 
(A) Schematic overview and (B) logic gate for the Ssw combined with a ribozyme flanked scRNA and a constitutive 
RNA polymerase II promoter. Both showing, that MCP-VP64 and the HH- scRNA-HDV are continuously expressed, 
whereas the dCas9 is inducible by galactose. When all components are expressed, they bind to tetO and induce Venus 
expression. (C) Genomic overview for the Ssw including homologous flanks for genomic integration as well as the 
gene combinations, that were already genomically integrated. 
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Figure 43 Galactose induction of the Ssw, 7x tetO, HH-scRNA-HDV strain. 
Comparative induction experiment for the strains Ssw, 7x tetO and Ssw, 7x tetO, HH-scRNA-HDV. Both clones were 
grown in SD-ura medium (Ssw black, Ssw HH-scRNA-HDV grey) as a negative control and in SG-ura medium (Ssw 
khaki, Ssw HH-scRNA-HDV green) for induction. 
 
From these results, it can be assumed that the ribozyme setup is functional in the utilized three 
component CRIPSR/dCas9 system. The scRNA ribozyme construct expressed by RNA pol II 
works as well as the plain scRNA does which is expressed by RNA pol III. Therefore, the HH-
scRNA-HDV setup can successfully be used for scRNA transcription from RNA pol II promoters. 
As a next step, the inducible lexA-minimal promoter construct should be tested with the HH-
scRNA-HDV setup. 
 
5.5.4. Construction of an ES inducible scRNA and assembly to an AND gate 
The general functionality of the HH-scRNA-HDV setup was verified using the constitutive RNA 
pol II promoter Adh1. Since the setup proved to be functional, it was used to build an AND gate 
based on an ES inducible scRNA and a galactose inducible dCas9 (Figure 44A+B). In order to 
build such an AND gate, the galactose-inducible strain Ssw, 7x tetO was transformed with the 
necessary genes for ES inducibility. Since the strain Ssw, 7x tetO already contained two genomic 
integrations, the hTF LexA-ER-B112 was implemented as a plasmid named pAH015 (Figure 
44C). The lexA_HH-scRNA-HDV construct was also implemented as a plasmid, namely pAH021. 
For the design and construction of the plasmid pAH015 containing the hTF LexA-ER-B112, the 
backbone of p425_αAde was combined with the hTF insert amplified from the plasmid 
pFRP880. The backbone contained a 2µ ori and LEU as selection marker. The fragments and 
utilized concentrations for the new plasmid pAH015 are listed in Table 31.  
Table 31 Fragments and concentrations utilized for the construction of pAH015. 
Fragment Method fw rv Template Size [bp] c [ng/µL] Use [µL] 
FP1 PCR, Phu FP9 FP10 p425_aAde 6822 22,24 50 
FP2 PCR, Phu FP11 FP12 pFRP880 3017 23,82 50 
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Figure 44 Schematic and genetic overview of the AND gate achieved by an inducible scRNA. 
(A) Schematic overview and (B) logic gate for the Ssw combined with an inducible scRNA. Both showing, that MCP-
VP64 is continuously expressed, whereas the dCas9 is inducible by galactose and the HH-scRNA-HDV is inducible by 
ES. When all components are expressed, they bind to tetO and induce Venus expression. (C) Genomic overview for 
the Ssw including homologous flanks for genomic integration as well as the gene combinations, that were already 
genomically integrated. Additionally, the plasmid based hTF lexA-ER-B112 is shown. 
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In order to perform gap repair, the DNA was prepared according to the protocol described in 
4.1.7. After gap repair in chemo competent yeast cells, correct plasmid assembling was verified 
by cPCR using the oligonucleotides lexA FP 7 and lexA FP 13. A correct clone was chosen, 
isolated using the Zymoprep™ Yeast Plasmid Miniprep II Kit (Zymoresearch), transformed into 
electrocompetent E. coli cells and isolated using the PureYield™ Plasmid Miniprep System Kit 
(Promega). The correct plasmid sequence was verified by sequencing using the oligonucleotide 
lexA FP 7 (data not show).  
For design and construction of the inducible scRNA plasmid pAH021, multiple cloning steps 
were necessary. In total three different plasmids were generated to integrate all required parts. 
Each plasmid was generated as described for pAH015. Hence, only the cPCR and sequencing 
primers are noted without further experimental explanations. The plasmid cards for the 
intermediate plasmids pJZC588/lexA and pAH013 are not shown.  
In a first step the intermediate plasmid pJZC588/lexA was generated by gap repair. The 
backbone of the plasmid pJZC588, containing a CEN/ARS ori and an URA selection marker, 
was combined with the 4x lexA boxes from the plasmid pFRP793. The fragments and utilized 
concentrations for the new plasmid pJZC588/lexA are listed in Table 32. For cPCR the 
oligonucleotides fw_lexA+scRNA_ColonyPCR and rv_lexA+scRNA_ColonyPCR were used and 
for sequencing the oligonucleotide fw_lexA+scRNA_ColonyPCR (data not shown). 
Table 32 Fragments and concentrations utilized for the construction of pJZC588/lexA. 
Fragment Method fw rv Template Size [bp] c [ng/µL] Use [µL] 
scRNA1 digestion XbaI EcoRI pJZC588 5255 - 8 
scRNA2 PCR, Q5 lexA up lexA lo1 pFRP793  489 - 10 
 
After successful integration of the lexA boxes into the scRNA-plasmid backbone, in the second 
transformation step, the HH-scRNA-HDV construct was implemented into the new plasmid 
pH013. Therefore, the backbone of the plasmid pJZC588/lexA was digested and fused via gap 
repair to the HH-scRNA-HDV insert amplified from the plasmid pJZC625. The fragments and 
utilized concentrations for the new plasmid pJZC588/lexA are listed in Table 33. For cPCR the 
oligonucleotides fw_lexA+scRNA_ColonyPCR and scRNA32 were used. For sequencing the 
oligonucleotide fw_lexA+scRNA_ColonyPCR was used (data not shown). 
Table 33 Fragments and concentrations utilized for the construction of pAH013. 
Fragment Method fw rv Template Size [bp] c [ng/µL] Use [µL] 
V5 digestion BamHI EcoRI pJZC588/lexA 5353 23,86 40 
scRNA6 PCR, Q5 scRNA33 scRNA34 pJZC625 776 62,76 16,3 
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In a control experiment, the plasmid pAH013 was able to partially induce Venus expression in 
absence and fully in the presence of ES (data not shown). Since the directly attached URA 
selection marker did not possess a terminator, translational read-trough lead to the 
transcription of (some) HH-scRNA-HDV mRNAs (217). Due to the self-catalyzed cleavage of the 
ribozymes, functional scRNA could be produced from any transcript. Nevertheless, the plasmid 
already contained the lexA_HH-scRNA-HDV construct, which was used for the construction of 
the final plasmid pAH021. The plasmid pAH021 was built from a pJZC588 backbone containing 
a CEN/ARS ori and an URA selection marker, the lexA_HH-scRNA-HDV construct amplified 
from pAH013 and the CYC1 terminator placed behind the URA selection marker amplified from 
pFRP793. The assembled plasmid is shown in 3.2. The fragments and utilized concentrations 
for the new plasmid pAH021 are listed in Table 34. For cPCR the oligonucleotides oAH007 and 
rv_lexA+scRNA_ColonyPCR and for sequencing the oligonucleotide oAH011 and rv_ 
lexA+scRNA_ColonyPCR were used (data not shown). 
Table 34 Fragments and concentrations utilized for the construction of pAH021. 
Fragment Method fw rv Template Size [bp] c [ng/µL] Use [µL] 
fAH010 PCR, Q5 oAH005 oAH006 pAH013, I 1212 24,72 50 
fAH011.1 digestion KpnI NsiI pJZC588 4025 34,26 25 
fAH012 PCR, Q5 oAH009 oAH010 pFRP793 250 11,42 25 
 
After the successful generation of pAH015 and pAH021, transformation of both plasmids was 
performed into electrocompetent Ssw, 7x tetO cells. Selection was performed using SD-leu-ura 
drop-out agar plates. Cells were grown for 48 h at 30 °C. Correct plasmid integration was 
verified by cPCR using the oligonucleotides lexA FP 7 and lexA FP 13 for pAH015 and oAH007 
and rv_lexA+scRNA_ColonyPCR for pAH021 (data not show). The strain now contained all 
genes for a functional AND gate based on the ES inducible scRNA and hence is called AND, 
scRNA.  
As a control the plasmid pAH021 was transformed into electrocompetent Ssw, 7x tetO cells as 
well. Without the plasmid pAH015 the hTF LexA-ER-B112 is missing, which is necessary to 
allow ES dependent induction, hence this strain served as negative control. After 
transformation, selection was performed using SD-ura drop-out agar plates. Cells were grown 
for 48 h at 30 °C. Correct plasmid integration was verified by cPCR using the oligonucleotides 
oAH007 and rv_lexA+scRNA_ColonyPCR for pAH021 (data not show). This strain is named 
NC in the following experiment. 
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5.5.5. Examination on the functionality of the ES inducible ribozyme-flanked scRNA 
After the successful generation of the strains AND, scRNA and NC, a first comparative 
experiment was performed. Therefore, the cells were inoculated and induced in tubes according 
to the protocol described in 4.4.2. The AND, scRNA cells were grown in medium with the 
dropout mixture -ura-leu, whereas the NC was grown in medium with the drop-out 
mixture -ura. Cells were induced by growth in SG + 1 nM ES, 10 nM ES and 100 nM ES. This 
setup allows one to check whether ES dose-dependent inducibility was achieved. As control the 
cells were grown in SD, SD + 100 nM ES and SG. The tGFP fluorescence was measured via 
Accuri™ (BD) and analysis was performed using the Accuri™ software (BD). The mean 
fluorescence and the percentage of fluorescent cells were exported to Microsoft Excel 
(Microsoft). The percentage of fluorescent cells was calculated from Accuri flow cytometry 
measurements (Figure 45, bright colors). For the comparison of the mean fluorescence the 
sample AND, scRNA SG + 100 nM ES was set as 100 % and the respective percentage 
fluorescence in comparison to this sample was calculated for the controls and samples (Figure 
45, light colors).  
The NC did show approximately the same percental mean fluorescence of only 5 % and fraction 
of fluorescent cells of 20 % for all samples. In comparison, the AND, scRNA did show an 
increased tGFP expression when induced with ES. Hence, the strain NC was suited to serve as 
a negative control and the AND, switch was demonstrated to be functional. The number of 
fluorescent cells and the mean fluorescence correlated well. Hence, it is sufficient to analyze 
only one of the parameters in future experiments.  
 
 
Figure 45 Induction experiment for the inducible scRNA based AND gate. 
For the experiment cells of the strains Ssw, 7x tetO, HH-scRNA-HDV (NC, blue) and AND, scRNA (peach) were used. 
Both strains were grown in SD, SD + 100 nM ES, SG, SG + 1 nM ES, SG + 10 nM ES and SG + 100 nM ES. For all samples 
the percentage of fluorescent cells (dark color) and percentual mean fluorescence (light color) was applied. 
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For the control cells grown in SD or SG, no difference between NC and AND, scRNA was 
detected. Hence, the ES inducible scRNA is tightly regulated. A significant difference between 
the strains was visible for the control SD + 100 nM ES, where the AND, scRNA did show an 
increased number of fluorescent cells as well as an increased mean fluorescence. To investigate 
the effect of the HH-scRNA-HDV complex, an analysis on RNA (5.5.6) and DNA level was 
performed (5.5.7).  
After induction of the strain AND, switch with 1 nM ES a slight increase in the number of 
fluorescent cells and in the mean fluorescence was observed. But when induced with 10 nM ES 
or 100 nM ES, nearly 80 % of the cells did show fluorescence and a bright mean fluorescence 
was achieved. As a matter of fact, the difference between 1 nM and 10 nM ES was significantly 
greater than that for 10 nM to 100 nM ES. Therefore, it can be assumed that 10 nM ES is already 
close to the smallest concentration for maximum induction. This dose-dependency was 
investigated in further experiments (5.5.8).  
 
5.5.6. Analysis of the HH-scRNA-HDV construct on RNA level 
For the analysis of the HH-scRNA-HDV construct, it was important to examine the actual 
ribozyme self-cleavage capacity. Therefore, the RNA was extracted from the cells, purified and 
reverse transcribed into cDNA. This cDNA was then used for PCR to determine, if none, one or 
both ribozymes were attached to the scRNA (Figure 46A).  
Therefore, five different strains were utilized. Four of the five strains contained a scRNA, three 
the HH-scRNA-HDV setup. The AND, scRNA strain was used twice, once induced and once not 
induced. The strain cSLQ.sc002 was used as negative control, since it did not contain any scRNA 
genes. The utilized strains and the growth/induction media are described in Table 35.  
Table 35 Strains utilized for RNA analysis with the gene of interest and growth/induction medium. 
Number GOI Strain  Medium 
1 NC cSLQ.sc002 SD 
2 scRNA Ssw, 7x tetO scRNA SD-ura 
3 HH-scRNA-HDV Ssw, 7x tetO HH-scRNA-HDV SD-ura 
4 lexA_ HH-scRNA-HDV AND, scRNA SD-ura-leu 
5 Ind. lexA_ HH-scRNA-HDV AND, scRNA SG-ura-leu + 50 nM ES 
 
 
For scRNA expression, the strains were freshly inoculated in 5 mL of the corresponding medium 
and grown overnight. The cell density was determined and 5 mL of the corresponding medium 
were inoculated towards an OD600 of 1. The cells were grown for 20 h at 25 °C. Afterwards the 
cells were pelleted and both, RNA and DNA extracted as described in 4.3.1. The DNA was 
removed by addition of TURBO-DNase and subsequent RNA purification. The concentration of 
the extracted RNA was determined using the ND-1000 Spectrophotometer and adjusted to 
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100 ng/µL for further experiments. For quality control, 500 ng of the RNA samples were applied 
on a 1 % agarose gel (Figure 46B). As marker, the 1kb DNA-ladder (vwr) was used. Extraction 
was successful for all five samples, even though the bands for the NC were faint.  
The extracted RNA was used for cDNA synthesis as described in 4.3.2. Reverse transcription 
was performed using the reverse transcriptase M-MuLV (New England Biolabs). As a control, the 
same experiment was performed without the addition of the reverse transcriptase, hence no 
cDNA was produced. The obtained cDNA was used for PCR amplification with four different 
oligonucleotide pairs. First a pair of the oligonucleotides oAH019 and oAH21 was used, that 
amplified HH-scRNA (HH-scRNA), the second pair oAH020 and oAH22 amplified scRNA-HDV 
(scRNA-HDV) and the third pair oAH20 and oAH21 amplified the scRNA only (scRNA). As a 
control the oligonucleotide pair ura3 204 and ura3 205 was used, that amplified a 200 bp long 
fragment from the yeast ura3 gene (PC), which is present in all yeast strains. This sample served 
as a positive control. After PCR with the Taq polymerase (New England Biolabs), the samples 
were applied to a 3 % agarose gel. As marker, the Ultra Low Range DNA-Leiter II, 
peqGOLD (vwr) was used. The results of the experiment are shown in Figure 46C. The 
experiment was performed twice in order to verify the results. The results for the second 
experiment are shown in Supplementary Figure 55. 
For the control experiment, in which no reverse transcriptase was added, no PCR product was 
obtained. Hence, no off-target binding to e.g. remaining RNA did occur. When reverse 
transcriptase was added, the correct sized PCR product was obtained for the ura gene for all 
five strains. Hence, the RNA extraction, reverse transcription into cDNA and amplification via 
PCR did generally work. The oligonucleotides to amplify the scRNA were used to verify the 
expression of the scRNA. The detection of scRNA was possible for the strains 2 - 5. The sample 
2 and 3 expressed the scRNA gene constitutively. For the samples of the AND, scRNA strain, 
only the ES induced sample 5 should lead to a PCR fragment. For samples 2, 3 and 5, the scRNA 
fragment was confirmed, but a slight band was also visible for sample 4. Due to the sensitivity 
of the method PCR, already small amounts of DNA are sufficient for amplification and 
achievement of a PCR fragment (218). Additionally, as described in 5.5.4, after read-trough of 
other genes on the plasmid, the HH-scRNA-HDV construct allows the successful expression of 
the scRNA. It can be assumed, that a small amount of functional scRNA was either achieved by 
basal expression, which is rather low for the ES switch (4,46,45), or by read-trough of the 
plasmid (217), which led to the weak band detectable for sample 4. 
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Figure 46 RNA extraction and cDNA analysis for the HH-scRNA-HDV construct. 
(A) The planned PCR strategy, in which three different fragments should be tested. (B) Isolated RNA applied on a 
1 % agarose gel. As marker, the 1kb DNA-ladder (vwr) was used. (C) PCR of the reverse transcribed cDNA showing 
which fragment could be amplified. On the top, cDNA was reverse transcribed using the M-MuLV reverse 
transcriptase (New England Biolabs). On the bottom the control is shown, where no -MuLV reverse transcriptase was 
added. Samples were applied to a 3 % agarose gel. As marker, the Ultra Low Range DNA-Leiter II, peqGOLD (vwr) 
was used. 
 
After successfully demonstrating that the scRNA is expressed, the other two oligonucleotide 
pairs were used to investigate whether the ribozymes were cleaved off. If the ribozymes had 
successfully performed auto-cleavage, amplification with these primers should not be possible 
and no band should be detectable. Only the strains 3 to 5 contained the HH-scRNA-HDV 
construct and thus only bands could occur here. After PCR, no fragments were detected for any 
of the samples. Hence, auto-cleavage of the HH ribozyme was successfully performed. For 
scRNA-HDV no fragments were detected for sample 4 and 5. However, a band was amplified 
for sample 3, which expressed the HH-scRNA-HDV construct from the strong constitutive Adh1 
promoter. This leads to the assumption that due to the high expression rate, at the time of the 
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RNA isolation of the sample, not all HDV ribozymes were cleaved off eventually leading to the 
generation of a cDNA/PCR product. 
To sum up, the expression of the scRNA on RNA level as well as the successful and complete 
auto-cleavage of the ribozyme HH and the mostly complete auto-cleavage of the ribozyme HDV 
were demonstrated. The results were confirmed by the Supplementary Figure 55. In a next step, 
it should be investigated to what extent the ribozymes are actually necessary to express a 
functional scRNA by the lexA-minimal promoter. 
  
5.5.7. Analysis of the HH-scRNA-HDV construct on DNA level 
To analyze, if none, one or both ribozymes are necessary and/or sufficient for functional scRNA 
expression, three new plasmids were designed, build and implemented into the Ssw, 7x tetO 
strain together with pAH015. The plasmids pAH024, containing lexA_scRNA, the plasmid 
pAH025, containing lexA_HH-scRNA, and the plasmid pH026, containing lexA_scRNA-HDV 
were built by gap repair after 4.1.7. For all plasmids the backbone was generated by digestion 
of pAH021, bringing in a CEN/ARS ori, an URA selection marker and the lexA_minimal 
promoter. The inserts were amplified from the plasmids pJZC588 and pJZC625. The fragments 
and utilized concentrations for the new plasmids pAH024, pAH025 and pAH026 are listed in 
Table 36. 
Table 36 Fragments and concentrations utilized for the construction of pAH024-26. 
For plasmid Fragment Method fw rv Template Size [bp] c [ng/µL] Use [µL] 
pAH024-26 fAH018 digestion PstI AleI-v2 pAH021 5236 29,97 12 
pAH024 fAH019 PCR, Q5 oAH025 oAH026 pJZC588 212 14,00 20 
pAH025 fAH020 PCR, Q5 oAH027 oAH028 pJZC625 230 20,00 15 
pAH026 fAH021 PCR, Q5 oAH025 oAH029 pJZC625 277 15,00 25 
 
In order to perform gap repair, the DNA was prepared according to the protocol described in 
4.1.7. After gap repair in chemo competent yeast cells, correct plasmid assembly was verified 
by cPCR using the oligonucleotides fw_lexA+scRNA_ColonyPCR and oAH031. A correct clone 
was chosen, the plasmid isolated using the Zymoprep™ Yeast Plasmid Miniprep II Kit 
(Zymoresearch), transformed into electrocompetent E. coli cells and isolated using the 
PureYield™ Plasmid Miniprep System Kit (Promega). The correct plasmid sequence was verified 
by sequencing using the oligonucleotide fw_lexA+scRNA_ColonyPCR (data not show).  
The successfully generated plasmids were transformed into electrocompetent Ssw, 7x tetO cells 
together with the plasmid pAH015 containing the hTF LexA-ER-B112 enabling ES inducibility. 
Selection was performed using SD-leu-ura drop-out agar plates. Cells were grown for 48 h at 
30 °C. Correct plasmid integration was verified by cPCR using the oligonucleotides lexA FP 7 
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and lexA FP 13 for pAH015 and fw_lexA+scRNA_ColonyPCR and oAH031 for pAH024-26 (data 
not shown).  
For the comparative analysis of the AND, scRNA gate with the strains containing the newly 
generated plasmids, all strains were freshly inoculated into a deep-well plate and grown shaking 
overnight at 30 °C. Induction was performed in biological triplicates in a 96-deep-well plate. 
Therefore, 50 µL of the precultured cells were mixed with either 450 µL of SD medium or SG 
medium + 50 nM ES. If desired, 2.5 µL of an ES stock solution were added to the cell 
suspension. The Venus fluorescence was measured via Accuri™ (BD) with a 488 nm laser and 
the filter options 533/30. For analysis the Accuri™ software (BD) was used. The percentage of 
fluorescent cells was exported to Microsoft Excel (Microsoft) and applied to Figure 47. 
Induction was successful for the AND, scRNA strain. In the absence of galactose and ES, the 
fluorophore expression was tightly regulated, whereas in presence of both nearly 80 % of the 
cells showed fluorescence beyond the arbitrarily set 5% threshold of control cells. As expected, 
neither the uninduced nor the induced NC showed an increased cellular fluorescence. The 
strains containing the plasmids pAH024-26 showed approximately the same fraction of 
fluorescent cells as the NC when uninduced. Interestingly, the fraction of fluorescent cells even 
decreased for those clones, when induced with galactose and ES. Hence, for neither of the three 
constructs scRNA only, HH-scRNA and scRNA-HDV an induction was achieved. As are result, 
both ribozymes flanking the scRNA are necessary to achieve a functional scRNA generation.  
 
 
Figure 47 Comparative induction of different lexA_scRNA-Ribozyme constructs. 
For the experiment cells of the strains containing the constructs lexA_scRNA, lexA_HH-scRNA, lexA_scRNA-HDV, 
lexA_HH-scRNA-HDV (AND, scRNA) and a NC. The strains were grown in SD for not induced (orange) or SG + 50 nM 
ES for induction (blue). Y-axis showing fluorescent cells beyond the 5 % threshold. Error bars indicate the standard 
deviation of the biological triplicates. 
 
Summing up the results of the RNA and DNA analysis, it can be concluded that the expression 
of the scRNA by an RNA pol II promoter is possible only with the help of the flanking ribozyme 
setup and that the auto-cleaving properties of the utilized ribozymes work sufficiently well. 
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5.5.8. Dose-dependent analysis of the AND, scRNA gate 
In a last experiment, the dose-dependency of the AND, scRNA gate should be determined. 
Therefore, the AND, scRNA strain was induced with different ES concentrations between 
0.005 nM ES and 100 nM ES. Induction was performed in a 96-deep well plate in triplicates 
following the protocol described in 4.4.3. For induction, cells were freshly inoculated in 15 mL 
SD-ura-leu medium and grown at 30 °C overnight. The cell density was measured and a cell 
suspension was obtained by inoculation of different media towards an OD600 of 1. Subsequently, 
475 µL of this cell mixture were pipetted into a 96-deep-well plate and mixed with 25 µL of 
medium or an ES solution. For the controls, cells were grown in SD, SD + 100 nM ES or SG. 
For induction cells were grown in SG and different ES solutions. For the ES solutions, two serial 
dilutions in PBS were performed. One starting at 100 nM and ending at 0.1 nM ES and one 
starting at 50 nM ES and ending at 0.005 nM ES. During the analysis it has to be considered, 
that through the two dilution series, the applied concentrations do not decrease proportionally. 
Additionally, as controls the strains NC and Ssw, 7x tetO, pAH015 + pAH024-26 were grown 
and induced the same way. The Venus fluorescence was directly measured with BD Accuri™ C6 
(BD) using the 96-well plate. The mean fluorescence and the percentage of fluorescent cells 
were exported to Microsoft Excel (Microsoft). The mean fluorescence of the AND, scRNA was 
applied to Figure 48. The number of fluorescent cells of the AND, scRNA and the controls as 
well as the percentage of fluorescent cells for the controls were applied to the Supplementary 
Figure 56.  
 
 
Figure 48 ES dose-dependent induction experiment for the inducible scRNA based AND gate. 
For the experiment cells of AND, scRNA were used. Cells were grown in SD, SD + 100 nM ES and SG for controls. The 
samples were grown in SG plus decreasing concentrations of ES. Error bars indicate the standard deviation of the 
biological triplicates. 
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For the controls, the same results were obtained as before. Both, mean fluorescence and the 
number of fluorescent cells did not increase due to induction with galactose and any ES 
concentration. For the AND, scRNA strain, the control growth in SD and SG did show the 
expected negative results. For the samples, the fraction of fluorescent cells beyond threshold of 
the AND, scRNA strain was about the same for all concentrations of 5 nM and above. This raises 
the assumption that the maximum shift of mean fluorescence resulting from induced cells in 
this setup is already reached at an ES concentration of 5 nM. Afterwards the fraction of 
fluorescence decreased fast to nearly 0 %. A similar decrease was obtained for the shift of mean 
fluorescence. From 100 nM to 5 nM ES a slight decrease of the mean fluorescence was detected. 
For concentrations below 5 nM ES, a strong decrease was observed and reached at 0.1 nM ES 
the level of the SD only control. Hence, a dose-dependent behavior similar to the AND, AND, 
GO and AND, vNAR gates (5.2) was obtained.  
However, in contrast for the previously tested AND gates, for the AND, scRNA gate again high 
basal activity was observed for the control SD + ES. It is generally possible, that the leakiness 
of the galactose-inducible switch led to a relatively high basal dCas9 expression that in 
combination with high level synthesis of scRNA accounts for this finding. In recent work, the 
limiting factor of a CRISPR/(d)Cas9 system was demonstrated to be the gRNA expression 
and/or the assembly of the gRNA into Cas9 (204). When expressed from a RNA pol II promoter 
the excess of scRNA may aid assembly of a transcription activator complex.  
In conclusion, these experiments showed that a dose-dependent induction of the AND, scRNA 
gate is possible. Hence, a functional and dose-dependent AND gate was built not only for dCas9 
and MCP-VP64, but also for dCas9 and scRNA. It is likely, that the AND gate setup can also be 
applied to other systems and thus can be understood as a synthetic toolbox for targeted gene 
expression. 
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Within the presented work, different routes for targeted gene expression were applied to the 
yeast S. cerevisiae and a genetic toolbox was established. An AND gate was developed that 
allows a modular and tightly regulated gene expression. To this end, a CRISPR/dCas9 system 
was utilized, which allows for targeted gene expression with the help of the three components 
dCas9, MCP-VP64 and scRNA (5). All components were implemented into S. cerevisiae cells 
along with the scRNA tetO-binding site preceding the reporter gene Venus. This setup offered 
the possibility to efficiently and quickly test the reporter gene using the Tet-On system (74). 
Different tetO copy numbers were used. Gene expression of the reporter gene construct was 
successfully induced by doxycycline addition.  
With the implementation of a GAL promoter in front of the dCas9 coding sequence, the dCas9 
expression was placed under control of galactose addition and a first switch was implemented. 
To achieve this, strains were generated containing different tetO copy numbers preceding 
reporter gene Venus. The established single switch strains were compared with the 
conventionally used two component CRISPR/dCas9-VP16 transcription activator (141). The 
galactose-dependent single switch was not only functional, but also reached significantly higher 
expression levels compared to the conventional CRISPR/dCas9-VP16 system. This effect is likely 
to be mainly caused by the two MCP-VP64 hairpin loops (179) attached to the scRNA. In 
combination with up to seven scRNA binding sites, the recruitment of multiple transcription 
activation molecules at the same time is possible. Unfortunately, these high expression rates 
lead to an increased basal expression level. Particularly due to the inherent leakiness of the GAL 
promoter (57), a certain amount of dCas9 is expressed even in the absence of galactose. dCas9 
builds a complex with the constitutively expressed MCP-VP64 and scRNA and especially when 
a high tetO copy number was used, a small amount of Venus was unintentionally produced.  
To solve this problem, and also to allow dose-dependent induction, a second switch reliant on 
ES as an inducer was added to the CRISPR/dCas9 system. After integration of the hTF 
LexA-ER-B112 and 4x lexA boxes in front of MCP-VP64 (45), a functional AND gate was 
generated. Only when induced with galactose and ES at the same time, Venus expression was 
detectable. The AND gate showed the expected concentration and time-dependent behavior 
while being tightly regulated. In addition to the reporter Venus, a more biologically relevant 
setup was investigated in which a GOI was linked to a tGFP by the ribosomal skipping sequence 
T2A (157). With the help of this setup, the enzyme GOase and the shark antibody fragment 
vNAR were successfully produced and verified by SDS-PAGE or ABTS assay. To allow simple 
and quick analysis a signal sequence was N-terminal fused to GOase and vNAR, and for vNAR 
additionally a C-terminal hexahistidine tag. Due to this setup it was possible to simply centrifuge 
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the cells suspension and to detect GOase directly in the supernatant. No further purification 
steps were needed allowing quick and easy purification as well as analysis of GOase expression. 
In contrast, the His tag containing vNAR needed to be purified by IMAC after expression. 
Despite this additional purification step, the vNAR was insufficiently purified and thus could 
not be detected by ELISA. However, the verification of vNAR expression succeeded with SDS 
gel and western blot analysis. For all samples successful co-verification of induction was 
performed by measurement of the tGFP fluorescence in the cells. Thanks to a collaboration with 
Johannes Falk from the group of Prof. Drossel (Physics Department of TU Darmstadt), it was 
possible to develop a simple model that perfectly reproduced the AND gate data. In the future, 
the model will make it possible to predict target gene expression/AND gate output based on the 
ES concentration (4,198). Thus, with the help of the T2A setup, the AND gate enables the tightly 
regulated expression of any target gene and the level of target gene expression can be precisely 
adjusted by the ES concentration used. 
The AND gate is based on the assembly of two switches; one depending on galactose and the 
other on ES as inducer. However, growth in galactose is known to be a burden to S. cerevisiae 
strains (202,203). In order to reduce this burden, a positive feedback loop was designed and 
built which, after a short induction with galactose, should allow growth and reporter gene 
expression in glucose. A plasmid was established, which contained the dCas9 gene behind 3x 
tetO binding sites and transformed to the AND gate clone. The established strain contained 
both, the genes for a functional CRISPR/dCas9 system and the plasmid for the positive feedback 
loop. After induction of the CRISPR system, not only the reporter gene tGFP, but also the dCas9 
can be expressed. Thus, galactose does not have to be further added to maintain a sufficient 
dCas9 concentration. After induction with galactose was performed for 30 or 120 min, 
respectively and ES was constantly added to the medium, the strain was demonstrated to be 
functional even after removal of the galactose inducer by transfer to glucose containing 
medium. In addition, unexpectedly high expression values were achieved with the help of the 
positive feedback loop. Among others, the assembly of the gRNA/scRNA into dCas9 is the 
limiting factor of a CRISPR/dCas9 system (204). Hence, the overexpression of dCas9 may have 
resolved this expression limitation of the AND gate. To get a deeper understanding of how the 
feedback loop works, a degradation tag was added to the N-terminus of the tGFP reporter, 
which should allow a more precise analysis of the feedback process. However, the degron used 
was too efficient and no tGFP fluorescence was detectable. To allow more precise analysis of 
the functionality of the positive feedback loop and time-dependent tGFP expression, a weaker 
degradation mechanism would have to be used in further experiments. If this degradation 
mechanism would demonstrate to be functional, the construction of a negative feedback loop 
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would be conceivable. A negative feedback loop would allow for even more precise tuneability, 
as well as a further reduction in basal activity (219,220). 
To demonstrate that the AND gate setup is modular, the ES switch was transferred to the scRNA 
synthesis. In order to achieve an ES inducibility of the scRNA transcription, the utilized RNA 
polymerase III promoter first had to be replaced by the ES inducible RNA polymerase II lexA 
minimal promoter construct. In order to circumvent problems with processing of the scRNA by 
RNA pol II (212), a ribozyme-scRNA-ribozyme setup was implemented (158). This construction 
proved to be successful for scRNA expression from the constitutive Adh1 promoter as well as 
from the ES inducible lexA minimal promoter construct. Thus, a dose-dependent AND gate was 
constructed based on a galactose inducible dCas9 and an ES inducible scRNA. The AND gate 
was tightly regulated, except when grown in ES containing medium. A possible explanation is 
basal level dCas9 expression, which in combination with high ES-induced scRNA expression 
may allow for facile assembling of scRNA and dCas9 at low concentration of dCas9. A possible 
experiment to prove/disprove this model would be to determine the exact amount of scRNA as 
a function of time by RT-qPCR (221) and to further reduce the dCas9 basal level of expression. 
For future work, it will be interesting to see whether more sophisticated genetic switches and 
circuits can be implemented using the toolbox of strains and DNA constructs developed in this 
work. For example, it might be interesting to investigate, whether expression of two reporters 
can be individually controlled by two different dCas9/scRNA constructs, each addressing a 
different operator (Figure 49A+B). Likewise, positive and negative feedback loops could be 
implemented in a single cell as well as oscillators (222–224). Further work is required to 
investigate whether the complexity of this type of dCas9/scRNA derived switches, gates and 
circuits can be expanded and whether the behavior of such type of complicated integrated 
systems can be modeled and predicted.  
In summary, in this work it was successfully demonstrated that the AND gate operates in a 
modular fashion, maintaining computable features, such as concentration dependency, 
independent of the setup used. Therefore, the AND gate setup designed, assembled and 
extensively characterized in this work can be considered as a contribution to the SynBio 
toolboxes for yeast. 
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Figure 49 Schematic idea for expression of two reporters, individually controlled by two different dCas9/scRNA 
constructs, each addressing a different operator. 
(A) Strain design for the double gene expression control. (B) scheme of the corresponding genetic switches. tetO, P1 
and P2 indicate individual operator sequences that can be addressed with complementary scRNAs. 
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8.3. List of Abbreviations 
Table 37 List of abbreviations used within the scope of this thesis. 
Abbreviation Long term 
A  
aa 
AD 
AND 
AND, GO 
AND, vNAR 
Amp 
Aq 
ARS 
amino acid 
activation domain 
AND gate with Venus as reporter gene 
AND gate with GOase and tGFP as reporter genes 
AND gate with vNAR and tGFP as reporter genes 
ampicillin 
aqueous solution 
autonomously replicating sequence 
B  
bp base pairs 
C  
°C 
Cas 
Cas9 
CEN 
CHO cells 
CRISPR 
CRISPRa 
CRISPRi 
cPCR 
crRNA 
cTF 
Degree 
CRISPR-associated 
CRISPR-associated protein 9 
yeast centromere 
Chinese hamster ovary cells 
clustered regularly interspaced short palindromic repeats 
CRISPR activation  
CRISPR interference  
colony PCR 
CRISPR RNA 
chimeric transcription factor 
D  
dbd 
dCas9 
dc-VP64 
ddH2O 
DMSO 
DNA 
dNTP 
dox 
DS 
DSB 
DTT 
dYT 
DNA binding domain 
catalytically dead Cas9 mutant 
strains containing dCas9 fused to VP64 
distilled water 
dimethyl sulfoxide 
deoxyribonucleic acid 
desoxiribonucleotide phosphate  
doxycycline 
double strand 
double strand break 
dithiotreitol 
double concentrated Yeast Tryptone medium  
E  
E. coli 
e.g. 
ES 
eSpCas9 
Escherichia Coli  
exempli gratia  
β-estradiol 
“enhanced specificity” SpCas9 
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ER 
evoCas9 
human estrogen receptor 
evolved Cas9 
F  
FACS fluorescence-activated cell sorting  
G  
g 
Gal 
Glu 
GOase 
GOI 
gRNA 
gramm 
galactose 
glucose 
galactose oxidase 
gene of interest 
guide RNA 
H  
HCl 
HDR 
His 
HR 
hTF 
hydrochloric acid 
homology-directed repair  
histidine 
homologous recombination 
heterologous transcription factor 
L  
L 
LD 
L/Leu 
lexA 
liter 
loading dye 
leucine 
lexA operator 
M  
µg 
µL 
µM 
M 
mg 
mL 
mM 
microgramm 
microliter 
micromolar 
Molar 
milligramm 
milliliter 
millimolar 
N  
NaCl 
NC 
NHEJ 
nm 
nM 
nTF 
sodium chloride 
negative control 
non-homologous end-joining 
nanometer 
nanomolar 
natural transcription factor 
O  
OD 
ori 
optical density 
origin of replication 
P  
P 
PAM 
promoter 
protospacer adjacent motif 
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PBS 
PC 
PCR 
POI 
phosphate buffered saline  
positive control 
polymerase chain reaction  
protein of interest 
R  
RNA  
Rpm 
RT PCR 
rtTA 
ribonucleic acid  
rounds per minute  
roof tile PCR 
reverse tetracycline-controlled transactivator 
S  
S. cerevisiae 
scRNA 
sgRNA 
Ssw 
SpCas9 
SynBio  
Saccharomyces cerevisiae  
scaffold RNA 
single guide RNA 
single switch 
Streptococcus pyogenes Cas9 
synthetic biology 
T  
TALE 
TALEN 
tc 
TetR 
tetO 
TF 
tGFP 
tracrRNA 
TRIS  
tTA 
Transcription Activator-like Effector 
Transcription Activator-like Effector Nucleases 
tetracycline 
Tet repressor 
tetracycline-controlled operator 
transcription factor 
turbo GFP 
trans-acting RNA 
tris(hydroxymethyl)aminomethane 
tetracycline-controlled transactivator 
V  
vNAR 
v/v 
variable domain of new antigen receptors 
volume per volume 
W  
W/Trp 
w/v 
tryptophan 
weight per volume 
Z  
ZF 
ZFN 
Zinc-finger 
Zinc-finger nucleases 
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 Appendix 
9.1. Supplementary figures 
 
Figure 50 Histograms for doxycycline induction for the different tetO clones. 
The histograms show Venus fluorescence after induction with 100 µg/mL dox. The fluorescence strongly depends on 
the tetO copy number. The fluorescence was measured with the 488 nm laser of BD Accuri™ C6 [533/30]. 
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Figure 51 Histograms for galactose induction for the different Ssw, tetO clones. 
The histograms show Venus fluorescence after induction with galactose or 100 µg/mL dox. The fluorescence strongly 
depends on the tetO copy number. The fluorescence was measured with the 488 nm laser of BD Accuri™ C6 [533/30]. 
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Figure 52 ES concentration-dependent cell distribution. 
Single reporter AND gate, 7x tetO cells were grown in SD-ura and different ES concentrations. Depending on the ES 
concentration the cell distribution changed. Hence, cell distribution directly correlates with the amount of ES. 
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Figure 53 Influence of induction of reporter gene expression on cell growth. 
Cells of the strains AND, 7x tetO (solid) and AND, GO (hatched) were grown in different media. Therefore, cells were 
inoculated to an OD600 of 1 in SD-ura medium and grown over night in SD-ura medium, SG-ura medium or induction 
medium containing SG-ura and 1 nM, 10 nM or 100 nM ES, respectively. Cell growth was determined photometrically. 
For the AND switch no significant influence in growth could be detected, whereas with increasing amount of ES the 
cell density of the AND, GO switch decreased slightly.  
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Figure 54 Induction experiment for the positive Ubi-tGFP feedback loop. 
For the experiment cells of the AND, GO, AND, GO, pFL, Ubi wt (not containing a scRNA), Ubi pJZC588 and Ubi 
pJZC588 + pAH019 were used. As negative control cells were grown in SD. As positive control cells were grown in SG 
+ 10 nM ES for 48 h. Error bars indicate the standard deviation of the biological triplicates. 
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Figure 55 RNA extraction and cDNA analysis for the HH-scRNA-HDV construct, repetition of the experiment. 
(A) The planned PCR strategy, in which three different fragments should be tested. (B) Isolated RNA applied on a 
1 % agarose gel. As marker, the 1kb DNA-ladder (vwr) was used. (C) PCR of the reverse transcribed cDNA showing 
which fragment could be amplified. On the top, cDNA was reverse transcribed using the M-MuLV reverse 
transcriptase (New England Biolabs). On the bottom the control is shown, where no -MuLV reverse transcriptase was 
added. Samples were applied to a 3 % agarose gel. As marker, the Ultra Low Range DNA-Leiter II, peqGOLD (vwr) 
was used. 
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Figure 56 ES dose-dependent induction experiment for AND, scRNA gate and controls containing pAH024-26. 
For the experiment cells of AND, scRNA, Ssw, 7xtetO, PAH024-26 and NC were used. Cells were grown in SD, SD + 
100 nM ES and SG for controls. The samples were grown in SG plus decreasing concentrations of ES. Error bars 
indicate the standard deviation of the biological triplicates. 
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